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ABSTRACT 
Hodgkin lymphoma (HL) is a malignant lymphoma that is diagnosed mostly in young 
adults, and is the second most common malignancy to affect this age group.  This 
disease is subdivided into two entities with different aetiologies: classical HL (cHL) 
(~95%  of  cases)  and  nodular  lymphocyte-predominant  HL.    In  Europe,  ~82%  of 
young  adults  with  cHL  are  non-Epstein-Barr  virus-associated  and  epidemiological 
studies have suggested that a common infectious agent may play a key role in the 
aetiology  of  these  cases.    The  molecular  biology  of  HL  is  not  well  understood, 
primarily due to the low number of Hodgkin and Reed-Sternberg (HRS) cells present 
within these tumours.  However, recently developed techniques for the selection and 
micromanipulation  of  single  HRS  cells  from  tumours,  and  the  development  of 
molecular  cytogenetic  techniques  (i.e.  array-comparative  genomic  hybridisation 
(CGH)) are overcoming these difficulties.   
 
To investigate a potential candidate virus, DNA samples from cHL biopsies were 
screened  for  the  measles  virus  (MV)  and  polyomaviruses  (PyV),  using 
immunohistochemistry and highly sensitive PCR assays.  Chromosomal imbalances in 
six well-established cHL-derived cell lines and a cHL case were analysed by array-
CGH.  To obtain sufficient DNA for array-CGH from the cHL case, single HRS cells 
were isolated using laser microdissection.   DNA  was extracted then  amplified  by 
degenerate oligonucleotide primer polymerase chain reaction. 
 
MV  and  PyV  genomes  were  not  detected  within  cHL  biopsies.    Recurrent 
chromosomal imbalances were confirmed within the cHL-derived cell lines and cHL      
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case, in addition to several novel imbalances.  This is the first time that a cHL case 
has been analysed by array-CGH.      
  v 
 
 
ACKNOWLEDGEMENTS 
I  would  like  to  express  my  gratitude  to  my  supervisors  Professor  Ruth  Jarrett 
(Leukemia  Research  Fund  (LRF)  Virus  Centre,  University  of  Glasgow)  and 
Dr Sabrina Tosi (Brunel University) for allowing me the opportunity to undertake this 
degree, and for their guidance throughout my period of study at Glasgow University. 
 
The  completion  of  this  investigation  would  not  have  been  possible  without  the 
assistance of my colleagues at the LRF Virus Centre in Glasgow.  I would particularly 
like to thank Dr Alice Gallagher, Mrs June Freeland and Miss Lesley Shield, for their 
invaluable knowledge and expertise on PCR techniques, immunohistochemistry and 
laser microdissection. 
 
I performed all the array-CGH experiments at the Wellcome Trust Centre for Human 
Genetics in Oxford under the guidance of Dr Samantha Knight and Dr Regina Regan.  
I  thoroughly  enjoyed  working  in  the  Neurogenetics  &  Psychiatric  Genetics 
Laboratory  and  would  like  to  thank  Sam  and  her  group  for  making  me  feel  so 
welcome during these visits. 
 
To all my colleagues in the Glasgow office of CMG, I would like to express  my 
thanks for all the encouragement  and support they  have  given me throughout  the 
writing up of this thesis. 
 
Finally, a huge thank you to my family and friends who, throughout my studies, have 
provided encouragement, support, sustenance and laughter. 
      
  vi 
 
 
LIST OF CONTENTS 
 
 
    Page 
number 
  List of Figures  xii 
  List of Tables  xiv 
  Abbreviations  xvi 
     
CHAPTER 1  INTRODUCTION  1 
1.1  Hodgkin Lymphoma  2 
1.2  Classification of Hodgkin Lymphoma  4 
1.2.1  NLPHL  5 
1.2.2  NSHL  5 
1.2.3  MCHL  6 
1.2.4  LDHL  6 
1.2.5  LRCHL  6 
1.3  Origin and clonality of HRS cells  7 
1.3.1  cHL-derived cell lines  7 
1.3.2  The origin of HRS cells  7 
1.3.3  The phenotype of HRS cells  11 
1.3.4  Anti-apoptotic mechanism of the HRS cells  12 
1.3.4.1  CD95 death receptor pathway  12 
1.3.4.2  The NF B signalling pathway  13 
1.4  Epstein-Barr Virus  15 
1.4.1  Lytic and latent infection of EBV  16 
1.4.2  EBV and HL  19 
1.4.3  Epidemiology of HL  21 
1.4.4  Epidemiology of EBV and HL  23 
1.4.5  Non-EBV-associated HL cases  27 
1.5  Classical cytogenetics  30 
1.5.1  Chromosome banding techniques  30 
1.5.2  Classical cytogenetics and HL  31 
1.6  Molecular cytogenetics  32      
 vii 
 
 
1.6.1  In situ hybridisation  32 
1.6.2  Flourescence in situ hybridisation  33 
1.6.3  FICTION analysis  34 
1.6.4  Comparative Genomic Hybridisation  35 
1.6.4.1  Investigation of lymphoma using CGH  39 
1.6.4.2  Limitations of CGH  40 
1.6.5  Whole genome amplification  41 
1.6.5.1  Linker-adaptor PCR  41 
1.6.5.2  Primer-extension pre-amplification PCR  42 
1.6.5.3  Degenerate oligonucleotide-primed-PCR  42 
1.6.5.4  Multiple displacement amplification  43 
1.6.6  Whole genome amplification, CGH and lymphomas  44 
1.6.7  Laser microdissection and whole genome amplification  45 
1.6.8  CGH analysis of classical HL  45 
1.6.9  Array-CGH  49 
1.7  Aims of thesis  51 
     
CHAPTER 2  MATERIALS AND METHODS  52 
2.1  Materials  53 
2.2  Methods  53 
2.2.1  Tissue collection  53 
2.2.2  Tissue biopsy processing  54 
2.2.3  Preparation of viable cell suspensions  54 
2.2.4  Cell counting  55 
2.2.5  Enrichment of mononuclear cells from lymph nodes  55 
2.2.6  Storage of viable mononuclear cell suspensions  55 
2.2.7  Cell lines  56 
2.2.7.1  Recovery and maintenance of cell lines  56 
2.2.8  Preparation of cytospin slides  58 
2.2.9  CD30-staining using the ABComplex Method  58 
2.2.10  Laser microdissection from cytospin slides  59 
2.2.11  Total RNA extraction  60 
2.2.12  DNA extraction from tumour samples or cell lines  61      
 viii 
 
 
2.2.13  Ethanol precipitation of DNA  62 
2.2.14  Quantitification of nucleic acids  63 
2.2.15  Polymerase chain reaction  63 
2.2.15.1  DOP-PCR  63 
2.2.16  Analysis of PCR products  66 
2.2.16.1  Agarose gel electrophoresis  66 
2.2.16.2  Polyacrylamide gel electrophoresis  67 
2.2.17  Cloning and plasmid preparations  67 
2.2.18  Nucleotide sequence analysis  68 
     
CHAPTER 3  NO EVIDENCE FOR A DIRECT ASSOCIATION  
BETWEEN MEASLES VIRUS AND  
HODGKIN LYMPHOMA 
69 
3.1  Introduction  70 
3.2  Materials and methods  76 
3.2.1  Case selection  76 
3.2.2  Immunohistochemistry  79 
3.2.3  Reverse Transcription (RT)-PCR  80 
3.2.4  Conventional PCR  81 
3.2.5  Quantitative real-time PCR  84 
3.3  Results  86 
3.3.1  Epidemiology  86 
3.3.2  Immunohistochemistry  86 
3.3.3  Reverse Transcriptase (RT)-PCR   87 
3.4  Discussion  93 
     
CHAPTER 4  NO EVIDENCE OF POLYOMAVIRUS GENOMES  
IN HODGKIN LYMPHOMA 
95 
4.1  Introduction  96 
4.2  Materials and methods  102 
4.2.1  Clinical samples  102 
4.2.2  Quantitative real-time PCR analysis  104 
4.2.3  Degenerate PCR  106      
  ix 
 
 
4.2.3.1  Design of polyomavirus degenerate PCR primers  106 
4.2.3.2  Degenerate PCR methodology  110 
4.2.3.3  Assay specificity and sensitivity  111 
4.2.3.4  Hodgkin lymphoma samples  111 
4.2.3.5  Cloning of degenerate PCR products for sequence 
analysis 
112 
4.3  Results  113 
4.4  Discussion  116 
     
CHAPTER 5  INVESTIGATION OF GENOME IMBALANCES AND  
GENE EXPRESSION IN CHL-DERIVED CELL LINES 
118 
5.1  Introduction  119 
5.2  Methods  122 
5.2.1  Cell lines  122 
5.2.2  RNA and DNA extraction  122 
5.2.3  Preparation of samples for array-CGH  122 
5.2.4  Labelling of genomic DNA by random priming  123 
5.2.5  Array fabrication and processing  124 
5.2.6  Array-Comparative Genome Hybridisation  125 
5.2.7  Post-hybridisation washes  126 
5.2.8  Image acquisition and data analysis  126 
5.2.9  Dye-swap hybridisation  131 
5.2.10  Gene expression array hybridisation  132 
5.2.11  Gene expression array analysis  133 
5.2.12  Correlation between array-CGH and gene expression 
array analysis 
133 
5.3  Results  134 
5.3.1  Array-CGH analyses   134 
5.3.2  Gene expression array analysis  161 
5.3.3  Correlation of array-CGH and gene expression array 
analyses 
164 
5.4  Discussion  167 
          
  x 
 
 
CHAPTER 6  ANALYSIS OF PRIMARY HRS CELLS BY ARRAY-
CGH 
177 
6.1  Introduction  178 
6.2  Optimisation experiments  181 
6.2.1  Validation of DOP-PCR products for use in array-CGH  181 
6.2.1.1  The GF-D8 cell line  181 
6.2.1.2  Array-CGH performed using the GF-D8 cell line  182 
6.2.2  Comparison of different fixation and staining methods 
prior to array-CGH 
187 
6.2.3  Comparison of array-CGH using different cell numbers  189 
6.2.3.1  Array-CGH of cHL-samples using 200 laser 
microdissected HRS cells 
189 
6.2.3.2  Validation of 1000 cell-DOP-amplified HRS DNA for 
array-CGH 
195 
6.2.3.3  Validation of 6000 cell-DOP-amplified HRS DNA for 
array-CGH 
197 
6.3  Array-CGH of a cHL case sample  198 
6.3.1  Preparation of DNA sample from case# 6992  198 
6.3.2  Results  198 
6.4  Discussion  205 
     
CHAPTER 7  FINAL DISCUSSION  209 
7.1  The search for potential pathogenic agents for cHL  210 
7.2  Recurrent chromosomal imbalances in cHL  212 
7.3  Conclusions  215 
     
     
     
APPENDICES    216 
Appendix A  Combined hybridisation charts of cHL-derived cell lines   217 
Appendix B  Chromosome regions containing known functional  
genes in which gains were identified in three or more  
cHL-derived cell lines. 
223      
  xi 
 
 
Appendix C  Chromosome regions containing known functional genes 
in  which losses  were identified in  three or more cHL-
derived cell lines. 
225 
Appendix D  Gene  expression  array  analysis  results  for  the  EBV-
positive cHL cell line KMH2 
228 
Appendix E  Gene  expression  array  analysis  results  for  the  EBV-
positive cHL cell line L428 
230 
Appendix F  Gene  expression  array  analysis  results  for  the  EBV-
positive cHL cell line L591 
232 
     
  Reference list   234 
  Publications from these studies  275      
 xii 
 
 
LIST OF FIGURES 
 
    Page 
number 
Figure 1.1  Cellular origin and B-cell differentiation within secondary 
lymphoid organs 
10 
Figure 1.2  The four disease model of HL  26 
Figure 1.3  CGH on both metaphase spreads and arrays  38 
Figure 1.4  Summary of conventional CGH analysis of HRS cells 
isolated from cHL biopsies 
48 
Figure 3.1  Schematic diagram of the measles virus and its RNA 
genome 
73 
Figure 3.2  Detection of measles virus (MV) by immunohistochemistry  87 
Figure 3.3  Quantitative real-time PCR results for the GAPDH assay.    89 
Figure 3.4  Quantitative real-time PCR results for the measles virus 
(MV) hemagglutinin assay   
90 
Figure 3.5  Quantitative real-time PCR results for the measles virus 
(MV) nucleoprotein assay 
91 
Figure 3.6  Quantitative real-time PCR results for the measles virus 
(MV) haemagglutinin assay showing amplification curves 
for replicates of serial 10-fold dilutions of cDNA extracted 
from MV-infected HOS cells 
92 
Figure 4.1  Conserved amino acid motifs within the large T antigen of 
polyomaviruses 
108 
Figure 4.2  Electropherograms from GeneScan analysis of degenerate 
PCR products 
115 
Figure 5.1  Schematic diagram of the array-CGH analysis process  130 
Figure 5.2  The combined hybridisation charts from array-CGH of 
HDLM2 DNA versus IM9 DNA 
135 
Figure 5.3  Ideogram depicting locations of clones representing gains in 
chromosomal material within each cHL-derived cell lines 
147 
Figure 5.4  Ideogram depicting locations of clones representing losses in 
chromosomal material within each cHL-derived cell lines 
151 
          
 xiii 
 
 
Figure 5.5  Schematic diagrams depicting smallest regions of overlap 
across three or more cHL-derived cell lines 
155 
Figure 6.1  Array-CGH analysis results obtained using non-amplified 
and DOP-amplified genomic DNA of the GF-D8 cell line 
183 
Figure 6.2  Scatterplot of the array-CGH data from both the non-
amplified and amplified GF-D8 DNA 
184 
Figure 6.3a  DOP-PCR products from amplification of laser 
microdissected IM9 cells stained with either CD30 
monoclonal antibody or the DiffQuik staining system 
188 
Figure 6.3b  Combined and ethanol precipitated DOP-PCR products (500 
ng) from 200 CD30-stained or 200 DiffQuik-stained laser 
microdissected cells 
188 
Figure 6.4  Hybridisation chart from the array-CGH of 200 cells-DOP-
amplified case #6992 DNA versus 200 cells-DOP-amplified 
IM9 DNA 
190 
Figure 6.5  Four  array-CGH  analyses  of  laser  microdissected,  DOP-
amplified  IM9  DNA  versus  laser  microdissected,  DOP-
amplified-IM9 DNA 
194 
Figure 6.6a  Array-CGH analysis of 1000 cells-DOP-amplified HDLM2 
DNA versus 1000 cells-DOP-amplified IM9 DNA 
196 
Figure 6.6b  Array-CGH analysis of non-amplified HDLM2 DNA versus 
non-amplified IM9 DNA 
196 
Figure 6.7  Hybridisation  chart  of  6000  cells-DOP-amplified  HDLM2 
DNA versus 6000 cells-DOP-amplified IM9 DNA. 
197 
Figure 6.8  Array-CGH analysis of 6000 cells-DOP-amplified DNA 
from HRS cells of the cHL case 6992 versus 6000 cells-
DOP-amplified DNA from IM9 cells. 
200 
Figure 6.9  Array-CGH chart showing sliding averages of 6000 cells-
DOP-amplified 6992 DNA versus 6000 cells-DOP-amplified 
IM9 DNA 
200      
 xiv 
 
 
LIST OF TABLES 
 
    Page 
number 
Table 1.1  The Ann Arbor staging system for HL  3 
Table 1.2  The four disease model of cHL  25 
Table 2.1  Details of cell lines used in array-CGH and gene expression 
array analyses 
57 
Table 3.1  Details of patients in case series 1  78 
Table 3.2  Details of patients in case series 2    78 
Table 3.3  Conventional PCR primers  83 
Table 3.4  Quantitative real-time PCR primers and probes  85 
Table 4.1  Patient characteristics  103 
Table 4.2  Quantitative real-time PCR (TaqMan®) primers and probes  105 
Table 4.3  Degenerate PCR primers for detection of polyomaviruses  109 
Table 5.1  Chromosomal regions in each cHL-derived cell line where a 
gain of DNA has been identified by array-CGH 
137 
Table 5.2  Chromosomal regions in each cHL-derived cell line where a 
loss of DNA has been identified by array-CGH 
139 
Table 5.3  Selected genes of interest in newly identified regions of gain  143 
Table 5.4  Selected genes of interest in newly identified regions of loss  144 
Table 5.5  Selected genes with known function that are located within 
gained chromosome regions identified as smallest regions of 
overlap (SROs) in three or more cells lines 
156 
Table 5.6  Selected genes with known function that are located within 
lost chromosome regions identified as smallest regions of 
overlap (SROs) in three or more cells lines 
158 
Table 5.7  Genes which are upregulated or downregulated within all 
three cHL-derived cell lines that were screened by gene 
expression array analysis 
162 
Table 5.8  Differentially expressed genes in the EBV-negative cHL-
derived cell lines KMH2 and L428 
163 
Table 5.9  Genes within regions of chromosomal imbalance, identified 
by array-CGH analysis, which were also differentially 
166      
  xv 
 
 
expressed in gene expression array analysis 
Table 6.1  Chromosomal rearrangements present in the GF-D8 cell 
line, identified by multiplex FISH and convention196al 
CGH 
182 
Table 6.2  Comparison  of  the  gains  identified  by  CGH  to 
chromosomes, array CGH of non-amplified DNA and array 
CGH of DOP amplified DNA 
185 
Table 6.3  Comparison  of  the  losses  identified  by  CGH  to 
chromosomes, array CGH of non-amplified DNA and array 
CGH of DOP amplified DNA 
186 
Table 6.4  The percentage of probes with ratios lying outwith the 
threshold range <0.7 and >1.3, and the percentage of clones 
excluded from analysis due to SD >0.2 
195 
Table 6.5  Gains and losses of chromosomal regions identified within 
cHL case #6992 DNA 
201 
Table 6.6  Selected  genes  with  known  function  in  newly  identified 
regions of gain 
202 
Table 6.7  Selected  genes  of  known  function  in  newly  identified 
regions of loss 
204      
 xvi 
 
 
ABBREVIATIONS 
ALL  Acute lymphoblastic leukaemia 
BAC  Bacterial artificial chromosome 
BCR  B-cell receptor 
BLAST  Basic Local Alignment Search Tool 
Bp  Base pairs 
cDNA  Complementary deoxyribonucleic acid 
CGH  Comparative genomic hybridisation 
cHL  Classical Hodgkin lymphoma 
CI  Confidence interval 
CO2  Carbon dioxide 
Cy3  Cyanine 3 
Cy5  Cyanine 5 
dATP  2'-Deoxyadenosine 5'-triphosphate 
dCTP  2'-Deoxycytidine 5'-triphosphate 
dGTP  2'-Deoxyguanosine 5'-triphosphate 
dNTP  2'-Deoxynucleoside 5'-triphosphate 
DNA  Deoxyribonucleic acid 
DOP  Degenerate oligonucleotide primer 
EBER    EBV-encoded RNA 
EBNA  EBV-determined nuclear antigen 
EBV  Epstein-Barr virus 
FICTION  Fluorescence immunophenotyping and interphase cytogenetics as a tool 
for the investigation of neoplasms 
FISH  Fluorescence in situ hybridisation 
GC  Germinal Centre 
H  Haemagglutinin 
HL  Hodgkin lymphoma 
HOS  Human osteosarcoma 
HRS  Hodgkin and Reed-Sternberg 
Ig  Immunoglobulin 
IHC  Immunohistochemistry 
I B  I kappa B      
  xvii 
 
 
IKK  I kappa B kinase 
IM  Infectious mononucleosis 
ISH  In situ hybridisation 
Kb  Kilobase 
L&H  Lymphocytic and histiocytic 
LCL  Lymphoblastoid cell line 
LDHL  Lymphocyte-depleted Hodgkin lymphoma 
LMD  Laser microdissection 
LMP1  Latent membrane protein 1 
LPA  Lymphotropic papovavirus 
LRCHL  Lymphocyte-rich Hodgkin lymphoma  
LRF  Leukemia Research Fund 
l  Microlitres 
M      Matrix 
MAPH  Multiplex amplification and probe hybridisation 
MCHL  Mixed cellularity Hodgkin lymphoma 
MDA  Multiple displacement amplification 
M-FISH  Multiplex fluorescence in situ hybridisation 
mins  Minutes 
ml  Millilitres 
MLPA  Multiplex ligation-dependent probe amplification 
mRNA  Messenger ribonucleic acid 
MV  Measles virus 
NP  Nucleoprotein 
NCBI  National Center for Biotechnology Information 
NF B  Nuclear factor kappa B 
NHL  Non-Hodgkin’s lymphoma 
NLPHL  Nodular lymphocyte-predominant Hodgkin lymphoma 
NOS  Not otherwise specified 
NSHL  Nodular sclerosis Hodgkin lymphoma 
O/N  Overnight 
PCNSL  Primary central nervous system lymphomas 
PCR  Polymerase chain reaction      
  xviii 
 
 
PEP-PCR  Primer-extension pre-amplification polymerase chain reaction 
PyV  Polyomaviruses 
QRT-PCR  Quantitative real-time polymerase chain reaction 
RCA  Rolling circle amplification 
REAL  Revised European-American Classification of Lymphoid Neoplasms 
RMA  Robust multi-chip average 
RNA  Ribonucleic acid 
RP  Rank products 
RS  Reed Sternberg 
RT-PCR  Reverse-transcription polymerase chain reaction 
SAGE  Serial analysis of gene expression 
SD  Standard deviation 
SHM  Somatic hypermutation 
SNEHD  Scottish and Newcastle Epidermiological Study of Hodgkin’s Disease 
SNLG  Scotland and Newcastle Lymphoma Group 
SRO  Smallest region of overlap 
TCR  T-cell receptor 
TNFR  Tumour necrosis factor receptor 
tRNA  Total ribonucleic acid 
U  Units 
WGA  Whole genome amplification 
WHO  World Health Organization 
YAC  Yeast artificial chromosome 
      
  1 
 
 
CHAPTER 1 
 
INTRODUCTION 
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1.1  HODGKIN LYMPHOMA 
Hodgkin  lymphoma  (HL)  is  a  malignant  disease,  mainly  affecting  lymph  nodes, 
which was first described in 1832 (Hodgkin 1832).  The majority of HL  patients 
present  with  lymphoadenopathy,  typically  in  the  supraclavicular  or  lower  cervical 
region.  In the absence of treatment, the disease follows a predictable course spreading 
from one group of lymph nodes to those adjacent in a systematic process.  Mediastinal 
masses are frequent and patients often present with chest discomfort and coughing or 
breathlessness.   Approximately a quarter of HL cases manifest systemic B symptoms 
including fatigue, weight loss, intermittent fevers and itchy skin associated with night 
sweats.    Diagnosis  is  usually  made  by  histological  examination  of  an  excisional 
biopsy of an enlargened lymph node.  The disease is then staged using the Ann Arbor 
staging system (see Table 1.1) developed in 1971 (Carbone et al 1971) and modified 
in 1989 (Lister et al 1989).  This system defines the extent of disease progression and 
helps predict prognosis and direct treatment.  Four stages are described followed by 
the  letter  A  or  B,  indicating  the  absence  (A)  or  presence  (B)  of  B  symptoms.  
Treatment is by chemotherapy, radiotherapy or a combination of both.  Autologous 
stem cell transplantation is widely recommended for cases where first-line high-dose 
chemotherapy has not been successful and there is a high risk of disease progression 
or relapse (Josting et al 2000; Pavone et al 1997).  If left untreated HL is fatal, but 
with early diagnosis and the use of highly effective treatment strategies it is now 
curable in most cases (Klimm et al 2005). 
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Table 1.1. The Ann Arbor staging system for HL (Carbone et al 1971). 
STAGE  SYMPTOMS 
1  Involvement of one lymph nodes or lymphoid structure  
2  Involvement of two or more lymph nodes on the same side of the diaphragm  
3  Involvement of lymph nodes on both sides of the diaphragm 
4  Involvement of extranodal site(s), with or without associated lymph node involvement 
 
Diagnosis rests on the identification of typical large multinucleated cells, the Reed-
Sternberg (RS) cells, surrounded by a heterogeneous cellular infiltrate composed of 
lymphocytes,  histiocytes,  eosinophils,  plasma  cells  and  polymorphonuclear 
leukocytes.  RS cells measure 20-60 m in diameter and have at least two nuclei with 
prominent  acidophilic  or  amphophilic  nucleoli  (Pileri  et  al  2002).  Hodgkin  (H) 
mononuclear cells display similar cytological features to RS cells, and these cells are 
collectively referred to as HRS cells (Pileri et al 2002). Cells with morphology similar 
to RS cells have been identified in both infectious mononucleosis (IM) and non-
Hodgkin’s Lymphoma (NHL), but the presence of the specific heterogeneous cellular 
background is unique to HL.  Unusually for human lymphomas, the neoplastic cells 
make up a very low proportion (<1%) of the tumour cell population and this, in the 
past, has restricted a detailed investigation of these cells (Gruss and Kadin 1996; Stein 
et al 1997; Cossman et al 1998). 
 
Abundant T-lymphocytes are found within the reactive cellular infiltrate surrounding 
the HRS cells.  These are thought to reflect a non-specific response to the release of 
cytokines by HRS cells.  T-lymphocytes express early activation markers and have 
cytokine production and immunophenotypic properties characteristic of  a Th2-type 
response (Poppema and van den Berg 2000).      
  4 
 
 
1.2  CLASSIFICATION OF HODGKIN LYMPHOMA 
The first comprehensive classification of HL, then known as Hodgkin’s disease, was 
the Rye Classification (Lukes and Butler 1966).  The proportion of HRS cells in the 
tumour cell population and the nature of the infiltrate allowed four HL subgroups to 
be  identified:  nodular  sclerosis  (NSHL),  mixed  cellularity  (MCHL),  lymphocyte-
depleted (LDHL) and lymphocyte-predominant HL. 
 
The  International  Lymphoma  Study  Group  was  founded  in  Berlin  in  1990  and 
published  the  Revised  European-American  Classification  of  Lymphoid  Neoplasms 
(REAL)  in  1994  (Harris  et  al  1994).    This  system  took  into  account  the 
morphological, immunological, molecular and genetic components of lymphomas and 
leukaemias and also recognised entities commonly diagnosed in routine practice.  The 
three  major  classified  groups  were  HL,  B-cell  lymphomas/leukaemias  and  T-cell 
lymphomas/leukaemias.  Diseases were initially classified by their cell of origin and 
then further subdivided by their histological grade.  This classification was expanded 
upon  by  the  Society  for  Hematopathology  and  the  European  Association  of 
Hematopathologists for the World Health Organisation (WHO) (Harris et al 2000).  
The WHO classification encompasses haematopoietic and lymphoid neoplasms and is 
in  global use.   Two distinct  groups of HL are  characterised in  this  classification, 
classical  HL  (cHL)  and  nodular  lymphocyte-predominant  HL  (NLPHL),  with  the 
former  being  further  subdivided  into  NSHL,  MCHL,  LDHL  and  lymphocyte-rich 
classical HL (LRCHL).  NLPHL and cHL differ in the origin of their tumour cells, 
their clinical behaviour and their immunophenotype (Nogova et al 2006). 
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Immunophenotyping is an important diagnostic tool for differentiating between these 
two HL groups.  In cHL, HRS cells are usually positive for CD15 and CD30, and 
either positive or negative for CD20 (Schmid et al 1991).  In NLPHL cells are usually 
negative for CD15 and CD30, but positive for CD20 (Anagnostopoulos et al 2000). 
 
1.2.1  NLPHL 
NLPHL is regarded as a rare type of B-cell lymphoma histologically distinct from 
cHL due to the presence of lymphocytic and histiocytic (L&H) cells, also known as 
‘popcorn’ cells, in a background cellular infiltrate of predominantly B-lymphocytes.  
L&H  cells  are  smaller  than  HRS  cells  and  have  less  pronounced  nucleoli.    They 
display a unique immunophenotype (i.e. CD15-, CD20+, CD30-, CD45+), which is 
different from that of classical HRS cells (i.e. CD15+, CD20-, CD30+, CD45-).  This 
subgroup accounts for approximately 8% of all HL cases (Jarrett et al 2003).  NLPHL 
will not be discussed further in this thesis since cHL is the focus of this study. 
 
1.2.2  NSHL 
NSHL is the most prevalent HL-type accounting for approximately 60% of all HL 
(Holman et al 1983; Jarrett et al 2003).  Most at risk are individuals aged 15-34 years, 
with neither sex predominating.  Diagnosis of this disease is by the identification of 
nodular areas separated by sclerotic bands, a predominance of T-lymphocytes in the 
reactive cell population, lacunar cells and a low number of HRS cells.  Lacunar cells 
are RS cell variants observed in NSHL; they are multilobular  in shape with large 
nuclei (Hansmann and Kaiserling 1982).  Further categorisation of NSHL cases into 
nodular sclerosis grade 1 (NS-1) and grade 2 (NS-2) with good and poor prognosis, 
respectively, is advocated by some workers (Haybittle et al 1985).      
  6 
 
 
1.2.3  MCHL 
MCHL accounts for 20% of HL cases, with no age group being at particular risk 
(Jarrett et al 2003).  Histologically there is a heterogeneous cell population of plasma 
cells,  neutrophils,  eosinophils  and  small  lymphocytes  (predominantly  T-cells) 
clustered around HRS cells (Patsouris et al 1989). 
 
1.2.4  LDHL 
The least common (0.8%), but most aggressive, HL subtype is LDHL (Pileri et al 
2002).  This preferentially affects the older age group (>49 years of age) and has the 
shortest median survival period.  Patients usually present with B symptoms and are 
often in stage III-IV.  Histopathologically, tumour tissue exhibits cellular depletion 
with  disordered  fibrosis  and  a  high  variability  in  HRS  cell  number.   Many  cases 
previously  classified  as  LDHL  are  now  thought  to  be  NHLs,  and  this  subtype  is 
seldom diagnosed in current practice. 
 
1.2.5  LRCHL 
A fourth cHL subtype was first introduced as a provisional entity in the REAL (Harris 
et al 1994) then as a distinct category in the WHO classification (Harris et al 2000).  
This cHL subtype has similar histological characteristics to NLPHL, but an HRS cell 
phenotype (CD20-, CD30+, CD15+) and morphology identical to that seen in NSHL 
and  MCHL  (Anagnostopoulos  et  al  2000;  Pileri  et  al  2002).    B-cells  are  the 
predominant lymphocytes within the cellular infiltrate.  LRCHL cases account for 
2.6% of HL (Jarrett et al 2003).  The majority of cases are older adults.  LRCHL 
shares many common features with NLPHL, but a lower frequency of stages I-II and 
splenic infiltration are common (Pileri et al 2002).      
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1.3  ORIGIN AND CLONALITY OF HRS CELLS  
1.3.1  cHL-derived cell lines 
The establishment of permanent cell lines has allowed the biological characterisation 
of many human neoplasms, but only a few cell lines have been derived from cHL 
cases:  CO,  HDLM2,  HDMyZ,  Ho,  KMH2,  L1236,  L428,  L540  and  L591.    The 
origins of some are, however, dubious (eg HDMyZ) and some (eg CO) have been 
reported  to  have  been  cross-contaminated  with  the  T-cell  acute  lymphoblastic 
leukaemia (ALL)  cell line, CCRF-CEM  (Drexler 1993;  Drexler et  al  1999).  The 
remainder have generally been derived from body fluids extracted from patients with 
end-stage disease.  Only the L1236 cell line has been shown to definitely be derived 
from HRS cells (Kanzler et al 1996a; Wolf et al 1996). 
 
1.3.2  The origin of HRS cells 
Analysis  of  established  cHL-derived  cell  lines  has  shown  that  HRS  cells  do  not 
display specific lineage markers, and often coexpress markers typical for a number of 
different  hematopoietic  cell  types.    Developments  in  micromanipulation  and 
microdissection procedures, coupled with single cell polymerase chain reaction (PCR) 
assays  for  immunoglobulin  (Ig)  gene  rearrangements,  have  enabled  the 
characterisation  of  single  HRS  cells.    Ig  gene  rearrangements  involve  variable, 
diversity and joining regions and are unique to B-cells.  These rearrangements are 
therefore distinct markers which can be used to determine the origin of B lineage cells 
and assess clonality.  Several studies have identified Ig gene rearrangments within 
HRS  cells,  micromanipulated  from  cHL  cases,  which  indicates  that  these  cells 
originate from B-cells (Kanzler et al 1996b; Kuppers et al 1994; Marafioti et al 2000).   
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Germinal centres (GCs) are specialised microanatomical structures, within secondary 
lymphoid follicles, which develop from antigen-specific B-cells that have clonally 
expanded during immune responses (Thorbecke et al 1994).  Upon entering the GC, 
B-cells automatically begin the cell death program and are only able to escape this 
process if they display key positive selection signals.  They undergo several rounds of 
proliferation, somatic hypermutation (SHM) and selection in order to develop high 
affinity antigen receptors (see Figure 1.1).  The process of SHM is known to take 
place in secondary lymphoid organs, within the dark zone of the GC, during T-cell-
dependent immune responses (see Figure 1.1).  SHMs are detectable in the majority of 
immunoglobulin gene rearrangements.  Non-functional gene rearrangements, resulting 
from SHM, were identified within HRS cells micromanipulated from approximately 
25% of cHL cases (Kanzler et al 1996b).  Any GC B-cells acquiring non-functional 
gene rearrangements within the GC undergo apoptosis instead of differentiation, and 
do not develop into memory B-cells or plasma cells.  The presence of SHMs in HRS 
cells suggested, therefore, that these cells may derive from preapoptotic B-cells that 
have gained crippling mutations preventing them from undergoing antigenic selection. 
 
The expression of T-cell markers in a small proportion of HL cases suggested that 
some HRS cells could originate from T-cells (Marafioti et al 2000; Muschen et al 
2000a; Seitz et al 2000).  In one study HRS cells with a cytotoxic T-cell phenotype 
were isolated from 3 cHL cases (Muschen et al 2000a).  Germline configuration of 
IgH and T-cell receptor (TCR)-  loci, and both Ig and TCR-  gene rearrangements 
were investigated.  In two of the HL cases, cytotoxic T-cell markers were identified in 
the HRS cells and the authors suggested that these cells were derived from
 mature GC 
B cells that aberrantly express T-cell markers.  In the third HL case a typical T-cell      
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gene rearrangement pattern was observed in the HRS cells indicating these cells were 
of T-cell origin.  TCR  gene rearrangements were detected in 2 of 13 T-cell marker-
expressing HL cases in a separate study (Marafioti et al 2000; Seitz et al 2000).  The 
remaining 11 HL cases in this study were of B-cell in origin.  This demonstrated that 
it is possible for HRS cells with a T-cell phenotype to have a B cell genotype, and that 
in the vast majority of cases HRS cells are derived from B-cells.      
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Figure  1.1:  Cellular  origin  and  B-cell  differentiation  within  secondary  lymphoid 
organs eg lymph nodes and spleen [adapted from (Kuppers and Hansmann 2005)].  
The marginal zone (MgZ) contains post-germinal centre (GC) B-cells and naïve B-
cells.  The mantle zone (MnZ) is formed by naive B-cells, which are replaced by 
proliferating B-cells and displaced to the outside of the primary B-cell follicle.   Naive 
antigen-activated B-cells are transferred into primary B-cell follicles in lymph nodes, 
known as GC, where they become proliferating GC B-cells within the dark zone.  A – 
V-region gene recombination in the bone marrow; B – clonal expansion; C – somatic 
hypermutation; D – mutations increasing antigen affinity; E – class switching; F – 
selection; G – differentiation. 
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From  the  unique  morphology  and  the  frequent  identification  of  additional 
chromosomal copies in both the multinucleated RS and the mononucleated H cells, it 
was proposed that these cells may arise from fusion between a B-lymphocyte and a 
dendritic cell.  A study of 5 cases of HL with two known rearranged IgH alleles 
sought to investigate this theory (Kuppers et al 2001).  The majority of B-cells carry 
two  rearranged  IgH  alleles  whereas  IgH  alleles  in  non-B-cells  show  a  germline 
configuration.  The presence of additional IgH alleles in a germline configuration 
would therefore be consistent with a cell fusion between a B-cell and a non-B-cell.  
Single HRS cells were micromanipulated from selected HL cases and amplification 
reactions were performed to identify rearranged alleles in IgH and T-cell receptor   
VDJ and DJ genes.  None of the cases showed evidence of additional IgH or TCR  
alleles to those already identified indicating that HRS cells do not represent fusions of 
B-cells. 
 
1.3.3  The phenotype of HRS cells 
HRS cells have a unique phenotype unrelated to any hematopoietic cell type.  They 
usually express some T-cell markers, dendritic cell markers (eg fascin, thymus and 
activation-regulated chemokine (TARC)), myeloid cell markers (eg CD15), plasma 
cell markers (eg CD138) and some B-cell markers (eg Pax-5).  Other B-cell markers 
(eg CD20, Oct-2) and B-cell receptors are rarely identified on HRS cells.  Hence, the 
revelation that HRS cells originated from B-cells prompted a large gene expression 
study comparing gene expression profiles of HL-derived cell lines and normal B-cells 
(Schwering et al 2003a).  A global downregulation of B-cell specific genes within 
HRS cells was revealed.  It was suggested that the loss of B-cell gene expression 
could result in these cells not being recognised as B-cells and failing, therefore, to be      
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identified for apoptosis, the mechanism within the GC by which defective B-cells are 
normally apoptosed. 
 
1.3.4  Anti-apoptotic mechanisms of the HRS cell 
The mechanisms by which HRS cells escape apoptosis are therefore of interest for 
understanding the pathogenesis of cHL.  The CD95 death receptor pathway, the 
nuclear factor kappa B (NF B) pathway, or Epstein-Barr virus (EBV) infection (see 
Section 1.4) may all protect from apoptosis by the following processes. 
 
1.3.4.1 CD95 death receptor pathway 
Death receptors, members of the tumour necrosis factor receptor (TNFR) superfamily, 
activate intracellular adaptor proteins and thereby start a signalling cascade that can 
result in cell apoptosis (Ricci-Vitiani et al 2000).  CD95 (APO-1, Fas) is the most 
well studied death receptor which is expressed in the B cell lineage at the GC stage of 
differentiation  and  is  directly  involved  in  the  negative  selection  of  B  cells  by 
apoptosis in the GC.  Functional mutations in the CD95 gene may therefore result in 
GC B cells becoming resistant to apoptosis.  This has been shown in CD95-deficient 
lpr mice in which autoreactive B cells escape negative selection (Watanabe-Fukunaga 
et  al  1992).    Clonal  mutations  of  CD95  have  been  detected  in  single 
micromanipulated  HRS  cells  from  two  out  of  ten  cHL  cases,  suggesting  that  the 
survival of these cells may be dependent upon CD95 malfunction (Muschen et al 
2000b).      
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1.3.4.2 The NF B signalling pathway 
NF B  transcription  factors  regulate  apoptosis  and  cytokine  production,  and  are 
associated with cell proliferation, transformation and tumour development (Graham 
and Gibson 2005).  The NF B/RelA family consists of 5 members: p50, p52, p65 
(RelA), c-Rel and RelB, which form various homodimers or heterodimers (Graham 
and  Gibson  2005).    In  normal  cells  NF B  is  maintained  in  the  cytoplasm  in  an 
inactive form bound to I kappa B (I B) (Karin 1999).  In response to a stimulus, the 
I B  kinase  (IKK)  complex  is  activated  and  members  of  the  I B  family  are 
phosphorylated  promoting  their  degradation.    NF B  dissociates  from  I B  and 
translocates to the nucleus where it can activate target genes.  Genes activated by 
NF B are implicated in cell activation, the immune response and cellular resistance to 
apoptosis.   Inducible NF B responses are mediated mainly by the NF B heterodimer 
p50/RelA.   
 
Abundant constitutive NF B p50/RelA activity has been identified in HRS cells from 
7 cHL-derived cell lines, using electrophoretic mobility-shift assays and an anti-RelA 
antibody (Bargou et al 1996).  Sections from NHL cases were included as negative 
controls in these assays.  No RelA could be detected within these samples.  In situ 
immunolabelling of sections from NSHL cases identified a high level of RelA activity 
in RS cells (Bargou et al 1997).  Furthermore, 288 HL biopsies were assessed by 
tumour  microarray  analysis  and  76%  of  these  cases  had  nuclear  expression  of 
p65/RelA (Garcia et al 2003). 
 
There  are  several  possible  mechanisms  of  NF B  activation  in  HL.    HRS  cells 
consistently express the surface receptor CD40, which regulates the NF B activation      
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pathway.    Many  T-cells  in  surrounding  HRS  cells  express  the  CD40  ligand.  
Signalling from CD40 and related molecules is mediated by TNFR-associated factors 
(TRAFs), which perform a central role in NF B activation.  One study reported the 
detection of TRAFs 1, 2 and 3 at mRNA level within single HRS cells that had been 
micromanipulated from 6 HL cases (Messineo et al 1998).  The EBV latent membrane 
protein  1  (LMP1)  mimics  an  activated  CD40  molecule  and,  through  TRAFs,  can 
initiate NF B activation (Devergne et al 1996). 
 
Mutations within the C-terminus of NFKBIA (the I B  gene), resulting in truncated 
proteins,  have  been  identified  in  two  cHL-derived  cell  lines,  KMH2  and  L428 
(Cabannes et al 1999; Emmerich et al 1999; Wood et al 1998).  This region of the 
gene interacts with the RelA subunit of NF B, inhibiting its activity.  A deletion of 
this region would therefore result in a loss of I B  activity and allow constitutive 
NF B activity.  Emmerich et al. (1999) micromanipulated HRS cells from ten lymph 
node biopsies from HL patients and examined exons 2-6 of  I B  (Emmerich et al 
1999).  A point mutation, resulting in a stop codon, was located in the HRS cells of 
one of these cases.  A later study also identified clonal deleterious somatic mutations, 
resulting in truncated I B  proteins, within HRS cells micromanipulated from two of 
three non-EBV-associated HL cases (Jungnickel et al 2000), but not in either of two 
EBV-associated HL cases.  Further investigation suggested that the two mutations 
detected in one of these cases were located on different alleles implying that no full 
length  I B   protein  would  be  synthesised  within  these  HRS  cells.    Nucleotide 
sequence analysis demonstrated that the truncated abnormal I B  proteins would lack 
the region of the ankyrin repeat and/or COOH-terminal proline, glutamate, serine and 
threonine-rich (PEST) domain required for interaction with NF B, thus preventing      
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I B association with NF B within HRS cells.  A more detailed study from our group 
has shown clonal mutations of NFKBIA in 4/20 cases; however, bi-allelic inactivating 
mutations were detected in only one case and the mutation would not have affected 
function (Lake et al., submitted).  All four cases were non-EBV-associated, but the 
majority of non-EBV-associated cases had wild-type NFKBIA genes. 
 
1.4  EPSTEIN-BARR VIRUS  
The  EBV  is  a  ubiquitous  human  gamma-herpesvirus,  that  establishes  a  persistent 
infection  (Henle  and  Henle  1966).    It  is  found  in  all  human  communities  as  a 
predominantly  asymptomatic  infection.    Primary  infection  usually  occurs  in  early 
childhood following oral transmission of the virus.  Late infection during adolescence 
is a frequent occurrence in developed countries and in approximately 25-70% of such 
cases this results in IM (McAulay et al 2007). 
 
The virus was first isolated from a Burkitt’s lymphoma specimen (Henle and Henle 
1966), and it is estimated that  approximately 96% of these tumours contain EBV 
(Magrath  1990).    EBV  has  also  been  associated  with  post-transplant 
lymphoproliferative  disorders  (Young  et  al  1989),  some  T-cell  lymphomas,  all 
nasopharyngeal  carcinomas  (Klein  et  al  1974),  a  small  proportion  (approximately 
10%) of stomach cancers (Leoncini et al 1993) and a subset of HL cases (Levine et al 
1971).  
 
The EBV genome is a double-stranded DNA molecule (172kb), which encodes for 
more than 80 genes (Rickinson and Kieff 2001).  In the virion, prior to infection, EBV 
DNA is an encapsidated linear molecule with cohesive tandem repeat sequence sites 
at each terminus.  Upon infection of a host cell, these termini fuse to form covalently      
  16 
 
 
closed circular episomes within the host cell nucleus.  Each circularisation event 
generates different sized terminal repeat regions which represent a constant clonal 
marker for the virus and, therefore, for the infected cell (Rickinson and Kieff 2001).  
It is these terminal repeat fragments upon which the study of clonality in EBV-
associated diseases is based. 
 
1.4.1  Lytic and latent infection of EBV 
EBV infection can be either lytic or latent.  Lytic infection involves the production of 
viral particles and ultimately results in death of the host cell.  In latent infection only a 
restricted group of latent genes is expressed and there is no production of infectious 
virus. The switch from latency to lytic infection is tightly controlled by the BZLF1 
trans-activator protein (the BamHI fragment Z Epstein-Barr replication activator or 
ZEBRA) (Countryman et al 1987). This protein initiates the transcription of a set of 
genes essential for the production of new virus particles.  A particular characteristic of 
latent infection is the expression of two highly abundant, non-polyadenylated small 
EBV-encoded transcripts (EBER1 and EBER2) present at a level of 10
5-10
7 copies 
per cell. 
 
Three patterns of viral and cellular gene expression have been described in latent EBV 
infection of B-cells: latency I, II and III (Rowe et al 1992).  The set of EBV-encoded 
proteins determining these patterns include three membrane proteins (LMP1, 2A and 
2B) and six nuclear proteins (EBV-determined nuclear antigen (EBNA) 1, 2, 3a, 3b, 
3c and LP).  Burkitt’s lymphomas and some Burkitt’s lymphoma cell lines display the 
latency  I  pattern  where  only  EBV-encoded  EBNA-1  and  EBERs  are  expressed.  
Latency II is characterised by a larger display of EBV gene expression consisting of      
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EBNA-1,  LMP1,  LMP2A,  LMP2B  and  EBERs.    This  group  of  genes  has  been 
detected in nasopharyngeal carcinoma, some peripheral T-cell lymphomas and HL.  
The  expression  of  the  full  set  of  nuclear  (EBNA  1,  2,  3a,  3b,  3c  and  LP)  and 
membrane (LMP1, 2A and 2B) proteins, along with EBERs, characterises the latency 
III  pattern  found  in  lymphomas  of  immunocompromised  patients  and  EBV-
transformed lymphoblastoid cell lines (LCLs).  A consistent  characteristic cellular 
phenotype is also observed for latency III with a high expression of the cell activation 
markers CD23, CD30, CD39 and CD70.  The cellular adhesion molecules leukocyte-
function-associated  molecule  1  (LFA-1)  and  intercellular  adhesion  molecule  1 
(ICAM-1) are usually absent or expressed at low levels on resting B cells, but are 
expressed at high levels during latency III EBV infection. 
 
An  understanding  of  the  function  of  latent  proteins  is  key  to  understanding  the 
pathogenesis  of  EBV-associated  tumours.    The  DNA  binding  protein  EBNA1  is 
required for the maintenance and replication of the episomal EBV genome, and also 
negatively regulates its own expression (Nonkwelo et al 1996).  It has been suggested 
that  EBNA1  may  play  a  direct  role  in  oncogenesis  after  transgenic  mice  studies 
showed that B cell lymphomas develop when EBNA expression is directed to B cells 
in  transgenic  mice  (Wilson  et  al  1996).    EBNA2  plays  an  essential  role  in  the 
transformation of B cells.  It activates both cellular and viral genes, including LMP1 
and LMP2.  Of the EBNA3 proteins, EBNA3A and EBNA3C are required for B cell 
transformation in vivo, but EBNA3B is not essential.  EBNA3B has been shown to 
induce the expression of vimentin and CD40 (Silins and Sculley 1994) and EBNA3C 
to  induce  the  upregulation  of  cellular  (e.g.  CD21)  and  viral  (i.e.  LMP1)  gene      
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expression (Allday and Farrell 1994).  EBNA-LP is required for the efficient growth 
of LCLs, but is not essential for B cell transformation (Allan et al 1992). 
 
LMP1  is  essential  for  EBV-dependent  B-cell  transformation  in  vitro  (Kaye  et  al 
1993).  When expressed in cells, LMP1 has pleiotropic effects including induction of 
cell-surface  adhesion  molecules  and  B-cell  activation  antigens  (eg  CD23),  and 
upregulation  of  anti-apoptotic  proteins  (eg  BCL2)  (Wang  et  al  1990).    LMP1  is 
implicated in both the NF B and JAK/STAT signalling pathways (Gires et al 1999; 
Huen et al 1995).  In addition, LMP1 functionally mimics CD40, and can partially 
substitute for CD40 in vivo, providing growth and differentiation signals to B-cells 
(Uchida et al 1999). 
 
LMP2A  aggregates  within  the  plasma  membrane  of  latently-infected  B-cells 
(Longnecker and Kieff 1990).  In transgenic mice with B cell lineage expression of 
LMP2A, normal  B-cell  development  was  blocked, resulting in  Ig-negative B-cells 
lacking in B-cell receptor (BCR) expression colonising the peripheral lymph organs 
(Caldwell et al 1998).  B-cell precursors that are lacking in functional Ig receptors are 
usually eliminated by apoptosis in the bone marrow (Rajewsky 1996).  These results, 
therefore, suggested that LMP2A can mimic the BCR and activate proliferation and 
survival of B-cells in the absence of signalling through the BCR (Caldwell et al 1998; 
Schaadt et al 2005).  Immunohistochemical studies have detected LMP2A in 52% of 
EBV-associated HL cases, but not in non-EBV-associated HL cases (Niedobitek et al 
1997).    Furthermore,  gene  expression  studies  demonstrated  that  LMP2A-induced 
alterations  in  gene  expression  profiles  of  LMP2A  transgenic  mice  and  LMP2A-
expressing B-cell lines are similar to those reported in HRS cells (Portis et al 2003).       
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The presence of LMP2A in HRS cells has suggested that LMP2A is directly involved 
in  the  mechanism  by  which  these  cells  escape  apoptosis,  despite  their  lack  of  a 
functional BCR (Portis et al 2004). 
 
Since LMP1 and LMP2A have been shown to mimic CD40 and BCR, respectively, it 
was  proposed  that  EBV  infection  could  provide  a  survival  mechanism  for  pro-
apoptotic GC B-cells containing a non-functional BCR or lacking BCR expression 
(Mancao  et  al  2005).    BCR-negative  GC  B-cells  were  isolated  and  successfully 
infected with EBV and immortalised, indicating that EBV is able to rescue these cells 
from apoptosis (Mancao et al 2005). 
  
1.4.2  EBV and HL 
An association between EBV and HL was first reported from seroepidemiological 
studies  conducted  in  the  early  1970s  (Levine  et  al  1971)  although  the  direct 
involvement  of  an  infectious  agent  in  HL  had  been  proposed  earlier  (MacMahon 
1966).    Elevated  antibody  titres  to  EBV  early  antigens,  viral  capsid  antigens  and 
nuclear antigens were observed in HL cases compared with control cases (Levine et al 
1971).  An increased risk of HL was documented in patients with a past history of IM, 
known  to  be  a  result  of  late  primary  EBV  infection  (Munoz  et  al  1978).    An 
interesting  case  was  subsequently  reported  where  EBNA-positive  B  immunoblasts 
were  detected  in  a  patient  initially  diagnosed  with  infectious  mononucleosis 
(Poppema et al 1985).  After 6 months, the patient developed MCHL with EBNA-
positive HRS cells.  This was the first publication to show positive EBNA-staining 
within the nuclei of HRS cells. 
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Early molecular assays failed to detect EBV genomes in HL due to the low levels of 
HRS cell within the total tumour population and the insensitivity of the assays at this 
time (Lindahl et al 1974).  It wasn’t until the late 1980s that EBV genomes were 
shown to be present within HL biopsy samples.   In a number of small case studies 
EBV genomes were detected in 17-41% of HL biopsies (Boiocchi et al 1989; Gledhill 
et al 1991; Staal et al 1989; Weiss and Movahed 1989).  In many of these studies 
EBV  infection  was  shown  to  be  clonal,  which  indicated  that  the  infected  cell 
population had been derived from a single EBV-infected cell. 
 
At the time these results invoked some scepticism and it was suggested that these 
assays were detecting latent EBV within B cells of the reactive component, and not 
within HRS cells.  It was important therefore to determine the cellular localisation of 
the EBV.  This was initially achieved using immunohistochemistry (IHC) with both 
acetone-fixed  cryostat  sections  and  paraffin  sections,  and  monoclonal  antibodies 
directed against LMP1 and EBNA2 (Pallesen et al 1991).  In 40 out of 84 HL cases all 
HRS cells positively stained for LMP1, but were negative for EBNA2.  In this study, 
LMP1  expression  in  HRS  cells  was  found  to  correlate  strongly  with  the  HL 
histological subtype with 96% of MCHL cases, 32% of NSHL cases and 10% of 
LPHL cases harbouring positively stained HRS cells.  These results indicated that HL 
cases have a different latent infection protein phenotype from other EBV-associated 
lymphomas and LMP expression is HL subtype specific.  As mentioned earlier (see 
Section 1.4.1), EBERs are expressed at high levels (10
5-10
7 copies per viral genome) 
in all cells latently infected with EBV.  Probes hybridising with these RNAs have 
been  developed  for  use  with  paraffin-embedded  tissue  (Wu  et  al  1990)  and  EBV 
EBER in situ hybridisation is a highly sensitive tool for detecting EBV infection in      
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HL.    Using  EBER  in  situ  hybridisation,  the  presence  of  EBV  genomes  has  been 
demonstrated within HRS cells in 33% of cHL cases (Jarrett 2002).  PCR can also be 
used to screen for the presence of EBV genomes, but does not permit the cellular 
localisation  of  the  genomes,  unless  coupled  with  either  flow  cytometry  or  laser 
microdissection, and therefore is less useful.    
 
In order to determine which EBV latency type is associated with HRS cells, reverse 
transcriptase PCR (RT-PCR) was conducted on HL biopsies and subsequently RNA 
expression  of  LMP1,  LMP2A,  LMP2B  and  EBNA1  was  observed  (Deacon  et  al 
1993).  This latency II pattern of expression of EBV genes is a consistent feature of 
HL.  The expression of the transactivator protein BZLF1, which controls the switch 
from latent to lytic infection, was reported within some HL biopsies examined using 
in situ hybridisation and IHC (Brousset et al 1993; Pallesen et al 1991).  In these two 
series  the  BZLF1  protein  was  expressed  in  6%  (Pallesen  et  al  1991)  and  16.7% 
(Brousset et al 1993) of the EBV-associated HL cases, and was detected in only some 
of the HRS cells in these cases.  This suggests that lytic infection of HRS cells is a 
rare event. 
 
1.4.3  Epidemiology of HL 
HL accounts for less than 1% of cancers in the U.K. (Cancer Research UK: Hodgkin 
Lymphoma incidence statistics 2007).  The incidence of HL in the U.K. population is 
2.4 cases per 100,000 and 3 cases per 100,000 in the U.S.A (Glaser 1987; McKinney 
et al 1989).  HL is one of the most common forms of malignancy amongst young 
people and has an unusual age distribution.   A bimodal age incidence curve has been 
reported  by  the  majority  of  studies,  but  the  shape  of  the  curve  varies  across      
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geographical  locations  (MacMahon  1966).    This  led  to  the  identification  of  three 
epidemiological patterns of HL: type I is found in developing countries, type III is 
specific to developed countries, and type II represents a transition from type I to III 
seen in rural areas of developed countries and associated with an improvement in 
living conditions (Merk et al 1990).  In type I the first peak occurs in childhood, with 
low incidence in those aged 30-39, and the second peak is in older individuals.  Type 
III is defined by low childhood rates, a peak in young adults and a second peak in 
older adults. 
 
Epidemiological  studies  have  consistently  provided  evidence  suggesting  that  the 
development  of  HL  is  dependent  upon  a  combination  of  environmental  and  host 
factors.    A  high  socioeconomic  status  during  childhood  is  related  to  the  risk  of 
developing HL in young adulthood (Alexander et al 1991; Glaser 1987; Gutensohn 
and Cole 1981).  The incidence of young adult HL cases (aged between 15 and 39 
years old) in the USA was reported to be on the increase in 1990 (Glaser and Swartz 
1990).  An epidemiological study in the USA found a significant association of the 
risk of developing HL with pre-school attendance (Chang et al 2004).  Young adults 
who had attended nursery school were found to have a decreased risk of developing 
HL, and it was suggested that childhood exposure to common infections aided the 
maturation of cellular immunity in these individuals.  Another USA study of 325 HL 
cases was unable to find a link between social status and the onset of older adult HL 
(Gutensohn 1982).  The results of this epidemiological study suggested that other 
factors are involved in the aetiology of older adult cases. 
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Within young adult HL there is no sex bias, but male cases predominate in childhood 
and the older adults age group (Glaser and Swartz 1990; Jarrett et al 2003; McKinney 
et al 1989). 
 
 
1.4.4  Epidemiology of EBV and HL 
In  situ  hybridisation  and  immunohistochemistical  studies  in  Western  Europe  and 
North America provide evidence for EBV infection of HRS cells in 26-50% of HL 
cases (Herbst et al 1992; Jarrett et al 1996; Poppema and Visser 1994). These cases 
display latency II pattern of EBV gene expression.  The presence of EBV infection in 
HL cases is associated with a number of factors i.e. histological subtype, sex, age, 
geographical location and ethnicity.  In the UK, over 60% of MCHL cases are EBV-
associated compared to approximately 25% of NSHL cases (Jarrett et al 2003).  Only 
2.4%  of  NLPHL  and  1.8%  of  LDHL  cases  are  EBV-associated.    From  a  large 
epidemiological study of 622 HL cases in Scotland and northern England, researchers 
were able to examine both the age- and sex-specific incidence of EBV-associated and 
non-EBV-associated HL cases analysed separately (Jarrett et al 2003).  Among cHL 
cases, one third were identified as EBV-associated.  EBV-associated and non-EBV-
associated cases showed distinct age-specific incidence curves.  The majority (66%) 
of EBV-associated HL cases in this study were male.  The incidence of early age of 
infection is higher in developing countries, which is most likely to be due to poor 
socioeconomic  conditions  resulting  in  malnutrition-induced  immunological 
impairment (Weinreb et al 1996).  In two studies EBV latent gene products were 
detected in the HRS cells of 40-46% of Hispanic and Asian (predominantly Chinese) 
HL biopsies using LMP1 IHC and/or  EBERs in situ hybridisation (Glaser et al 1997; 
Gulley  et  al  1994).    In  both  studies  more  MCHL  than  NSHL  cases  were  EBV-     
  24 
 
 
associated and age was reported to be a confounding factor with older HL patients 
more likely to be EBV-associated. 
 
Combining the results of epidemiological studies examining both the incidence of HL 
and risk factors for HL development, a new model of HL status has been proposed – 
the 4 disease model (Jarrett 2002) (see Figure 1.2; Table 1.2).  This model outlines a 
single group of non-EBV-associated cases and three groups of EBV-associated HL 
that are characterised by  their age  at  diagnosis:  childhood (below the age of 10); 
young adults (aged 15-34) and older adults (>50 years).  The majority of those cases 
diagnosed within childhood and older adults are male.  In developed countries only, 
the  largest  group  in  the  four  disease  model  accounts  for  non-EBV-associated  HL 
cases in  young adults.  The majority of this group are NSHL and both sexes are 
equally affected. 
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Table 1.2: The four disease model of cHL (Jarrett 2002) 
Disease  Age range  Histological subtype  Male:female ratio  Epidemiological features 
EBV-associated cHL of childhood  <10 years  MCHL=NSHL  Males > females   More common in developed countries 
            Most probably related to young age of infection, high infectious dose, decreased immunity 
            Associated with material deprivation and independently with Asian ethnicity in UK (Flavell et al 1999) 
Young adult EBV-associated cHL  15-24 years  Predominantly MCHL  Equal  Occurs following IM 
            More common in developed countries 
Older adult EBV-associated cHL   ≥50 years   MCHL=NSHL  Males > females   Includes all adult cases of cHL occurring in context of immunosuppression 
            Probably related to reactivation of EBV 
            Poorer clinical outcome than non-EBV-associated age-matched cases 
            Often associated with other malignancies 
Non-EBV-associated cHL   15-24 years  Predominantly NSHL  Equal  Characteristic of developed countries 
            Associated decreased pre-school attendance 
            Associated decreased exposure to childhood pathogens 
cHL, classical Hodgkin lymphoma; EBV, Epstein-Barr virus; IM, infectious mononucleosis; MCHL, mixed cellularity Hodgkin lymphoma; 
NSHL, nodular sclerosis Hodgkin lymphoma  
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Figure 1.2. The four disease model of HL (Jarrett 2002).  The red, green and orange 
lines represent the three groups of EBV-associated HL cases and non-EBV-associated 
HL cases are indicated by the yellow line.  The height magnitudes of the various 
curves will vary in different geographical locales, and be influenced by genetic and 
environmental factors. 
 
Two  independent  studies  investigated  the  association  between  EBV-associated  IM 
and  risk  of  developing  HL  (Alexander  et  al  2003;  Hjalgrim  et  al  2003).    An 
epidemiological study of 408 cHL cases from Scotland and Newcastle (Alexander et 
al 2003) noted a significant increase of EBV-associated HL in young adults who had 
either IM or who have a blood relative with a history of IM.  This was also reported 
by a Scandinavian study in which patients with previous IM were found to be at a 
significantly increased risk of developing EBV-associated HL (Hjalgrim et al 2003).  
Although these studies provide compelling evidence for an association between IM 
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and development of EBV-associated HL, two American groups (Glaser et al 2005; 
Sleckman et al 1998) have failed to confirm these findings. 
 
1.4.5  Non-EBV-associated HL cases 
Approximately 82% of young adult cHL cases in European countries are non-EBV-
associated  (Alexander  et  al  2001).      The  risk  of  developing  young  adult  cHL  is 
associated with a high social class background, small family size, high standard of 
education  and  early  birth  order  position  in  childhood  (Gutensohn  1982).      These 
factors  may  diminish  an  individual’s  exposure  to  infectious  agents  and  thereby 
increase their susceptibility to developing a virus-induced pathogenesis later in life.  It 
has  been  suggested  that  such  an  infection  later  in  life  could  account  for  the 
development  of  HL  in  non-EBV-associated  cases.    The  identity  of  such  an  agent 
remains unknown, but a candidate virus is likely to be a common virus that can infect 
most people.  
 
The inability to detect EBV in some HL cases could be explained by a failure to 
detect low copy number viral genomes, but this is unlikely given the high sensitivity 
of the standard screening techniques.  It is possible that EBV never infected HRS cells 
in non-EBV-associated HL cases; or alternatively these cells may have been infected 
with EBV, but viral genomes were lost after the initial infection, the so-called ‘hit and 
run’ mechanism (Ambinder 2000).  It is also possible that some fragments of the EBV 
genome remain integrated into the host cellular DNA.  This has been demonstrated in 
EBV-associated Burkitt’s lymphoma (Razzouk et al. 1996).  In non-EBV-associated 
HL cases, however, fluorescence in situ hybridisation (FISH) using cosmid clones 
spanning the genome failed to detect deleted viral genomes integrated into host cell      
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DNA  (Staratschek-Jox  et  al  2000).    The  results  of  a  combined  serological  and 
molecular investigation of biopsies from 30 young adult cHL cases with confirmed 
non-EBV-association provided further evidence to disprove the hit and run theory 
(Gallagher et al. 2003).  These cases were screened with 7 highly sensitive real-time 
(QRT) PCR assays specific for the EBV genome.  Viral fragments were detected in 
equimolar amounts in the cHL cases, but there was no evidence of defective EBV 
genomes.    Rearranged  EBV  genomes  have  been  detected  in  31%  of  32  EBV-
associated and 33% of 24 non-EBV-associated paediatric HL tumours  (Gan et al. 
2002).  Such defective EBV genomes may disrupt gene regulation and, therefore, 
account for the loss of EBV from individual HRS cells.  However, Gallagher et al. 
(2003) did not detect EBV genome rearrangements in adult cHL samples using either 
conventional or quantitative real-time PCR (QRT-PCR) (Gallagher et al 2003). 
 
A  number  of  serological  and  molecular  studies  have  investigated  the  possible 
association of HL with variella zoster virus, herpes simplex virus, parainfluenza virus, 
human herpesvirus (HHV-8), JCV, BKV, cytomegalovirus (CMV), simian virus 40 
(SV40), lymphotropic papovavirus (LPV), human T-cell leukaemia virus types 1 and 
2  (HTLV-1  and  2)  and  adenoviruses  type  5  and  type  12  (Armstrong  et  al  1998; 
Berneman et al 1998; Evans and Gutensohn 1984; Gallagher et al 2002; MacKenzie et 
al 2003).  Other than the association between non-EBV-association and high human 
herpesvirus 6 antibody titres, none of these viruses has been associated with HL. 
 
A recent publication suggested a possible association of measles virus (MV) with cHL 
in Israel (Benharroch et al. 2003).  MV genomes were identified in 60.3% of 68 cHL 
cases tested by IHC and RT-PCR.  This study was later extended to include 143 HL      
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patients and MV antigens were identified in 73.4% of samples  (Benharroch et al. 
2004). This prompted us to test a group of UK cHL cases for any association with 
MV.  IHC was used to screen 97 cHL cases for the MV antigen, and both IHC and 
RT-PCR were used to test a second series of 20 cHL cases.  This study is discussed in 
chapter 3 of this thesis. 
 
We also investigated the possibility of an association of cHL with polyomaviruses 
using QRT-PCR and a set of degenerate PCR assays with the potential to detect the 
large T antigen of novel polyomaviruses.  Chapter 4 contains details of the assays 
performed and the results we obtained. 
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1.5  CLASSICAL CYTOGENETICS 
Cytogenetics  is  defined  as  the  study  of  structure,  function  and  evolution  of 
chromosomes.  Heinrich von Waldeyer-Hartz first used the term ‘chromosome’ in 
1888 (Waldeyer 1890; Waldheyer 1888), but the concept of the human chromosome 
had been proposed earlier in 1882 by Walther Flemming (Flemming 1882). 
 
Due to technical limitations, cytogenetics did not advance much further until 1952 
when the discovery of ‘hypotonic shock’, caused by submerging cells in a hypotonic 
salt solution before fixation, enabled the production of a good chromosome spread on 
slides (Hsu 1952).  Four years later it was discovered that adding colchicines to cell 
cultures destroys the mitotic spindle and halts the cell growth cycle in metaphase 
(Ford and Hamerton 1956a; Ford and Hamerton 1956b).  This enabled the production 
of the perfect metaphase chromosome spread on slides and it was therefore possible to 
determine that the number of chromosomes in a human cell is 46 (Tijo and Levan 
1956).  These chromosomes can be arranged into 8 different groups (A-G plus the sex 
chromosomes) according to their size and the location of the primary constriction, or 
centromere.  
 
1.5.1  Chromosome banding techniques 
A  more  precise  identification  of  the  unique  structure  and  sub-regions  of  each 
chromosome  was  achieved  using  a  number  of  chromosome  banding  techniques 
developed  in  the  1970s.    Several  banding  techniques  were  introduced  including 
staining with quinacrine (Q-banding) (Caspersson et al 1968; Caspersson et al 1970), 
or following various pre-treatments with Giemsa stain (G-banding) (Seabright, 1972) 
or acridine orange (Reverse or R-banding) (Caspersson et al 1968; Caspersson et al      
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1970; Verma and Lubs 1975).  The development of these banding techniques resulted 
in the detection of acquired and inherited chromosomal changes (i.e. translocations, 
insertions, inversions, deletions and duplications) within a number of diseases. 
 
The resolution of chromosome banding was limited at approximately 500 bands per 
haploid  genome  until  the  development  of  high-resolution  banding  in  1975,  which 
increased resolution to >1000 bands per haploid genome (Yunis and Sanchez 1975).  
Yunis and Sanchez (1975) synchronized lymphocyte cultures, which resulted in an 
increased  number  of  cells  arresting  their  cycle  at  the  pro-metaphase  or  prophase 
stages  instead  of  at  metaphase.    The  chromosomes  were  much  longer  and 
consequently the bands and sub-bands appeared separated and were easier to identify. 
 
Classical cytogenetic methods have played a significant role in the identification of 
distinct  subsets  and  specific  molecular  pathways  involved  in  human  lymphomas.  
Their application to the study of solid tumours, and HL in particular, has been limited 
however  by  the  scarcity  of  biopsy  material  and  the  low  number  of  high  quality 
metaphase  spreads  available.    These  problems  have  been  addressed  during  the 
development of molecular cytogenetic techniques. 
 
1.5.2  Classical cytogenetics and HL 
As just mentioned, karyotype analysis of HL using classical cytogenetics has been 
limited.  However recurrent breakpoints and translocations have been identified in HL 
cases  using  classical  cytogenetic techniques  (Dohner et  al  1992;  Tilly et  al  1991; 
Schlegelberger et al 1994; Falzetti et al 1999).  Imbalances were identified within all 
chromsomes  in  59%  of  HL  patients  analysed  in  one  study,  although  losses  in 
chromosomes 13 and Y occurred more frequently (Tilly et al 1991).  A later study      
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analysed metaphase cells from 25 HL patients identified gains in chromosomes 2, 9, 
11, 19 and 20, losses in chromosomes 10, 13, 15, 16, 21 and Y, and translocations 
involving 1p11-1p13, 1p36, 4q35, 14q11 and 15p11 (Dohner et al 1992). In addition, 
Dohner et al. (1992) observed recurrent losses on 1q, 4q, 6q and 17p and proposed 
that these losses of chromosomal material may be involved in the pathogenesis of HL. 
 
Classical cytogenetic analysis of HL cases, therefore, introduced the hypothesis that 
recurrent chromosomal imbalances are present within these tumours and may play an 
important role in the pathogenesis of this disease. 
  
1.6  MOLECULAR CYTOGENETICS 
1.6.1  In situ hybridisation 
The  resolution  of  chromosomes  was  improved  by  the  development  of  in  situ 
hybridisation (ISH).  This molecular technique is based upon the same principle as 
Southern  blot  analysis.    In  place  of  a  membrane,  the  target  DNA  of  metaphase 
chromosomes, interphase cells or tissue sections is bound to a glass microscope slide 
and either radioactive-labelled DNA probes (radioactive in situ hybridisation) (Gall 
and  Pardue  1969)  or  non-isotopic  DNA  probes  (i.e.  immunofluorescent,  biotin  or 
digoxigenin) are hybridised to this target DNA.  Biotin- or digoxigenin-labelled DNA 
can  be  detected  by  immunocytochemical  methods  using  peroxidase  or  alkaline 
phosphatase  enzymes  (Garson  et  al  1987),  and  visualised  under  a  brightfield  or 
reflection-contrast microscope.  ISH provides a resolution of 50kb-2Mb. 
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1.6.2  Fluorescence in situ hybridisation  
The application of ISH for routine screening came about with the development of 
fluorescence ISH (FISH).  This molecular cytogenetic technique uses the conjugation 
of different fluorochromes (i.e. fluorescein-isothiocyanate, rhodamine or Texas Red) 
to a DNA probe.  This is referred to as ‘direct labelling’.  Alternatively, ‘indirect 
labelling’ uses either immunological (i.e. anti-digoxigenin antibodies) or enzymatic 
(i.e. avidin to detect biotin-labelled sequence) detection of target DNA which have 
been incorporated into the DNA probe (Langer-Safer et al 1982).  Human Cot-1 DNA 
is introduced to the denatured probe prior to hybridisation in order to bind repetitive 
DNA sequences and thereby prevent non-specific binding.  The minimum size limit of 
a probe for reliable detection on metaphase chromosomes is  approximately 3-5kb.  
Thousands of different probes are now available across the genome so it is possible to 
specifically stain particular parts of a chromosome or the whole chromosome in a 
resolution range of 5kb-500kb. 
 
Probes  can  also  be  used  in  combination  in  a  single  hybridisation,  allowing  the 
simultaneous visualisation of all 23 human chromosome pairs with each fluorescing a 
different colour.  This approach is used in multiplex-FISH (M-FISH) (Speicher et al 
1996), spectral karyotyping (SKY) (Schrock et al 1997) and combined binary ratio 
labelling  (COBRA)  (Tanke  et  al  1999).    Increasing  the  number  of  fluorochrome-
labelled probes used improves the otherwise relatively low resolution (3Mb) of these 
multicolour techniques. 
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In addition to the advances that have been made in cytogenetic technology, 
considerable progress has been made in the development of both the hardware and 
software with which FISH images are analysed. 
 
1.6.3  FICTION analysis 
In immunocytochemical studies of cases with a low percentage of tumour cells, such 
as  HL  cases,  the  limited  number  and  banding  quality  of  analysable  mitoses  is  a 
problem.  In order to overcome this, a method has been developed which allows FISH 
and  IHC  to  be performed on the same preparation.  This  has  been referred to  as 
‘fluorescence  immunophenotyping  and  interphase  cytogenetics  as  a  tool  for  the 
investigation  of  neoplasms’  (FICTION)  (Weber-Matthiesen  et  al.  1992).    The 
genotypic and phenotypic features of a tumour cell are correlated whilst attempting to 
retain  cell  morphology.    This  technique  has  successfully  been  used  on  cytospin 
preparations, cryostat sections and bone marrow smears.  The results of FICTION 
analysis  of  30  cytogenetically  analysed  cHL  cases  have  been  published  (Weber-
Matthiesen et al. 1995).  CD30+ HRS cells were isolated from cytospin preparations 
and a variety of numerical chromosomal aberrations were observed in the majority of 
these cells.  In particular, gains of chromosomes X, Y, 1, 8, 12, 15 and 17 were 
observed.  More recently, FICTION analysis of 12 cHL cases detected a gain of the 
chromosomal  region  2p13-16,  which  includes  the  c-Rel  gene  (Barth  et  al.  2003).  
FICTION  has  also  been  used  to  demonstrate  the  presence  of  both  mantle  cell 
lymphoma (MCL) and HL in the same patient (Martinez-Ramirez et al. 2004). 
 
The methodology has been further developed with the introduction of multicolour 
FICTION  (M-FICTION),  which  allows  the  simultaneous  analysis  of  multiple      
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chromosomal aberrations in a single experiment (Martin-Subero et al. 2002).  Two 
assays, using multiple differentially-labelled probes, were established to demonstrate 
the use of M-FICTION in B-cell NHL and in anaplastic large-cell lymphomas.  For 
each assay, antigens were investigated using a combination of up to five FISH probes, 
to  detect  what  were  considered  the  most  important  diagnostic  chromosomal 
aberrations within these tumours. 
 
In order to analyse a sample using FISH or FICTION, details of the target sequence 
must be known in order to select a suitable probe.  An alternative method which 
requires no prior knowledge of likely genetic aberrations has now been established: 
comparative genomic hybridisation (CGH). 
 
1.6.4  Comparative Genomic Hybridisation 
CGH was developed as a method of screening the whole genome for loss or gain of 
chromosomal material in a single hybridisation, without the need for the sample to be 
mitotically active, and without knowing anything about the genetic makeup of the 
sample (Kallioniemi et al 1992).  The chromosomal origin of these gains and losses of 
genetic  material  can  be  identified  and  mapped  to  specific  chromosome  bands.   
Conventional CGH was introduced in 1992  as a method of chromosomal analysis 
obviating the need for obtaining metaphase spreads from tumour samples, a limiting 
factor  for  solid  tumours  as  mentioned  earlier  (Kallioniemi  et  al.  1992).    This 
molecular cytogenetics technique is based upon quantitative two-colour FISH and can 
detect and map the relative DNA copy number between genomes with a resolution in 
the range of 2-10 Mb.   Test (tumour) and reference genomic DNA are differentially 
labelled using, respectively,  biotin and digoxigenin conjugated to dUTP (see Figure      
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1.3).    The  samples  are  combined  and  hybridised  to  normal  human  reference 
metaphase chromosomes.  Two different fluorochromes, red-fluorescing rhodamine 
antidigoxigenin and green-fluorescing fluorescein isothiocyanate (FITC)-avidin, are 
used  to  detect  the  test  and  reference  DNA  respectively  and  the  relative  colour 
intensities of these fluorochromes indicate DNA copy number alterations within the 
tumour  genome.    Direct  labelling,  using  nick  translation,  of  test  and  reference 
genomic DNA was introduced by the same research group several years later and is 
now the recognised method of fluorescence labelling for CGH  (Kallioniemi et al. 
1994).       
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Figure 1.3. Schematic outline of CGH using arrays and metaphase spreads (adapted 
from  Mantripragada  et  al.  2004).    Reference  and  test  DNA  are  labelled  with  a 
fluorescent dye, then hybridised to either metaphase chromosomes on a glass slide or 
an array of genomic DNA samples spotted onto a glass slide.  The fluorescence of the 
two dyes can either be visualised under the microscope, as in conventional CGH, or is 
detected and analysed using specialised software packages, as in array-CGH.  For 
conventional  CGH, results  are depicted schematically, with  gains  (red) and losses 
(green) indicated adjacent to the chromosomal region in which they are located.  For 
array-CGH, the fluorescence intensity of each dye for each genomic DNA spot is 
combined  as  a  ratio  and  plotted  in  a  chart  against  chromosome  location.    Ratio 
thresholds are selected so that gains and losses can be identified.  For example, a gain 
of chromosomal material is indicated when a point on the chart has a ratio >1.15 and a 
loss is indicated by a ratio of <0.85. 
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In the first CGH paper (Kallioniemi et al. 1992) the authors investigated 11 cancer 
cell lines using CGH and identified 16 previously undetected gains of chromosomal 
material.  They suggested that CGH could be used to detect chromosomal imbalances 
within DNA extracted from solid tumours and that this may result in the identification 
of recessive mutant tumour suppressor genes.  Following this several different studies 
were published where CGH was used to analyse breast, bladder and ovarian cancer 
cell lines (Gay et al. 1994; Iwabuchi et al. 1995; Kallioniemi et al. 1995) and this has 
now become an established technique.   
 
1.6.4.1 Investigation of lymphomas using CGH 
The first publication to report the use of CGH to identify chromosomal aberrations in 
lymphomas  investigated  DNA  extracted  from  24  primary  mediastinal  B-cell 
lymphoma patients (Joos et al. 1996).  A subset of these cases was also examined 
using Southern blot analysis and FISH.  A common pattern of chromosomal gains on 
2p, 9p and Xq, and losses on 12q was observed in several of these cases.  The authors 
proposed  REL  as  a  candidate  gene  involved  in  the  tumourigenesis  of  primary 
mediastinal B-cell lymphoma due to its location on chromosome 2, within the region 
of chromosomal gain.  These results also confirmed the gain on chromosome 9 that 
had been reported earlier in a cytogenetic study of NHL cases (Offit et al. 1989).  In a 
later study, 29 T-cell NHL cases were screened with CGH to identify chromosomal 
changes (Renedo et al. 2001).  Chromosome gains of Xq were identified once more, 
along with gains of chromosomal material on 9q34 and on chromosomes 17, 19 and 
20. 
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CGH has been used to distinguish between different orbital NHL cases (Matteucci et 
al.  2003).    These  lymphomas  constitute  approximately  8%  of  all  extranodal 
lymphomas,  and  the  majority  are  histologically  derived  from  mucosa-associated 
lymphoid  tissue  (MALT).    FISH  had  been  used  in  previous  studies,  but  limited 
amounts  of  biopsy  material  and  limited  knowledge  of  suitable  probes  prevented 
analysis of these cases by this technique.  These limitations were resolved by the use 
of conventional CGH, which enabled the detection of chromosomal duplications in 
3q24-qter and 6p21.1-21.3; these are typical of marginal zone lymphomas and an 
orbital location respectively.  Chromosomal loss was detected in 1q, 6q, 9q, 11q and 
13q. 
 
1.6.4.2 Limitations of CGH 
Conventional CGH using metaphase spreads has limited resolution.  In the detection 
and mapping of DNA sequence copy number, gains and losses larger than 10-20 Mb 
were identified within the tumour genome (Isola et al. 1994).  A resolution of 40Mb 
was achieved when DNA amplified from a single cell was hybridised to metaphase 
chromosomes (Voullaire et al. 1999).  CGH is also limited to the detection of gains or 
losses of chromosomal material and point mutations, small intragenic rearrangments, 
balanced  translocations  and  inversions  are  all  undetectable  using  this  method.  
Furthermore, imbalances must be present within all cells to ensure detection.  It has 
also been noted that there is a decrease in the red and green fluorescence intensity at 
the  chromosome  telomeres,  which  can  result  in  difficulties  with  interpretation 
(Mantripragada et al. 2004). 
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Recurrent copy number variations or inversions have been identified within regions of 
the genome in healthy humans (Iafrate et al 2004).  The details of known structural 
variants  can  be  found  within  the  Database  of  Genomic  Variants 
(http://projects.tcag.ca/variation/), which is constantly updated (Zhang et al 2006). It 
is important that any chromosomal region of imbalance detected in a tumour sample is 
checked against this database representing the normal human genome. 
 
1.6.5  Whole genome amplification 
Obtaining sufficient quantity of DNA from small solid tumours can be very difficult 
and will limit  the choice of  subsequent methodologies.   However, whole genome 
amplification (WGA) techniques have been developed to produce large quantities of 
genomic DNA from small amounts of template material.  The success of WGA for 
use in CGH is determined by both the amount of product that is generated and how 
representative the final product is of the original DNA template.  Three PCR-based 
WGA  methods  and  a  cascading,  strand  displacement  methodology  have  been 
developed. 
 
1.6.5.1 Linker-adaptor PCR 
Linker-adaptor mediated (LA) PCR was the first PCR-based genome amplification 
technique  to  be  reported,  but  was  developed  for  the  detection  of  DNA  regions 
involved in DNA-protein interactions rather than for WGA (Ludecke et al 1989).  The 
DNA template is digested with a restriction enzyme and then adaptor sequences are 
ligated on to the ends of the DNA molecules.  The adaptor sequence is then used as a 
primer  in  a  subsequent  PCR.    Ten  years  after  the  first  publication,  LA-PCR  was 
adapted for WGA from a single cell for use in CGH; this technique was termed single      
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cell comparative genomic hybridisation (SCOMP).  Technical problems, related to the 
ligation reaction, have prevented the widespread use of this methodology (Klein et al. 
1999). 
 
1.6.5.2 Primer-extension pre-amplification PCR 
Primer-extension  pre-amplification  (PEP)  PCR  was  initially  designed  for  multiple 
genotyping from a single sperm nuclei (Zhang et al. 1992).  It uses multiple extension 
rounds  with  Taq  polymerase and  a random  mix of completely degenerate 15-mer 
primers.  It has been estimated that this method is able to amplify 78% of the genome 
from a single cell (Zhang et al. 1992).  An improved PEP-PCR protocol has been now 
been developed using a lysis buffer containing proteinase K, then an enzyme mix of 
Taq  DNA  polymerase  and  proofreading  Pwo  polymerase,  and  an  additional 
elongation step (Dietmaier et  al. 1999).  These changes result in  a more efficient 
WGA reaction. 
 
1.6.5.3 Degenerate oligonucleotide-primed-PCR 
Degenerate oligonucleotide-primed (DOP) PCR was developed in 1992 for genome 
mapping studies (Telenius et al. 1992).  Since then the technique has been adapted for 
use with lower starting amounts of DNA template, improved genomic representation 
and increased yield, fragment length and fidelity.  Each DOP-primer is designed to 
contain  a  CG-rich  5   end,  followed  by  6  random  degenerate  nucleotides,  and  6 
specific nucleotides at the 3  end.  The primer mix, therefore, contains 4
6 partially 
degenerate  primers.    The  first  PCR  uses  a  low  stringency  annealing  temperature 
(25
oC) to enable primer binding.  The annealing temperature is increased to 55
oC in 
the second part of the PCR allowing exponential amplification of sequences.      
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DOP-PCR  efficiently  produces  large  quantities  of  highly  representative  genomic 
DNA from very small amounts of starting material. When the reproducibility of DOP-
PCR was compared with PEP-PCR, results were comparible with 89% and 91% of 
loci successfully amplified, respectively (Wells et al 1999).  However, DOP-PCR can 
amplify a greater quantity of DNA product than PEP-PCR allowing visualisation of 
the product on an agarose gel. 
 
 
1.6.5.4 Multiple displacement amplification 
The multiple displacement amplification (MDA) reaction is based upon the rolling 
circle amplification used by circular DNA genomes for replication  (Kornberg and 
Baker 1992).  MDA was initially developed to amplify large circular DNA templates 
(Dean et al. 2001), but has been adapted for genomic DNA amplification (Dean et al. 
2002).    This  non-PCR-based  method  uses  phi29  DNA  polymerase  with  random 
exonuclease-resistant primers in a single reaction.  The DNA template is denatured 
before  a  single  extension  incubation  enables  the  cascading,  strand  displacement 
reaction to take place.  Initially, the random primers anneal to and extend from the 
denatured template DNA, then the 5  end of any extending product is displaced by an 
upstream  fragment  which  is  extending  in  the  same  direction.    A  hyperbranching 
mechanism is generated which is only stopped when the enzyme is inactivated by 
heating at the end of the reaction.  Large amounts of DNA can be produced with this 
method and products  are larger than is  possible with  PCR-based WGA.   A more 
complete coverage of the genome occurs with very low amplification bias (Dean et al 
2002).    A  number  of  commercial  kits  have  become  available  over  the  last  year: 
GenomiPhi and TempliPhi (Amersham Biosciences), GenomePlex (Sigma-Genosys).       
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Currently, however, MDA has not been successfully developed for WGA from single 
cells. 
 
To summarise, PEP-PCR, DOP-PCR and MDA are the most efficient methods of 
WGA.  Whilst PEP-PCR and MDA reliably amplify good representative DNA, DOP-
PCR is the preferred method at present when using small amounts of template.  This 
methodology  reliably  produces  high  quantities  of  DNA  with  a  reasonably  good 
representation of the genome. 
 
1.6.6  Whole genome amplification, CGH and lymphomas 
WGA has been used to produce DNA for CGH  analysis of NHL biopsies and to 
identify  chromosomal  imbalances  (Weber  et  al  2000).    Primary  central  nervous 
system lymphomas (PCNSL) form in the lymph tissue of the brain and/or spinal cord 
and are morphologically recognised as high-grade NHLs of the diffuse large B-cell 
type (DLBCL), but their origin is poorly understood.  These tumours are commonly 
removed by stereotactic surgery so only a minute amount of material is available for 
analysis.  In one study DOP-PCR was used to amplify DNA from 19 PCNSL cases, 
which was then used in both conventional CGH and array-CGH (see Section 1.6.8) 
where  the  target  sequences  were  PCR  products  derived  from  yeast  artificial 
chromosome  (YACs)  (Weber  et  al.  2000).    A  set  of  characteristic  chromosomal 
imbalances was observed within 18 of the cases with the most frequent, a gain on 12q, 
being detectable in 63% of cases.  Other abnormal regions were 1q, 9q, 11q, 12p, 16p, 
17q, 18q and 22q. 
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1.6.7  Laser microdissection and whole genome amplification 
Since many tumours contain large numbers of non-malignant cells, often accounting 
for over 50% of the total DNA content of the tumour, the fluorescence ratio calculated 
after CGH using whole tumour DNA will not be representative of the tumour cells 
(Kallioniemi et al., 1994).   The introduction of laser microdissection (LMD) has 
made possible the selection of a pure tumour cell population from biopsy material.  
Cells can be picked from cytospin slides, frozen tissue sections, or paraffin-embedded 
tissue sections.  A laser is used to cut around the cells, which either drop or are 
catapulted into a tube lid.   The cells then undergo either proteinase K digestion or 
alkaline lysis to extract the genomic DNA, which can be used as a DNA template for 
WGA.   
 
Combining LMD and WGA has provided a very powerful tool for the detection and 
identification  of  unknown  chromosomal  aberrations  in  tumours.  This  was  first 
successfully demonstrated using DNA extracted from microdissected peripheral blood 
lymphocytes and the breast cancer cell line MCF-7 (Kuukasjarvi et al. 1997).  DOP-
PCR was performed with only 50 pg of cell line DNA as template and the products 
were successfully hybridised to normal metaphase preparations. Many studies have 
now been published where LMD was used to collect pure cell populations from a 
tumour sample for CGH (Pyakurel et al 2006; Morandi et al 2006; Huang et al 2005b; 
Yan et al 2005; Chang et al 2005; Morohara et al 2005). 
 
1.6.8  CGH analysis of classical HL 
Three groups have analysed cHL using CGH.  Ohshima et al. (1999) selected HRS 
cells from 9 fresh cHL biopsies using a Fluorescent Activated Cell Sorter (FACS),      
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and the DNA was subsequently amplified using DOP-PCR (Ohshima et al. 1999).  
The products were hybridised to normal metaphase preparations.  Gains and losses 
were observed in the HRS cells from all nine cHL cases with the most common being 
a loss of 16q11-21 and a gain of 1p13 and 7q35-36.  Five of the HL cases were 
associated with EBV, but the authors reported no significant relationship between 
EBV and the chromosomal changes observed.  CGH was also performed using DNA 
from  B  and  T  lymphocytes  to  investigate  the  chromosome  imbalances  in  the 
multicellular infiltrate surrounding the HRS cells.  No chromosomal abnormalities 
were detected in the latter cells. 
 
Joos et al. (2000) selected HRS cells from 12 cHL biopsies for cytological analysis 
(Joos  et  al  2000).    For  each  case,  DNA  was  extracted  from  30  HRS  cells  and 
amplified  using  DOP-PCR  before  analysis  by  conventional  CGH.    A  number  of 
recurrent chromosomal imbalances were detected; including gains in 2p, 9p and 12q 
and losses in 17p (see Figure 1.4).  This study was expanded to 41 cHL cases (Joos et 
al 2002) and frequent gains in chromosomal material were identified on chromosomes 
2p,  9p,  12q,  16p,  17p,  17q  and  20q  (see  Figure  1.4).    The  most  frequent  losses 
affected  chromosome  13q.    Further  analysis  by  FISH  demonstrated  that  the  REL 
oncogene  was  amplified  within  chromosome  2p15-p16,  especially  in  HRS  cells 
isolated from NSHL cases (Joos et al 2000; Joos et al 2002).  Recurrent gains on 
chromosomes 2p and 9p were also detected in the cHL-derived cell lines HDLM2, 
KMH2,  L1236  and  L428  using  DOP-PCR,  CGH  and  M-FISH  (Joos  et  al  2003).  
FISH analysis identified amplification of the REL locus on chromosome 2p15-p16, in 
all four cHL-derived cell lines, and the JAK2 locus on chromosome 9p24, in the 
HDLM2, KMH2 and L428 cell lines.      
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In our laboratory, HRS cells were laser-microdissected from 20 cHL cases and 4 HL-
derived cell lines, amplified using DOP-PCR, and analysed by conventional CGH (see 
Figure 1.4) (Chui et al. 2003).  The most frequently occurring chromosomal gains 
were located on 2p, 9p, 12q, 14q, 16p, 17 and 22q.  The most frequently observed 
losses were on 4q, 6q, 11q and 13q.  There were significantly more gains in 2p and 
14q in older adult cHL cases, and a loss on 13q was associated with a poor outcome.  
These results are remarkably similar to those of the studies by Joos et al. (Joos et al 
2000; Joos et al 2002) and with the CGH analysis of four HL cell lines (L1236, L428, 
KMH2  and  HDLM2)  (Joos  et  al.,  2003).      This  suggests  that  recurrent  genomic 
imbalances are a feature of cHL.        
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Figure 1.4. Summary of conventional CGH analysis of HRS cells isolated from cHL 
biopsies.  Chromosomal gains are indicated by red (Chui et al 2003) and orange (Joos 
et al 2000; Joos et al 2002) vertical lines to the right of the chromosome ideograms, 
and losses by green (Chui et al 2003) and blue (Joos et al 2000; Joos et al 2002) 
vertical lines to the left.        
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1.6.9  Array-CGH 
In 1997 the replacement of the target metaphase chromosome spread in CGH with an 
array  of  bacterial  artificial  chromosome  (BAC),  P1-derived  artificial  chromosome 
(PAC) or yeast artificial chromosome (YAC) DNA was introduced (Solinas-Toldo et 
al. 1997) (see Figure 1.3).  This allows DNA copy number aberrations to be detected 
at  higher  resolution.    These  CGH  arrays  can  be  created  by  spotting  BAC  DNA 
(Solinas-Toldo  et  al.  1997),  DOP-PCR  derivatives  of  BAC  DNA  (Telenius  et  al. 
1992), or amplified fragment pools (AFP) of BAC DNA generated by linker mediated 
PCR (Pfeifer et al. 1989), onto a glass slide.  The resultant array can be used for high-
resolution  detection  of  copy  number  changes  and  is  limited  only  by  the  size  and 
spacing of large insert clones included in the array.   
 
In  array-CGH,  reference  and  test  DNA  samples  are  differentially  labelled  with 
fluorescent  dCTPs  (cyanine-3  (Cy3)  and  cyanine-5  (Cy5))  (see  figure  1.3).    The 
samples are then combined to form the probe DNA and, prior to hybridisation, Cot-1 
DNA  is  added  to  block  repetitive  sequences  and  prevent  non-specific  binding.  
Following hybridisation, the fluorescent ratios of each spot on the array are analysed 
in order to determine the copy number differences between the two DNA samples. 
Initially confocal microscopy was used for manual evaluation, but now analysis is 
automated with specialised software packages similar to those used in the analysis of 
cDNA microarrays.   A second ‘dye-swap’ hybridisation is usually performed where 
the initial labelling of both DNA samples is reversed.  This prevents scoring of any 
spurious results, which are not confirmed in the reciprocal hybridisation. 
      
  50 
The construction of a genomic array spanning the whole genome was reported by two 
studies which described the synthesis of an array using 2460 and 3500 BAC-derived 
DNAs  respectively  (Fiegler  et  al.  2003;  Snijders  et  al.  2001).    Each  DNA  clone 
sequence represented, on average, 1Mb  of the genome.  Recently, a submegabase 
resolution  array-CGH  (SMRT  array)  has  been  published  comprising  32,433 
overlapping BAC clones covering the entire human genome (Ishkanian et al. 2004).  
This  array  has  the  potential  to  identify  minute  recurrent  genomic  imbalances  and 
allow the detailed characterisation of critical genomic regions and genes of known or 
anticipated pathogenic relevance.  The technique can be used to aid the identification 
of  prognostic  markers,  to  which  a  specific  anti-tumour/cancer  therapy  can  be 
assigned, and thereby contribute to both a greater understanding of cancer biology and 
improved patient management. 
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1.7  AIMS OF THESIS 
In order to identify potential pathogenic agents for cHL, we screened a number of 
cHL cases for MV (Chapter 3) and polyomaviruses (Chapter 4) using IHC, 
conventional PCR and QRT-PCR.  In addition, we designed several degenerate PCR 
assays, against highly conserved regions of the virus genome, which would detect 
known and unknown members of the polyomavirus family. 
 
Recurrent chromosomal imbalances have previously been reported in cHL cell lines 
and cases using classical cytogenetic techniques and, more recently, conventional 
CGH, which has a limited resolution of 40 Mb.  To examine these chromosomal 
imbalances at a higher resolution (1 Mb) and to identify smaller chromosomal 
changes previously undetected, we analysed six well-established cHL cell lines using 
array-CGH analysis (Chapter 5). 
 
When this project began, there were no publications of studies using LMD and WGA 
to prepare genomic DNA samples for array-CGH analysis.  We, therefore, optimised 
the analysis of DOP-PCR amplified laser microdissected single cells, from a cHL-
derived cell line for array-CGH (Chapter 6).  Once optimised, these methodologies 
were performed to analyse chromosomal imbalances within single HRS cells from a 
cHL case sample (Chapter 6).  
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CHAPTER 2 
 
MATERIALS AND METHODS 
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The general materials and methods used in this project will be described in this 
chapter.  A more detailed account of the methodology related to array-CGH is 
detailed in chapter 5. 
 
2.1  MATERIALS 
All chemicals used were of Analar or Molecular Biology grade and were obtained 
from  either  the  Sigma-Aldrich  Company  Ltd.  (Poole,  Dorset,  UK)  or  VWR 
International  Ltd.  (Lutterworth,  Leicestershire,  UK),  unless  otherwise  stated.    De-
ionised water, from a Seradest S600 ion-exchange system, was used in the preparation 
of buffers.  Molecular biology grade water, supplied in aliquots of 1 ml by Microzone 
Limited (Haywards Heath, West Sussex, UK), was used in all enzymatic reactions. 
 
2.2  METHODS 
2.2.1  Tissue collection 
Freshly removed tissue biopsies were delivered in travel medium (see Appendix C) to 
the laboratory directly from collaborating hospitals in the West of Scotland on either 
the day of excision or the following day.  A patient information form with relevant 
clinical details was completed by the hospital pathologist and diagnostic information 
was obtained.  All relevant information was entered on a bespoke database in our 
laboratory, and a unique patient number was assigned.  All studies were approved by 
a Multicentre Research Ethics Committee and informed consent was obtained from all 
patients.  Samples were coded before use in research. 
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2.2.2  Tissue biopsy processing 
Specimens were processed as quickly as possible in order to maintain cell viability.  
Since  samples  were  used  in  several  different  projects,  sample  processing  was 
performed by several different group members in a containment level II laboratory 
within a Class II Microbiological Safety Cabinet (MSC), according to the local Code 
of Practice. 
 
2.2.3  Preparation of viable cell suspensions 
Following removal from travel medium, biopsy samples were transferred to a sterile 
Petri  dish  and washed in  70% ethanol to  remove any surface  contaminants.   The 
samples were then bisected and two touch imprints were made on polylysine slides 
(VWR International Ltd.); these were allowed to air dry before being stained with 
eosin G and thiazine using the DiffQuik staining system (Dade Behring Inc., Illinois, 
USA). 
 
The tissue was then cut into smaller pieces and forced through a cell strainer with Cell 
Suspension buffer (containing 10% 10x phosphate buffer solution (PBS), 2% heat-
inactivated  fetal  bovine  serum  (Invitrogen),  1  M  ethylene  diamine  triacetic  acid 
(EDTA;  Sigma-Aldrich  Company  Ltd.)  and  2.5  mg  bovine  serum  albumin  (BSA; 
Sigma-Aldrich Company Ltd.)) using the plunger of a 2 ml Plastipak sterile syringe 
(Becton Dickinson, New Jersey, USA).  The resultant suspension was centrifuged at 
1200  g  for  5  minutes  (mins)  and  the  cells  were  resuspended  in  10  ml  of  Cell 
Suspension buffer.    
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2.2.4  Cell counting 
A 20  l aliquot of the cell suspension was mixed with 20  l of 0.4% trypan blue 
solution (Sigma-Aldrich Company Ltd.), and approximately 20  l of this was pipetted 
beneath  a  coverslip  on  an  improved  Neubauer  haemocytometer  chamber  (Fisons 
Scientific Equipment, Loughborough, UK).  The total live cell count was made across 
16 large grid squares, and this number was multiplied by the dilution factor to give the 
concentration x 10
4 per ml. 
 
2.2.5  Enrichment of mononuclear cells from lymph nodes 
Mononuclear  cells  were  enriched  and  debris  removed  by  gradient  density 
centrifugation.    The  cell  suspension  was  slowly  layered  over  Lymphoprep  (Axis 
Shield, Norway) and then centrifuged at 1500 g for 20 mins in a bench top centrifuge 
(Allegra  GR,  Beckman  Couter,  High  Wycombe,  UK)  with  the  brake  off.    The 
mononuclear  cells  accumulated at  the interface between the two phases  and were 
removed carefully using a pipette.  Following washing in Cell Suspension buffer, a 
repeat cell count was performed.  The cells were then washed again and centrifuged at 
1000 g for 5 mins with the brake on.   
 
2.2.6  Storage of viable mononuclear cell suspensions 
A proportion of the cells was used for cytospin preparation (see Section 2.2.8).  The 
remainder were resuspended in an appropriate volume of foetal calf serum (92%) and 
dimethyl sulphoxide (8%), and divided into aliquots of 1x10
7 or 5x10
6 cells/ml in 1.5 
ml Nunc tubes (Nalgene, Herefordshire, UK).  These viable cell suspensions were 
initially stored overnight (O/N) at –80
oC in a Cryo 1
o freezing container (Nalgene) 
before being transferred the following day into liquid nitrogen for long term storage.      
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2.2.7  Cell lines 
Cell lines were handled in a class II MSC microbiological safety cabinet, and non-
EBV-infected, or EBV-negative, cell lines were handled prior to those which were 
EBV-infected, or EBV-positive.  Details of the cell lines used in array-CGH and gene 
expression array analyses are given in Table 2.1.   
 
2.2.7.1 Recovery and maintenance of cell lines 
All cell lines were cultured from viable stocks of 5 x 10
5 cells that had been stored 
long term in liquid nitrogen, as described in section 2.2.2.  The cells were defrosted 
slowly at 37
oC, washed once in the appropriate medium to remove DMSO, and then 
resuspended in 10 ml (5 x 10
4 cells/ml) of the appropriate medium in a vented tissue 
culture flask.  The cultures were incubated at 37°C in 5% CO2 and passaged twice a 
week with fresh medium.  Cell growth curves were compiled in order to calculate the 
optimal time for harvesting to use in RNA experiments.  Harvesting took place when 
cells were in log phase growth and at least 1x10
8 cells were available.  Four flasks of 
50 ml of culture at the pre-determined optimal density (see Table 2.1) were harvested 
at the appropriate time point and the resultant cell pellet was used for both DNA and 
RNA extraction.  
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Table  2.1.  Details  of  cell  lines  used  in  array-CGH  and  gene  expression  array 
analyses. 
 
Cell Line  Sex  Details  EBV status 
IM-9  Female  ATCC CCL-159 
Bone marrow cells from a multiple myeloma patient 
RPMI 1640 + 10% FCS 
Doubling time 48 hours 
Harvest at maximal density of 0.5-1.0x10
6 cells/ml  
Positive 
HDLM2  Male  DSMZ# ACC 17 
Pleural effusion from a NSHL (stage IV) patient 
RPMI 1640 + 10% FCS 
Doubling time 72 hours 
Harvest at maximal density of 2.0-2.5x10
6 cells/ml 
Negative 
KM-H2  Male  DSMZ# ACC 8 
Peripheral blood of MCHL (stage IV) patient  
RPMI 1640 + 10% FCS 
Doubling time 48 hours 
Harvest at maximal density of 1.0x10
6 cells/ml 
Negative 
L1236  Male  DSMZ# ACC 530 
Peripheral blood of MCHL (stage IV) patient  
RPMI 1640 + 10% FCS 
Doubling time 48 hours 
Harvest at maximal density of 0.6x10
6 cells/ml 
Negative 
L428  Female  DSMZ# ACC 197 
Peripheral blood of NSHL (stage IVB) patient  
RPMI 1640 + 10% FCS 
Doubling time 48 hours 
Harvest at maximal density of 0.5-1.0x10
6 cells/ml 
Negative 
L540  Female  DSMZ# ACC 72 
Bone marrow of NSHL (stage IVB) patient 
RPMI 1640 + 20% FCS 
Doubling time 48 hours 
Harvest at maximal density of 1.5x10
6 cells/ml 
Negative 
L591  Female  Kindly provided by Dr. David Jones, Southampton University 
RPMI 1640 + 10% FCS 
Doubling time 72 hours 
Harvest at maximal density of 0.5x10
6 cells/ml 
Positive 
ATCC,  American  Type  Culture  Collection;  DSMZ,  Deutsche  Sammlung  von 
Mikroorganismen und  Zellkulturen GmbH  (German cell culture  collection); FCS, 
foetal calf serum; MCHL, mixed-cellularity Hodgkin  Lymphoma; NSHL, nodular 
sclerosis Hodgkin lymphoma; RMPI, Roswell Park Memorial Institute. 
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2.2.8  Preparation of cytospin slides 
Cytospin slides for LMD were prepared in-house by attaching a piece (50 x 22 mm) 
of PENfoil membrane (PALM Microlaser Technologies, Bernried, Germany), with 
Fixogum rubber cement (Marabu, Tamm, Germany) along two opposing sides, to the 
surface of plain glass slides (BDH, Poole, UK).  The slides were left to dry for 2-3 
days in clean slide box and any with wrinkled PENfoil were discarded.   
 
Cytospins were prepared from cell line cultures or viable cells that were either fresh 
or had been stored in liquid nitrogen.  PENfoil slides and double or single chamber 
cytospin  funnels  (ThermoShandon,  Cheshire,  UK)  were  fastened  together  with  a 
cytospin clip and loaded into the cytospin holder.  Following a viable cell count, 100 
l of 2.5 x 10
5 cells in suspension were pipetted into each chamber and the cells were 
spun  at  450  rpm  for  10  mins  in  a  cytocentrifuge  (Cytospin  2;  ThermoShandon, 
Cheshire, UK).  The slides were immediately removed from the holders and air-dried.  
When completely dry, an Immunopen (Dakocytomation, Cambridgeshire, UK) was 
used to circle each cell spot and once these circles had dried the slides were either 
used immediately or wrapped in aluminium foil and stored at –80
oC until required. 
 
2.2.9  CD30-staining using the ABComplex method 
The cytopsins were CD30-stained by IHC, using the ABComplex method and Fast 
Red substrate, in order to facilitate the identification of HRS cells.  CD30-positive 
lymphocytes may also be present in cell suspensions from cHL biopsies, but these are 
usually smaller than HRS cells, have less prominent nucleoli and are less likely to 
rosette lymphocytes. 
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Cytospins  were  equilibrated  to  room  temperature  and  then  rehydrated  in  1x  Tris 
buffered saline (TBS) with 0.1% Tween 20 (TBST) (Serotec, Oxford, UK) for 5 mins.  
The whole staining procedure was performed at room temperature and the slides were 
washed twice in 1x TBST for 3-5 mins between each step.  Heat inactivated rabbit 
serum (20%) (Vector Labs) was added to the cell spots for twenty mins to inhibit non-
specific  binding.    An  anti-CD30  primary  monoclonal  antibody  (clone  HRS4, 
Immunotech, France) was then diluted 1:100 and pipetted onto each cell spot.  The 
cytospins were incubated for 30 mins at room temperature.  A third incubation, for 30 
mins at room temperature, was set up with a 1 in 300 dilution of biotinylated rabbit 
anti-mouse secondary antibody (DAKO).  An aliquot of ABComplex/AP (DAKO) 
was  then  added  to  each  cell  spot  and  incubated  for  thirty  mins,  followed  by  the 
addition of two drops of Fast Red substrate (DAKO).  After 15-17 mins, the slides 
were washed twice in distilled water, before being counterstained in 0.1% toludine 
blue and air-dried O/N.  
 
2.2.10  Laser microdissection from cytospin slides 
LMD was performed using a Leica AS Laser Microdissection system (Leica, Milton-
Keynes, UK) in a room set up specifically for this use.  This instrument uses a UV 
laser to cut around the cells enabling them to drop into the cap of an open 0.2 ml PCR 
tube.    The  0.2  ml  tubes,  equipment  and  the  cutting  room  were  UV-irradiated 
approximately one hour prior to cutting to decrease static and reduce the possibility of 
contamination. 
 
Ten single cells were laser microdissected into each tube lid, directly into 6  l of 
DOP-lysis buffer (1x Thermosequenase buffer [260 mM Tris-HCl pH 9.5, 65 mM      
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MgCl2], 0.25 mg/ml proteinase K, 0.45% Tween 20, 0.45% NP40).  An LMD cutting 
blank control was included after every 10 tubes of laser microdissected cells.  These 
control tubes contained only DOP-lysis buffer and were kept open in the microscope 
rack throughout a set of cutting experiments, but no cells were cut into these tubes. 
 
Once a cutting session was completed, the samples were incubated for an hour at 55
oC 
to enable proteinase K digestion.  This lysis method was selected over alkaline lysis 
since Dietmaier et al. (1999) suggested that protease degrades the nuclear proteins 
involved in packaging of chromosomes and thereby enables more efficient extraction 
of DNA from cells (Dietmaier et al 1999).  The lysis reaction was stopped by heating 
the sample to 96
oC for 10 mins in order to denature the enzyme.  The tubes were 
stored  at  4
oC  O/N  and  DOP-PCR  was  performed  the  following  day  (see  Section 
2.2.15). 
 
2.2.11  Total RNA extraction 
The RNAqueous
® kit (Ambion
®; Applied Biosystems, Warrington, UK) was used, 
according to the manufacturer’s protocol, for small scale extraction of RNA from 
≤5 x 10
6  cells.  The  RNA  pellet  was  resuspended  in  10-60  l  of  elution  buffer, 
supplied in the RNAqueous
® kit. 
 
Large  scale  extraction  of  RNA,  from  ≥6  x  10
7  cells,  was  performed  from  larger 
volumes  of  fresh  cultured  cells  using  1  ml  of  TRIZOL  reagent  (Invitrogen  Ltd., 
Paisley, UK) per aliquot of 1 x 10
7 cells, according to the manufacturer’s protocol.  
Following the addition of TRIZOL, the cells were lysed by repetitive pipetting, then      
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incubated in a 30
oC waterbath for 5 mins.  For every 1 ml of TRIZOL, 200  l of 
chloroform was added to the lysate and mixed by shaking vigorously for 15 seconds.  
The lysate was incubated again for 5 mins in a 30
oC waterbath, before centrifugation 
at 12000 g for 15 mins at 4
oC.  The colourless upper aqueous layer containing the 
RNA was removed using a Pasteur pipette and transferred into a fresh Falcon tube.  
Isopropyl alcohol (500  l per 1 ml of TRIZOL initially used) was added to precipitate 
the  RNA  and  the  sample  was  incubated  in  a  30
oC  waterbath  for  10  mins  before 
centrifugation at 12000 g for 10 mins at 4
oC.  The resultant RNA pellet was then 
washed once in 75% ice cold ethanol (1 ml per 1 ml of TRIZOL initially used), mixed 
by vortexing and then centrifuged at 7500 g for 5 mins at 4
oC.  The supernatant was 
removed and the pellet air-dried for 5-10 mins.  The resultant RNA pellet was then 
resuspended by adding 30  l of RNase-free water (Qiagen), for every 1 x 10
7 cells 
processed, and incubated at 55
oC for 15 mins.  All RNA samples were pooled stored 
at -80
oC until required. 
 
2.2.12  DNA extraction from tumour samples or cell lines 
The cell pellet was washed twice in 1x PBS (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2 mM NaH2PO4, pH 7.2) then resuspended in 1x TNE buffer (100 mM Tris 
Base, 10 mM EDTA, 2 M NaCl, adjusted to pH7.4), 0.5% sodium dodecyl sulphate 
(SDS) and 50  g/ml proteinase K.  Following incubation at 56
oC for 1.5-2 hours, an 
equal  volume of phenol  was  added to  the lysate and the solution  was thoroughly 
mixed by gentle inversion for 10 mins.  The phases were separated by centrifugation 
at 1700 g for 10 mins.  The top layer of solution was pipetted off into a fresh tube to 
which an equal volume of phenol was added.  The phases were thoroughly mixed 
together again and separated by centrifugation.  This mixing and separation of phases      
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was repeated twice with phenol: chloroform: isoamyl alcohol (25:24:1; Sigma-Aldrich 
Company  Ltd.)  and  once  with  chloroform:  isoamyl  alcohol  (24:1;  Sigma-Aldrich 
Company  Ltd.).  Two volumes  of ice cold  100% ethanol were then added to  the 
solution and the DNA was spooled on the end of a pipette tip and transferred to a 1.5 
ml microfuge tube.  The pellet of DNA was washed in ice cold 70% ethanol, air-dried, 
and resuspended in 1x TE buffer (10 mM Tris pH 8.0, 1 mM EDTA, pH 8.0) (500  l 
was required to resuspend DNA extracted from 1 x 10
7 cells).  Overnight incubation 
at 37
oC enabled the DNA to completely resuspend. 
 
2.2.13  Ethanol precipitation of DNA 
Nucleic acids were cleaned up and concentrated using ethanol precipitation.  One 
tenth volume of 3 M sodium acetate was added to the DNA solution, followed by 2 
volumes of ice-cold 100% ethanol.  The solution was mixed well, then placed at -
20
oC O/N to allow precipitation to take place.  The following day the mixture was 
centrifuged  at  13000  g  in  a  microfuge  (Minispin  Plus,  Eppendorf  UK  Ltd., 
Cambridge, UK) for 30 mins at 4
 oC.  The supernatant was discarded and 250  l of 
70%  ethanol  was  added  to  the  pelleted  nucleic  acid.    The  mixture  was  briefly 
vortexed, then centrifuged for 30 mins at 4
 oC.  The supernatant was discarded and 
Parafilm
®  (VWR  International  Ltd.)  was  placed  tightly  over  the  top  of  the  open 
microfuge tube and pierced twice with a sterile needle.  The microfuge tube was left 
on the bench until all traces of supernatant had evaporated away.  The pellet was then 
resuspended in a suitable volume of TE buffer or water. 
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2.2.14  Quantification of Nucleic Acids 
The quantity and quality of DNA and RNA were assessed using a Nanodrop ND-1000 
Spectrophotometer (Nanodrop Technologies Ltd., Delaware, USA) to measure optical 
density (OD) at wavelengths of 230 nm, 260 nm and 280 nm.  The concentration of 
DNA was  calculated by assuming that 50  g/ml  of double stranded DNA has  an 
OD260nm of 1.0, and 40  g/ml of RNA has an OD260nm of 1.0.  The purity of a sample 
was indicated by an OD260nm/ OD280nm ratio reading of approximately 1.8 for DNA 
and approximately 2.0 for RNA.  For DNA a secondary measurement of nucleic acid 
purity is provided by the OD260nm/ OD230nm ratio; a value lower than 1.8-2.2 suggests 
the presence of contaminants. 
 
2.2.15  Polymerase chain reaction 
Several different PCR techniques were used in this project.  The protocols for reverse 
transcription (RT)-PCR, conventional PCR and QRT-PCR are outlined in Chapter 3 
and degenerate PCR is described in Chapter 4.  The methodology for DOP-PCR is 
discussed below. 
 
2.2.15.1  DOP-PCR 
DOP-PCR was performed using a protocol devised by Huang et al. (2000), which had 
then been adapted and optimised by Dr Daniel Chui in this laboratory (Huang et al 
2000; Chui et al 2003).  The initial template for the two-step WGA was 6  l of either 
genomic DNA or DNA extracted from LMD cells by proteinase K digestion.  Each 
tube  containing  10  microdissected  cells  was  treated  as  a  separate  amplification 
reaction, and 40 tubes were DOP-amplified at the same time.  The universal UN1      
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DOP-primer, also called 6MW (Telenius et al 1992), was used in both rounds of PCR, 
unless otherwise stated. 
 
The  first  amplification  involved  a  10  l  reaction  containing  1x  Thermosequenase 
reaction  buffer  (Amersham  Biosciences),  200  M  of  each  dNTP  (Amersham 
BioScience,  Buckinghamshire,  UK),  1  M  DOP-primer  (NAP-purified;  Sigma-
Genosys)  and  4  U  of  Thermosequenase  polymerase  (Amersham  Biosciences).  
Thermal cycling conditions were 3 mins at 95
oC, followed by 4 cycles of 1 minute at 
94
oC, 1 minute at 25
oC, and then 3 mins ramping up to an extension step of 72
oC for 2 
mins.  This was followed by a final extension step at 72
oC for 10 mins.  The total 
reaction  volume  from  the  first  amplification  was  used  as  template  for  the  second 
amplification reaction, which was set up in the same tubes as the first reaction.  The 
second reaction contained 1x custom-made buffer (WMegaMix, Microzone Limited, 
West Sussex, UK).  A master mix was then added to give a final reaction volume of 
50  l  containing  200  M  dNTPs,  the  UN1  DOP-primer  at  1  M  and  5  units  of 
AmpliTaq
®  DNA  polymerase  (Applied  Biosystems).    Thermal  cycling  conditions 
were as follows: an initial denaturation at 95
oC for 3 mins, followed by 35 cycles of 
94
oC for 1 minute, 56
oC for 1 minute and 72
oC for 2 mins, with a final extension step 
at 72
oC for 10 mins.  All amplifications were performed using the GeneAmp PCR 
System 2400 or 9700 (Applied Biosystems).  
 
A positive control of 60 pg of normal human genomic DNA (either male or female; 
Promega)  was  amplified  in  every  DOP-PCR  assay.    Negative  controls  were  also 
included (one per ten reaction tubes), by substituting the DNA for molecular biology      
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grade  water  (Microzone  Limited),  in  order  to  check  for  the  introduction  of  DNA 
contamination during PCR set up. 
 
Initially,  DNA  contamination  was  consistently  observed  within  negative  water 
controls  in  the  DOP-PCR  assays.    When  these  contaminated  controls  were 
investigated  using  QRT-PCR  assays  specific  for  the  human  housekeeping  genes 
adenosine monophosphate deaminase (AMPD),  -globin and heat shock protein 90 
(HSP90), results were negative confirming that the contamination was not of human 
origin.    Since  PCR  reagents  can  sometimes  be  the  source  of  bacterial  DNA 
contamination, several sources of each reagent were tested by DOP-PCR with the 
UN1 primer, and both a positive (normal human genomic DNA) and negative (water) 
control.    We  found  that  replacing  the  second  round  DOP-amplification  buffer 
GeneAmp  10x  PCR  Buffer  (Applied  Biosystems)  with  a  custom-made  buffer, 
WMegaMix  (Microzone  Limited,  West  Sussex,  UK)  removed  the  smear  of 
contaminating DNA.  The GeneAmp 10x PCR Buffer is composed of 500 mM KCl, 
100  mM  Tris-Hcl  (pH8.3),  15  mM  MgCl2  and  0.01%  (weight/volume)  gelatine.  
WMegaMix  contains  an  alternative  synthetic  stabiliser  to  gelatine  and  so  we 
concluded that the DNA  contamination  previously seen in  our DOP-products  was 
probably bovine DNA from gelatine in the GeneAmp 10x PCR Buffer. 
 
Following  amplification,  4  l  of  DOP-product  from  each  tube  was  subjected  to 
electrophoresis on 1% agarose gels in order to assess the size range and amount of 
amplified  products.  The  DNA  size  marker  HaeIII-digested  X174  RF  DNA 
(Invitrogen Ltd.) was always electrophoresed (0.5-1  g) alongside the DOP-products.      
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Successfully amplified DOP-products were then combined and subjected to ethanol 
precipitation, in order to remove free nucleotides that could interfere with subsequent 
labelling reactions and to concentrate the products.  The resultant DNA pellet was 
resuspended  in  dH2O.    Following  quantification  using  the  Nanodrop  ND-1000 
Spectrophotometer,  500  ng  of  the  resultant  DNA  was  electrophoresed  on  a  1% 
agarose gel (see below) to assess the size range of the DOP-products. 
 
2.2.16  Analysis of PCR products 
2.2.16.1  Agarose gel electrophoresis 
Agarose  gel  electrophoresis was  used to  analyse PCR products.   Agarose powder 
(Invitrogen) was dissolved (0.8% weight/volume) in 1x TBE buffer by  heating to 
>90
oC.  Once the gel solution had cooled to approximately 65
oC, 2  l of 0.5  g/ml 
ethidium bromide was added per 100 ml of gel mix.  The gel solution was poured into 
the Sub-Cell GT cell (Bio-Rad Laboratories, Hertfordshire, UK), with a well-forming 
comb in place, and left at room temperature to set.  Once set, the gel was submerged 
in 1x TBE buffer and the comb was removed.  One-tenth volume of gel-loading buffer 
(0.42% bromophenol blue, 0.42% xylene cyanol, 50% glycerol) was mixed with the 
DNA samples before loading into the wells.  A DNA size marker (0.5-1  g) was 
always included: either HindIII-digested bacteriophage lambda DNA (Invitrogen Ltd.) 
or HaeIII-digested  X174 RF DNA (Invitrogen Ltd.).  Electrophoresis was performed 
at 4-8 V/cm for approximately 90 mins, depending on gel size and the size of the 
fragments to be separated.  DNA was visualised using a UV emitting Spectroline 
Transilluminator (Model TC-254A) and the results were recorded with a UVIsave Gel 
Documentation System (Jencons-PLS, East Sussex, UK). 
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2.2.16.2 Polyacrylamide gel electrophoresis 
For the separation of PCR products of less than 1kb in length, polyacrylamide gel 
electrophoresis was used.  The gel was made from 5% acrylamide (Sigma Aldrich 
Company  Ltd.),  3%  bisacrylamide  (Sigma  Aldrich  Company  Ltd.),  and  1x  TBE 
buffer, and was polymerised by the addition of 0.06% (w/v) ammonium persulphate 
(APS) and 0.03% TEMED (N, N, N, N – tetramethylethyldiamine).  Gels were poured 
between glass plates, a well-forming comb was put in place and the apparatus (Mini-
Protean  System,  Bio-Rad  Laboratories,  Hertfordshire,  UK)  was  left  at  room 
temperature, for approximately 45 mins, for the gel to solidify.  The gel was then 
submerged in 1x TBE buffer and the comb removed.  Gel-loading buffer was added to 
each DNA sample, and these were loaded into the wells alongside a DNA size marker 
(HaeIII digested  X174 RF DNA; Invitrogen Ltd.).  Electrophoresis was performed at 
120 V for approximately 45 mins.  The gel was then carefully removed from the glass 
plates and stained in 0.5  g/ml ethidium bromide.  The separated DNA was visualised 
using a UV light source (Spectroline Transilluminator, Model TC-254A) and images 
captured using the UVIsave Gel Documentation System (Jencons-PLS). 
 
 
2.2.17  Cloning and plasmid preparations 
Following  purification  using  the  Quickstep  2  PCR  Purification  kit  (EDGE 
Biosystems), amplification products were cloned using the TOPO
TM
 TA Cloning
® kit 
(Invitrogen Ltd.) according to the manufacturer’s protocol.  Cloning was achieved 
using  the  PCR
®2.1-TOPO
®  vector  and  One  Shot
®  TOP10  chemically  competent 
E.Coli cells.  In order to identify a clone containing the sequence of interest following 
transformation, single colonies were picked with a sterile rod.  The rod was then 
dropped  into  3  ml  of  L-broth  containing  50  mg/ml  ampicillin  or  the  appropriate      
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antibiotic.  The cultures were placed in a 37
oC shaking incubator O/N.  The following 
day the High Pure Plasmid Isolation Kit (Roche, Lewes, East Sussex, UK) was used 
to  extract  plasmid  DNA  from  the  bacterial  culture.  At  the  end  of  the  protocol, 
purified plasmid DNA was eluted from the High Pure filter columns by the addition 
of 100  l of elution buffer and 60 seconds of centrifugation at 13000 g.  
 
One microgram of plasmid DNA was digested in a total reaction volume of 20  l 
containing 10 U of restriction enzyme (Invitrogen) and 2  l of the appropriate 10x 
restriction buffer (Invitrogen).  Reactions were incubated at 37
oC O/N and then the 
digests were analysed by agarose (0.8%) gel electrophoresis. 
 
2.2.18  Nucleotide sequence analysis 
Cycle  sequencing  was  performed  directly  on  plasmid  DNA  using  the  Big  Dye
® 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), forward or reverse M13 
primers  (Forward:  5 -GTAAAACGACGGCCAGTG-3 ;  Reverse:  5 -
GGAAACAGCTATGACCATG-3 )  and  a  GeneAmp  PCR  System  2400  or  9600 
(Perkin-Elmer).    Products  were  purified  through  Performa  DTR  Gel  Fitration 
Cartridges (EDGE Biocolumns), and then dried in a dessicator.  The resultant pellet 
was resuspended in 21  l of High Dye Formamide (Applied Biosystems) and then 
analysed  on  an  ABI  PRISM
®  3100  Genetic  Analyzer  (Applied  Biosystems).  
Nucleotide sequences were entered into the Basic Local Alignment Search Tool  for 
nucleotides  (blastn)  program    (http://www.ncbi.nlm.nih.gov/BLAST)  for 
identification.  
  69 
CHAPTER 3 
 
NO EVIDENCE FOR A DIRECT ASSOCIATION BETWEEN MEASLES 
VIRUS AND HODGKIN LYMPHOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The material presented in this chapter has been published as a scientific paper: 
 
Measles virus and classical Hodgkin lymphoma: No evidence for a direct association. 
Wilson KS, Freeland JM, Gallagher A, Cosby SL, Earle JA, Alexander FE, Taylor 
GM, Jarrett RF.  Int J Cancer. 2007. Jul 15;121(2):442-7.      
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3.1  INTRODUCTION 
In the four disease model, described in Section 1.4.3, the largest group of HL cases 
within the developed world are young adults aged 15-34 years old (Jarrett 2002).  The 
risk of developing young adult HL has been associated with high social class, a high 
level of maternal education, small family size, early birth order (Gutensohn 1982) and 
lack of preschool attendance  (Chang et al 2004).  It has been proposed that such 
factors diminish an individual’s exposure to infectious agents in early childhood and 
thereby increase their susceptibility to a virus-induced pathogenesis later in life – this 
is the so-called late host response model.   
 
Paradoxically,  since  <25%  of  young  adult  cases  are  EBV-associated  (Jarrett  et  al 
2003), EBV is not the elusive agent implicated in this group of cases.  A potential 
candidate virus should be common and infect most, or many, individuals in childhood.  
Serological  and  molecular  studies  have  explored  possible  associations  with  other 
members  of  the  herpesvirus  family,  the  polyomaviruses  (JCV,  BKV,  SV40  and 
lymphotropic papovavirus (LPV)), parainfluenza virus, human T-cell leukaemia virus 
types 1 and 2, and adenovirus types 5 and 12 (Armstrong et al 1998; Berneman et al 
1998; Evans and Gutensohn 1984; Gallagher et al 2002; MacKenzie et al 2003).  With 
the exception of an association between non-EBV-associated HL and high antibody 
titres  to  human herpesvirus 6, no positive  associations have emerged  (Clark et  al 
1990) (D. Clark and R. Jarrett, unpublished data). 
 
Recently an association between measles virus (MV) and HL in Israel was reported 
(Benharroch et al 2003).  Prompted by epidemiological findings, biopsies from 68 HL 
patients were analysed for the presence of MV proteins using IHC.  Using an anti-     
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MV-nucleoprotein  (NP)-specific  antibody  H14  cytoplasmic  MV  NP  was  detected 
within the HRS cells of 41 (60.3%) of their original cohort of 68 HL patients, the 
majority of which were classified as NSHL (Benharroch et al 2003).  This cohort was 
later expanded to 143 cHL cases and IHC was performed using a larger panel of anti-
MV antibodies (anti-NP [H14, L39/22, L39/61] and anti-hemagglutinin [K83, L77, 
NS32])  (Benharroch  et  al  2004).    Expression  of  MV  antigens  was  demonstrated 
within  the  HRS  cells  of  105  (73.4%)  cHL  cases,
a  but  there  was  not  complete 
concordance between the results from different antibodies.  EBV was detected in 44 
(30.8%) of cases but there was no evidence of an inverse relationship between EBV 
and MV positivity.  MV RT-PCR was subsequently performed on biopsy samples 
from 19 of the cHL cases, of which only 2 (10.5%) were positive. 
 
The MV is a member of the genus Morbillivirus within the Paramyxoviridae family 
(Griffin 2001).  The virions are spherical (see Figure 3.1a) with a helical nucleocapsid 
(NP) and are enclosed by an envelope containing two different surface projections 
(called peplomers) with distinct morphologies: the hemagglutinin (H) proteins appear 
conical in shape and the fusion (F) proteins are dumbbell-shaped.  The matrix (M) 
protein  lines  the  inside  of  the  envelope  and  interacts  with  the  peplomers  and  the 
nucleocapsid.    The  large  (L)  and  phosphoprotein  (P)  proteins  are  internal  virion 
components present in limited quantities and may represent part of the transcription 
complex.  The MV genome (see Figure 3.1b) is a linear, negative-sense, single-strand 
RNA  and  has  been  completely  sequenced.    It  is  approximately  15.9kb  in  length, 
although this differs slightly between virus strains or passage histories of the same 
strain.  Eight proteins are encoded from six genes which are arranged in the order 3 -
NP-P-M-F-H-L-5 .  Several proteins are encoded by the P gene: the P protein and 
aDNA sequences homologous to measles virus RNA have been identified in tissues affected with 
systemic lupus erythemotosus, providing evidence for the integration of these viruses into the cellular 
genome (Zhdanov, 1975). 
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three  non-structural  proteins  (C,  V  and  R),  which  are  translated  from  alternative 
reading frames. 
 
MV establishes a systemic infection beginning in the respiratory tract and spreading 
initially to the lymphatic tissues, then to organs and tissues.  Monocytes and 
macrophages have been identified in mice as early targets of MV infection, with both 
B- and T-lymphocytes infected at lower levels (Roscic-Mrkic et al 2001).  An 
efficient MV-specific immune response is usually initiated which eliminates the 
infection and incurs life-long immunity against the virus (Griffin 2001).  Secondary 
infections can occur in immunosuppressed individuals.      
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a) 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
Figure 3.1. Schematic diagram of a) the measles virus and b) its RNA genome (based 
on a figure from (Griffin 2001)).  P/V/C/R region encodes the phosphoprotein (P) and 
the V, C and R non-structural proteins.  The shaded region indicates untranslated 
RNA.    F,  fusion  protein;  H,  hemagglutinin;  L,  large  protein;  M,  matrix,  NP, 
nucleoprotein; P, phosphoprotein  
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There is a body of literature linking MV and HL.  In a study primarily designed to 
investigate the association between mumps virus and HL, Truant and Hallum (1976) 
detected measles-specific antigens in six out of seven HL lymph nodes using an anti-
measles antiserum (Truant and Hallum 1976).  The cellular localisation of the MV 
was not reported and MV antigens were also detected in 9 out of 18 control tissues in 
this study.  Despite these positive findings, a large serological study of HL in young 
adults found no significant difference between the distributions of measles antibody 
titres in cases and controls (Rocchi et al 1975).  A later case-control study of HL in 
young adults aged 15-24 years reported that the risk of developing HL was decreased 
in individuals with a past history of measles (Alexander et al 2000).  Case-control 
differences were significant for measles infection at all ages, measles infection at 5-10 
years of age, and for non-EBV-associated cases compared to controls.  These data 
suggest  a  specific  protective  effect  of  measles  in  school  age  children  and  are 
consistent with the late host response model described earlier. 
 
Overall, previous publications do not provide evidence for a consistent association 
between  MV  infection  and  the  development  of  HL.    In  addition  to  studies 
investigating an aetiological association between MV and HL, there are several case 
reports describing the regression of HL following measles infection (Mota 1973; Taqi 
et al 1981; Zygiert 1971).  It has been suggested that this regression may be related to 
interferon production or other immunomodulatory effects of MV (Gopas et al 1992; 
Schattner 1984).   
 
The live attenuated Edmonston B strain of MV is known to have a specific oncolytic 
effect  in  a  number  of  human  tumours,  including  B-cell  lymphoma  xenografts  in      
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severe combined immune deficient (SCID) mice (Grote et al 2001).  Infection has 
been shown to cause immediate cytopathic effect with extensive syncytial formation 
in  some  tumours,  with  minimal  damage  to  normal  cells  (Peng  et  al  2001).    The 
mechanism by which this occurs is not well understood.   
 
MV is normally associated with lytic infection and cell fusion.  Occasionally the virus 
is  able  to  establish  a  persistent  infection,  best  described  in  subacute  sclerosing 
panencephalitis.  Persistent infection of lymphoid cell lines has also been reported 
(Fernandez-Munoz and Celma 1992; Minagawa and Sakuma 1977) and the virus has 
been detected in peripheral blood mononuclear cells and lymphoid subsets (Jacobson 
and McFarland 1982; Joseph et al 1975; Kawashima et al 1996).  These data, coupled 
with the case reports mentioned above, suggest that MV may be able to infect and 
persist  in  HRS  cells.    Mechanisms  involved  in  the  establishment  of  persistent 
infection are not well understood but both virus and host cell variation have been 
implicated (Boriskin et al 1986; Hummel et al 1994; Rima et al 1977; Rustigian 1966; 
Young et al 1985). 
 
This chapter will describe how, in response in the publication by Benharroch and 
colleagues (2003), we expanded previous observations on reported history of measles 
infection  and  subsequent  risk  of  HL,  and  screened  HL  samples  from  the  UK  for 
evidence of MV infection. 
 
Aims 
  To investigate HL biopsies from UK patients for evidence of MV infection. 
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3.2  MATERIALS & METHODS 
3.2.1  Case selection 
A  population-based,  case-control  study  called  the  Scotland  and  Newcastle 
Epidemiological Study of Hodgkin’s Disease (SNEHD) has been undertaken by our 
group and described previously (Alexander et al 2003; Jarrett et al 2003).  HL cases 
were identified from the Scotland and Newcastle Lymphoma Group (SNLG) Registry, 
the Scottish Cancer Registry and Northern Region Cancer Registry.  Five hundred and 
eighty-four confirmed cases of HL aged between 16 and 74 years old were eligible for 
inclusion.  A similar number of controls were matched by age, sex and residential 
region.    Ethical  permission  was  obtained  and  interviews  were  conducted  with  a 
structured  questionnaire  being  completed  by  consenting  cases  and  controls.    Any 
childhood infections were recorded, including measles, mumps, chicken pox, rubella 
and pertussis.  The age of infection was noted and results were analysed with respect 
to the age of infection in three age groups: 0-4 years; 5-10 years; and over 10 years.  
Following the collection of data, four comparisons were performed systematically: all 
cases versus controls; non-EBV-associated HL cases versus controls; EBV-associated 
cases  versus  controls;  and  non-EBV-associated  versus  EBV-associated  cases.    All 
statistical  analyses  were  performed  by  Professor  Freda  Alexander  (University  of 
Edinburgh, UK).   
 
Biopsy material was retrieved from the SNEHD cases and subjected to histological 
review, which was approved by the pathology working party of the SNLG.  The EBV 
status of the tumours was determined by EBER ISH on paraffin-embedded sections 
(performed  by  Mrs.  June  Freeland).    In  cases  where  the  results  were  difficult  to 
interpret or where there were large numbers of EBV-positive cells, LMP1 IHC was      
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also performed.  A case was identified as EBV-associated if HRS cells were positive 
in either assay. 
 
A subset of 97 HL cases (see Table 3.1), from which surplus paraffin-embedded tissue 
was available, was investigated for the presence of MV antigen using IHC.  Viably 
stored biopsy material was available from a second group of 20 cHL cases (see Table 
3.2) and these samples were investigated for evidence of MV infection using RT-
PCR.  Thirteen lymph node biopsies, which demonstrated only reactive changes, were 
included as controls in these latter experiments.  
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Table 3.1. Details of patients in case series 1.   
 
    Histological subtype  EBV status 
Age group  n  MCHL  NSHL  LDHL  LRCHL  Non-EBV-
associated 
EBV-
associated 
15-34 years  51  7  43  -  1  38  13 
35-49 years  17  7  9  -  1  10  7 
50-74 years  29  11  17  1  -  17  12 
All  97  25  69  1  2  65  32 
 
MCHL,  mixed  cellularity  Hodgkin  lymphoma;  NSHL,  nodular  sclerosis  Hodgkin 
lymphoma; LDHL, lymphocyte depleted Hodgkin lymphoma; LRCHL, lymphocyte 
rich classical Hodgkin lymphoma; n, number of patients. 
 
Table 3.2.  Details of patients in case series 2.   
 
    LYMPH NODE HISTOLOGY 
Age group  n  MCHL  NSHL  LRCHL  Reactive node 
<35 years  24  -  11  -  13 
35-49 years  5  1  3  1  - 
50+ years  4  1  3  -  - 
All  33  2  17  1  13 
 
MCHL,  mixed  cellularity  Hodgkin  lymphoma;  NSHL,  nodular  sclerosis  Ho dgkin 
lymphoma; LRCHL, lymphocyte rich classical Hodgkin lymphoma; n, number of 
patients.     
  79 
3.2.2  Immunohistochemistry 
Sections of formalin-fixed, paraffin-embedded lymph node biopsy material from 97 
HL cases and 13 controls were examined by IHC (performed by Mrs. June Freeland 
and  myself)  using  a  mouse  monoclonal  antibody  (IgG1-   clone  49-21; 
Immunologicals Direct, Oxford, UK) known to be reactive with the MV NP.   
 
Sections on slides were dewaxed and rehydrated by the following series of immersive 
steps: Citroclear (HD Supplies, Aylesbury, UK) for 20 mins, 90% ethanol for 2 mins, 
70% ethanol for 2  mins, and water.  Antigen  retrieval  was  performed  by heating 
EDTA buffer (pH8.0) in a pressure cooker until boiling, then transferring the dewaxed 
slides into the pressure cooker and placing the lid on top securely.  The pressure 
cooker was allowed to reach full pressure for 3 mins, then the slides were removed 
and cooled to room temperature.  The remainder of the procedure was performed at 
room temperature and the sections were not allowed to dry out.  Initially the sections 
were washed twice in 1x Tris buffered saline (TBS; 50 mM Tris-HCl pH8.0, 150 mM 
NaCl, adjust to pH7.6) for 5 mins.  The slides were then immersed in 1.5 % hydrogen 
peroxide/methanol  for  10  mins  to  inhibit  endogenous  peroxidase,  which  may 
otherwise contribute to background staining.  Two washes in water for 5 mins each, 
followed by a further two 5 minute washes in 1x TBS were performed before 100  l 
of  20%  normal  horse  serum  (from  the  Vectastain   kit;  Vector  Laboratories, 
Peterborough, UK) was pipetted over each section and incubated for 10 mins.  The 
primary MV NP antibody (Immunologicals Direct, Oxford, UK), diluted 1:80, was 
pipetted over the sections, which were incubated for 1 hour.  The slides were washed 
twice in 1x TBS, as before, then 100  l of the secondary antibody (biotinylated anti-
mouse IgG from the Vectastain  kit; Vector Laboratories), was pipetted onto each      
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section and allowed to incubate for 30 mins.  The slides were washed twice in 1x TBS 
then  a  few  drops  of  the  avidin-biotin  peroxidase  complex  [ABC]  (from  the 
Vectastain  kit; Vector Laboratories) were added to each section, to detect bound 
antibody, and allowed to incubate for 30 mins.  The slides were immersed twice in 1x 
TBS  prior  to  incubation  in  the  chromogenic  substrate,  tetrahydrochloride  3,3 -
diaminobenzidine  [DAB]  (Sigma-Aldrich  Company  Ltd.,  Dorset,  UK),  for 
approximately 10 mins, until staining of the positive control could be visualised.  The 
slides were washed twice in 1x TBS before counterstaining with haematoxylin and 
dehydration by a series of immersions in methanol, 100% ethanol and citrate buffer 
(10mM Citric Acid, 0.05% Tween 20, adjust to pH 6.0).  Once dry, the sections were 
mounted, using the resinous mounting medium depex polystyrene (DPX), and left to 
dry O/N on a heat block. 
 
MV (Zagreb strain)-infected Vero cells were obtained from Dr. S.L. Cosby (Queen’s 
University, Belfast).  Cells were harvested at 72 hours after infection, pelleted, fixed 
in  formalin  and paraffin-embedded.  Sections  were subsequently used in the  IHC 
assay as positive controls.  In order to avoid contamination of case DNA with MV 
within the laboratory, the cells were handled within a Class II MSC hood, which was 
sterilised with formalin following the harvesting of infected cells. 
 
3.2.3  Reverse Transcription (RT)-PCR 
Single cell suspensions were prepared from lymph node biopsies and total RNA was 
extracted  using  the  RNAqueous®  kit  (Ambion  Ltd.,  Cambridgeshire,  UK).    One 
microgram  of  RNA  was  used  as  the  template  for  cDNA  synthesis  with  the 
Superscript
TM II RNase H
- reverse transcriptase (Invitrogen Ltd.) and 2.5  M random      
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oligonucleotide  primers  (Invitrogen  Ltd.),  according  to  the  manufacturer’s 
instructions.  The resultant cDNA was used as template in both conventional and 
QRT-PCR (100 ng and 50 ng used per reaction respectively). 
 
cDNA prepared from MV (Zagreb-strain) infected Vero cells and MV (Edmonston-
strain) infected human osteosarcoma (HOS) cells were included as positive controls.  
Total RNA was extracted from both cell types using the QIAamp Viral RNA Mini kit 
(QIAGEN Ltd, Crawley, West Sussex, UK).  cDNA was synthesised as above for use 
as positive control templates in both conventional and QRT-PCR studies. 
 
3.2.4  Conventional PCR 
Previously published oligonucleotides (see Table 3.3) for the amplification of the MV 
H and NP genes were synthesised and used for nested PCR (Chadwick et al 1998). 
 
First round PCR involved the use of 200  M of nucleotides (Amersham Pharmacia 
Biotech,  Buckingham,  UK), ReddyMix
TM  PCR Master Mix (containing 5 U/ l  of 
Thermoprime Plus DNA polymerase; Abgene®, Surrey, UK), primers at the stated 
concentrations (see Table 3.3) and 1  g of cDNA template in a total reaction volume 
of 50  l.  The following thermal cycling conditions were used on a GeneAmp PCR 
System 9700 (Applied Biosystems): 94
oC for 2 mins followed by 35 cycles (H assay) 
or 40 cycles (NP assay) of 94
oC for 30 seconds; 46
oC (H assay) or 55
oC (NP assay) 
for 1 minute; 72
oC for 30 seconds; and a final extension at 72
oC for 5 mins.  The 
nested PCRs were performed in a total reaction volume of 25  l and included 1  l of 
the first round product, the oligonucleotides shown in Table 3.3, and ReddyMix
TM 
PCR Master Mix and nucleotides as described above.  Thermal cycling conditions      
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were as detailed above, but for 25 and 40 cycles in the H and NP assays respectively.  
One hundred nanograms of positive control cDNA template, synthesised from both 
MV-infected Vero and MV-infected HOS cells, was included in each assay in order to 
confirm  specificity.    All  PCR  products  were  analysed  by  electrophoresis  on  8% 
polyacrylamide gels (see Section 2.2.16).  The outer primers and nested PCR assays 
were expected to result in amplicons of 595bp and 335bp respectively for the H assay, 
and 528bp and 459bp respectively for the NP assay. 
 
Confirmation that all samples contained sufficient amplifiable cDNA was provided by 
amplification of the GAPDH gene using the forward and reverse primers designed in-
house (see Table 3.3).  Reaction conditions were identical to those described for the 
initial  NP  outer  primer  set  and  an  amplicon  of  603bp  was  generated  from  each 
sample. 
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Table 3.3.  Conventional PCR primers.  
 
Conventional 
PCR primer 
Gene  Position 
(bp) 
Sequence  Final 
concentration 
in PCR  
(µM) 
H1 5’outer  H  8106-8125  CAG TCA GTA ATG ATC TCA GC  0.25 
H2 3’ outer  H  8677-8701  CTT GAA TCT CGG TAT CCA 
CTC CAA T 
0.25 
H3 5’ inner  H  8147-8171  GAG CTC AAA CTC GCA GCC 
CTT TGT C 
1 
H4 3’ inner  H  8458-8482  ATC CTT CAA TGG TGC CCA 
CTC GGG A 
1 
N1 5’ outer  NP  97-126  GGG ATA TCC GAG ATG GCC 
ACA CTT TTA AGG 
1 
N2 3’ outer  NP  597-625  GGG CTA GGA TGG TAC CCA 
GAA TCA TGT TG 
1 
N3 5’ inner  NP  106-128  GAG ATG GCC ACA CTT TTA 
AGG AG 
0.25 
N4 3’ inner  NP  564-587  GGG TCT TGC ACT TCA ATA 
TCT GAG 
0.25 
GAPDH 5`   GAPDH  210-228  TTC CAC CCA TGG CAA ATT C  1 
GAPDH 3`   GAPDH  791-811  TTT CTA GAC GGC AGG TCA 
GGT 
1 
 
H  –  hemagglutinin  primers;  NP  –  nucleoprotein  primers;  H1,  H3,  N1  and  N3  – 
forward primers; H2, H4, N2 and N4 – reverse primers      
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3.2.5  Quantitative real-time PCR 
The Primer Express
TM version 1.0 software (Applied Biosystems) was used to design 
TaqMan
® assays based upon regions of highly conserved sequence in the MV H and 
NP coding sequences (see Table 3.4).  Amplification reactions were performed in a 
final volume of 25  l (see Section 2.2.7) with 100 ng of cDNA template, and primers 
and  probes  used  at  the  concentrations  shown  in  table  3.4.    Thermal  cycling  and 
analysis  were  performed  on  an  ABI  PRISM®  7700  Sequence  Detection  System 
(Applied Biosystems).  Samples were initially incubated at 50
oC for 2  mins, then 
95
oC for 10 mins followed by 40 cycles of 95
oC for 15 seconds and 60
oC for 60 
seconds.    cDNA  was  extracted  from  MV-infected  HOS  cells  and  included  as  a 
positive control.  ‘No template controls’, containing molecular biology grade water in 
place of cDNA, were included after every second cDNA sample.  A TaqMan
® Pre-
Developed Assay for GAPDH (Applied Biosystems) was utilised to confirm that each 
sample contained amplifiable cDNA.  cDNA (50 ng per reaction) from seven HL-
derived cell lines (L1236, L428, L540, L591, KMH2, HDLM2 and HO) was also 
investigated using both MV TaqMan
® PCR assays.      
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Table 3.4.  Quantitative real-time PCR primers and probes. 
 
Primers & 
Probes 
Gene  Position 
(bp) 
Sequence  Final 
concentration 
in PCR 
(µM) 
MVH5’  H  7651-7677  GGA TAG GGA GTA CGA CTT CAG AGA 
TCT 
0.05 
MVH3’  H  7708-7734  GCA CAG TAT TGA TCA TAA TCC AAT 
TTG 
0.05 
MVH probe  H  7679-7706  FAM-ACT TGG TGT ATC AAC CCG CCA 
GAG AGA A 
0.2 
MVN5’  NP  301-319  AGC GGG CCC AAA CTA ACA G  0.3 
MVN3’  NP  371-391  GGT CAT CGG TGA TCC TCT GAA  0.3 
MVN probe  NP  330-369  FAM-AGG TAT ATT ATC CTT ATT TGT 
GGA GTC TCC AGG TCA ATT G 
0.2 
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3.3  RESULTS 
3.3.1  Epidemiology 
A self-reported history of previous measles was available for 463 controls and 344 
cHL cases included in the SNEHD study.  There was no significant difference in the 
proportion of cases reporting measles (237/463, 69%) compared to controls (343/463, 
74%) [odds ratio (OR) 0.82, 95% confidence interval (CI) 0.60-1.13].  Consistent with 
the introduction of the measles vaccine in the UK in the 1960s, a smaller proportion 
of young adults reported previous measles, but there was no significant difference 
between  cHL  cases  and  controls.    No  significant  differences  emerged  when  EBV 
status  of  cHL  tumours  was  included  in  the  case/control  analyses,  or  when  EBV-
associated cHL cases were compared with non-EBV-associated cHL cases.  When the 
analysis was restricted to young adults and age at infection with MV was taken into 
consideration,  all  cases  and  the  non-EBV-associated  cases  showed  considerable 
heterogeneity.    Similar,  though  weaker,  associations  are  evident  for  the  EBV-
associated cases.  Few infections occurred in subjects over the age of 10 years; among 
young adults only 6 controls and 4 cases reported measles after this age. 
 
3.2.2  Immunohistochemistry 
Sections from 97 HL biopsies and 13 reactive nodes were screened for the presence of 
MV nucleoprotein using IHC.  No positive staining was observed in any of these 
samples,  although  a  strong  reactivity  was  displayed  by  the  positive  controls  (see 
Figure 3.2).  Case histories were available for 78 of these patients, 52 of whom had 
reported prior measles infection.      
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Figure 3.2. Detection of measles virus (MV) by immunohistochemistry.  MV-infected 
Vero  cells  stained  with  a  mouse  monoclonal  antibody  reactive  with  the  MV  NP 
protein (x200). 
 
3.3.3  Reverse Transcriptase  (RT)-PCR  
RT-PCR was performed using RNA extracted from biopsy samples from cases in 
series 2 and seven HL-derived cell lines.  All resultant cDNA samples were shown to 
be  amplifiable  by  the  generation  of  positive  results  in  both  conventional  and 
quantitative  real-time  GAPDH  PCR  assays  (see  Figure  3.3).    Products  were  not 
detected following PCR of the cHL and reactive node cDNA samples using the H and 
NP assays (see Figures 3.4 and 3.5). 
 
In the H and NP QRT-PCR assays, MV+HOS cDNA was included to indicate the 
validity of each assay and to set up a standard curve which could be used to compare      
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positive  results.    Replicates  of  10-fold  serial  dilutions  of  the  positive  control 
MV+HOS cDNA were used for sensitivity analysis.  In the H assay, 2/2 replicates 
corresponding  to  1  x  10
-3  ng  amplified  MV+HOS  DNA,  and  1/2  replicates 
corresponding to 1 x 10
-4 ng amplified MV+HOS DNA were positive  (see Figure 
3.6).  In the final publication, serial dilutions of MV+HOS cDNA were amplified 
using the NP assay and products down to 1 x 10
-3 ng amplified MV+HOS DNA were 
detectable (performed by Dr Alice Gallagher). 
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(a) Serial dilutions of MV + HOS cDNA 
 
(b) cDNA extracted from reactive nodes 
   
(c) cDNA extracted from cHL samples 
   
 
Figure 3.3. Quantitative real-time PCR results for the GAPDH assay.  Amplification 
curves are shown for (a) serial dilutions of cDNA extracted from MV-infected HOS 
cells; (b) cDNA extracted from reactive nodes; and (c) cDNA extracted from cHL 
samples.     
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(a) Serial dilutions of MV + HOS cDNA 
 
(b) cDNA extracted from reactive nodes 
 
(c) cDNA extracted from cHL samples 
 
 
 
Figure  3.4.  Quantitative  real-time  PCR  results  for  the  measles  virus  (MV) 
hemagglutinin assay.  Amplification curves are shown for (a) serial dilutions of cDNA 
extracted from MV-infected HOS cells; (b) cDNA extracted from reactive nodes; and 
(c) cDNA extracted from cHL samples.  No amplification products were present in (b) 
and (c) so the amplification plots do not cross the threshold. 
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(a) Serial dilutions of MV + HOS cDNA  
 
(b) cDNA extracted from reactive nodes 
 
(c) cDNA extracted from cHL samples 
 
 
Figure  3.5.  Quantitative  real-time  PCR  results  for  the  measles  virus  (MV) 
nucleoprotein assay.  Amplification curves are shown for (a) serial dilutions of cDNA 
extracted from MV-infected HOS cells; (b) cDNA extracted from reactive nodes; and 
(c) cDNA extracted from cHL samples.      
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Figure  3.6.  Quantitative  real-time  PCR  results  for  the  measles  virus  (MV) 
haemagglutinin assay showing amplification curves for replicates of serial 10-fold 
dilutions of cDNA extracted from MV-infected HOS cells.  Replicates corresponding 
to 1 x 10
-3 ng of MV-infected HOS DNA were detected by this assay. 
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3.4  DISCUSSION 
Benharroch et al. (2003, 2004) previously reported an association between MV and 
HL.  Although cautious about attributing any causal role to the virus, they proposed 
an international effort to verify (or refute) their preliminary findings.  We therefore 
examined this association using both epidemiological and laboratory-based methods.  
In a population-based, case-control study we found no significant differences between 
the proportion of cases and controls reporting a previous history of MV infection, 
either in all cases or when only young adults were included in the analysis.  Few 
individuals reported measles over the age of 10 years.  These results do not, therefore, 
support the hypothesis that late exposure to MV, which can occur in unvaccinated 
patients and in vaccinated young adults with waning immunity, is associated with an 
increased  risk  of  developing  young  adult  cHL.    When  age  at  MV  infection  was 
considered, all cases and non-EBV-associated cHL cases in the young adult age group 
were significantly more likely to report measles below the age of 5 years, compared 
with those who reported measles at an older age.  A previous study of young adult 
(15-24 years) HL showed similar data, which suggests that this association could be 
true (Alexander et al. 2000).  It is not clear if measles occurring in school age children 
has a protective effect or may be proxy for another infection, which is aetiologically 
associated with cHL, and specifically non-EBV-associated cHL. 
 
IHC was used to examine 97 HL biopsies for the presence of MV antigens in HRS 
cells.  A monoclonal antibody reactive with the nucleoprotein was selected as this 
protein is expressed at high levels in infected cells and was the antigen detected most 
frequently by Benharroch et al. (2003).  In addition the antibody used is robust, works 
well on paraffin sections and shows little non-specificity (McQuaid and Cosby 2002).       
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We did not detect any positive reactivity in our samples suggesting that MV was not 
present in any of these biopsies.  Furthermore we were unable to detect evidence of 
MV RNA in lymph nodes affected by HL using RT-PCR, despite using previously 
described conventional PCR assays and a highly sensitive TaqMan® assay.  
 
Recently, a German-based research group has also reported no evidence of MV in 
cHL (Maggio et al. 2007).  Four cHL-derived cell lines (HDLM2, KMH2, L1236 and 
L428) and HRS cells microdissected from 25 cHL cases (from Germany and Israel) 
were analysed using nested RT-PCR assays, for the MV nucleoprotein, matrix and 
haemagglutinin genes, followed by Southern blot hybridisation.  IHC was performed 
on  12  cHL  paraffin-embedded  biopsies  using  an  anti-nucleoprotein  and  an  anti-
haemagglutinin MV antibody.  MV proteins had previously been reported in these 
Israeli cases by Benharroch et al. (2004).  However, Maggio et al. did not detect MV 
genomes or gene products in any of the samples or cell lines using these three highly 
sensitive  detection  techniques.  Our  results  are  completely  concordant  with  these 
findings. 
 
Technical  differences  between the methodologies  used and the possibility of non-
specific  immunohistochemical  staining  may  account  for  the  different  findings 
reported by Benharroch et al. (2003, 2004) with those from Maggio et al. (2007) and 
our study.  Additional studies including international collaborations should resolve 
these issues.  However, the combined results of our study and that of Maggio et al. 
(2007) make it highly unlikely that MV is a significant pathogen in cHL.  
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CHAPTER 4 
 
NO EVIDENCE OF POLYOMAVIRUS GENOMES  
IN HODGKIN LYMPHOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The material presented in this chapter has been published in two scientific papers: 
 
Viruses and Hodgkin lymphoma: no evidence of polyomavirus genomes in tumor 
biopsies.  
Wilson KS, Gallagher A, Freeland JM, Shield LA, Jarrett RF.   
Leuk Lymphoma. 2006 Jul;47(7):1315-21. 
 
Molecular methods for virus discovery.         
Jarrett RF, Johnson D, Wilson KS, Gallagher A. 
Dev Biol (Basel). 2006;123:77-88;119-32.      
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4.1  INTRODUCTION 
Polyomaviruses (PyV) are widely distributed in nature, infect most individuals at a 
young age and are known to be oncogenic in experimental systems (Cole 2001).  They 
can therefore be considered as etiological candidates in HL.   
 
Papillomaviruses  and  PyVs  are  non-enveloped,  circular,  double-stranded  DNA 
viruses belonging to the Papovaviridae family.  PyV are 45 nm in diameter, with a 
genome in the range of 4.7-5.3kb (Cole 2001).  These viruses have been isolated from 
humans (BKV, JCV), primates (SV40, lymphotropic papovavirus), bovines (BPyV), 
rodents (mouse and rabbit PyV) and birds (budgerigar fledgling PyV, goose PyV).  
Each PyV has a specific host range. 
 
BKV, JCV and SV40 are very similar to each other in size (approximately 5.2kb), 
genome organisation and DNA sequence.  The genome of these viruses is organised 
into  two  regions  of  approximately  the  same  size  containing  the  early  and  late 
transcription units.  Early transcription proceeds in a counterclockwise direction from 
the  origin  of  DNA  replication  (ori)  and  late  transcription  occurs  in  a  clockwise 
direction from ori.  The early region encodes two alternatively spliced transforming 
proteins: large T antigen and small t antigen.  The large T antigen directs production 
of  early  mRNA,  initiation  of  viral  DNA  replication  and  activation  of  late  gene 
transcription (Lee and Langhoff 2006).  The function of the small t antigen in human 
PyVs has not yet been confirmed, but it has been suggested that this protein supports 
the activity and cell transformation of the large T antigen (Lee and Langhoff 2006).  
The mouse and hamster PyVs encode three T antigens: large T, middle T and small t.        
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The late region of the PyV genome encodes a small regulatory protein called the 
agnoprotein as well as the capsid structural proteins VP1, VP2 and VP3, which are 
derived by alternative splicing from the same late transcript. 
 
A target cell may be either permissive or nonpermissive towards infection with PyV.  
A permissive cell is able to support DNA viral replication and lytic infection, whereas 
a non-permissive cell will not support viral replication and hence abortive infection or 
oncogenesis will result from viral entry into this cell (White and Khalili 2004). 
  
The two human PyVs were discovered in 1971.  BKV was isolated from the urine of a 
renal transplant recipient (with the initials BK) (Gardner et al 1971).  JCV was first 
identified in the brain of a progressive multifocal leucoencephalopathy (PML) patient 
(with the initials JC) (Padgett et al 1971).  Serological studies have detected JCV 
antibodies in 70-90% of normal healthy adults (Padgett and Walker 1973; Taguchi et 
al 1982), and BKV antibodies in approximately 80% of individuals (Chatterjee et al 
2000).    Both  PyVs  are  known  to  establish  asymptomatic  persistent  infections  in 
childhood, and are thought  to  be transported by  peripheral  blood  leucocytes  from 
primary infection sites (i.e. tonsil) to secondary sites of infection (i.e. kidney) where 
persistent latent infection continues throughout life (Atwood et al 1992; Dorries et al 
1994).    The  genomes  of  JCV  and  BKV  have  been  identified  in  peripheral  blood 
leucocytes  by  Southern  blot  analysis  and  immunofluorescence  (Smith  et  al  1998; 
Houff et al 1988; Dorries et al 1994).   In immunocompromised patients, however, 
JCV infection can become lytic and will induce the destruction of oligodendrocytes 
producing myelin, and result in PML (Major and Vacante 1989).  BKV infection of 
severely immunocompromised patients can induce acute urinary tract infections (e.g.,      
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BKV-associated  nephropathy),  which  often  leads  to  allograft  rejection  in  renal 
transplant patients (Nickeleit et al 1999). 
 
The oncogenic potential of these human polyomaviruses has been demonstrated by 
the development  of ependymomas,  pancreatic insulinomas  and osteocarcinomas  in 
BKV-inoculated newborn hamsters (Corallini et al 1978).  There have been recent 
reports  of  the  detection  of  the  BKV  large  T  antigen  in  osteosarcomas,  Ewing’s 
sarcoma, and brain tumours (De Mattei et al 1995).  JCV has been associated with 
brain cancer (Rencic et al 1996), paediatric medulloblastomas (Krynska et al 1999) 
and colon cancers (Enam et al 2002). 
 
It has been difficult to evaluate the exact role of JCV and BKV in human tumours due 
to the high level of seropositive individuals and the presence of latent BKV in normal 
human tissues.  One study has offered strong evidence against a causative role of 
these viruses in tumour development  (Knoll et al 2003).  QRT-PCR was performed 
using DNA extracted from microdissected cells of human urogenital carcinomas and 
normal surrounding tissue.  JCV and BKV DNA sequences were present to the same 
levels in both normal and tumour DNA.   
 
SV40 is a related primate virus which does not naturally infect humans but may have 
been introduced into human populations as a result of contamination of polio vaccines 
in the 1950s and early 1960s (Sangar et al. 1999;Shah & Nathanson 1976).  SV40 has 
been shown to be highly oncogenic in experimental animals and transforms rodent 
cells in culture (Diamandopoulos and Enders 1965).  Hamsters inoculated with SV40      
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develop lymphomas, brain tumours, oesteosarcomas and mesotheliomas (Carbone et 
al 1998). 
 
Two studies have reported the presence of the SV40 genome in a large proportion of 
NHLs in the USA using specific primers and probes designed against the large T 
antigen sequence of the viral genome (Shivapurkar et al. 2002;Vilchez et al. 2002).  
Shivapurkar et al. (2002) used conventional PCR to screen DNA samples extracted 
from 68 NHL tumours and identified SV40 sequences in 43% of cases.  The large 
number of amplification cycles (45 cycles) they required for reproducible detection 
led the authors to suggest that the virus was present at only low copy number within 
NHLs.  In a second study, by Vilchez et al. (2002), DNA samples extracted from the 
tumours of 154 NHL patients were screened for the polyomavirus large T antigen, 
using conventional PCR and consensus primers derived from a region of the antigen 
that is  highly  conserved across the human polyomaviruses.  Amplification  of this 
region of the large T antigen was achieved in 64/154 (42%) of the samples.  The 
authors  also  performed  Southern  blot  hybridisation  using  virus-specific  probes  to 
determine that the amplified sequences were derived from SV40 (Vilchez et al 2002).  
We were unable to confirm these findings following investigation of a series of 152 
NHL samples from the UK (MacKenzie et al 2003).  NHL samples were screened 
with  a  highly  sensitive  QRT-PCR  assay  for  SV40,  and  also  with  the  same 
polyomavirus consensus PCR assay that had been used by Vilchez et al. (2002).  All 
products from the consensus PCR assay underwent Southern blot analysis and were 
hybridised with an SV40-specific oligonucleotide probe (MacKenzie et al 2003).  No 
evidence  of  SV40  genomes  was  observed  within  this  series  of  NHL  cases.    A 
serological  study  in  the  USA  screened  520  lymphoma  cases  with  an  enzyme      
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immunoassay  for  SV40  antibodies  and  also  failed  to  find  any  evidence  for  an 
association of SV40 with lymphomas (de Sanjose et al. 2003).   They noted that HL 
cases  in  their  study  were  associated  with  a  non-statistically  significant  two-fold 
increased risk of being SV40 seropositive.  Since then a number of studies in the 
USA,  Germany  and  Tasmania  have  also  reported  a  lack  of  evidence  for  the 
association of SV40 with NHL (Schuler et al 2006; Sui et al 2005; Rollison et al 
2005; Engels et al 2005).  It has been suggested that a possible source of the false 
positives reported in previous molecular studies was contamination with laboratory 
plasmids, and that positive serological results may result from cross-reactivity with  
BKV and JCV (Shah 2007) and perhaps other polyomaviruses. 
 
Volter  et  al.  (1997)  previously  used  degenerate  PCR  to  screen  a  series  of  cases, 
including five cases of HL, for the presence of polyomaviruses (Volter et al. 1997).  
Degenerate PCR differs from conventional PCR by its use of a pool of degenerate 
primers.    These  degenerate  primers  are  designed  by  back-translating  a  highly 
conserved  peptide  motif  into  the  corresponding  nucleotide  sequence.    Degenerate 
assays have been used extensively to identify genes and proteins related to known 
proteins and are particularly useful when highly conserved regions or motifs of amino 
acids are present within proteins, including viral proteins.  Some amino acids are 
encoded by a number of different codons so in these positions a nucleotide variation is 
inserted within the oligonucleotide primer sequence during synthesis.  For example a 
Y  in  the  primer  sequence  indicates  that  either  a  cytosine  or  thymine-containing 
nucleotide  may  be  present  at  this  position.    The  degeneracy  level  of  a  primer  is 
defined  by  the  number  of  nucleotide  variations  present  within  its  sequence.    The 
higher  the  degeneracy  level  of  a  primer,  the  greater  the  number  of  nucleotide      
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variations  it  contains,  and  the  lower  the  predicted  sensitivity  of  subsequent 
amplification reactions.  Previously we determined that a primer degeneracy of 128-
fold or less is required to achieve an acceptable level of sensitivity for investigation of 
cHL biopsies (Jarrett et al 2006). 
 
The assays designed by Volter et al. were based on well conserved amino acid motifs 
within the structural protein VP1 and were reported to have the ability to detect single 
copy genomes (Volter et al. 1997).  Polyomavirus genomes were not detected in this 
study but, given the heterogeneous nature of HL, examination of a larger series of 
cases, with more sensitive assays based on the large T gene, appeared warranted.  A 
series of cHL cases was therefore investigated using specific QRT-PCR assays for the 
two human polyomaviruses and SV40, as well as degenerate PCR assays with the 
potential to detect novel polyomaviruses.  Our study was limited to cases of cHL; 
NLPHL was excluded since this histological subtype is thought to represent a distinct 
entity with a different cell of origin (Stein 2001). 
 
Aim 
  To screen biopsies from cHL patients for evidence of polyomavirus genomes.      
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4.2  MATERIALS AND METHODS 
4.2.1  Clinical Samples 
Lymph node biopsy samples from 35 non-selected cases of cHL were investigated 
(see Table 4.1); 17 cases were part of a previous study in which I had examined the 
association  between  SV40  and  lymphoma  (MacKenzie  et  al.  2003).    DNA  was 
extracted  from  fresh  or  frozen  lymph  nodes  using  either  proteinase  K  digestion 
followed by extraction with organic solvents, or the QIAamp DNA Blood Mini kit 
(Qiagen, Crawley, UK).  The EBV status of tumours was determined using EBV 
EBER in situ hybridisation (performed by Mrs. June Freeland).  Briefly, sections of 
paraffin-embedded  lymph  node  biopsies  were  hybridised  with  a  commercially 
available probe (Vector Laboratories, Peterborough, UK) and reactivity was detected 
using a hybridisation kit (Dako, Cambridgeshire, UK).  Cases in which the HRS cells 
were positive are designated EBV-associated.      
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Table 4.1. Patient characteristics. 
 
Patient characteristics  Number of patients 
Sex 
Male 
Female 
 
19 
16 
Age at diagnosis: 
≤14 
15-54 
≥55 
 
1 
32 
2 
Histological subtype: 
NSHL 
MCHL 
cHL NOS 
 
29 
5 
1 
EBV status: 
EBV-associated 
Non-EBV-associated 
 
12 
23 
 
NSHL - nodular sclerosis Hodgkin lymphoma; MCHL - mixed cellularity HL; cHL 
NOS – classical Hodgkin lymphoma not otherwise specified as further subtyping not 
possible. 
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4.2.2  Quantitative Real-Time PCR analysis 
 
DNA samples (500 ng) were screened using QRT-PCR assays for JCV, BKV and 
SV40 (MacKenzie et al. 2003) (see Table 4.2).  A QRT-PCR assay for β-globin was 
also  performed  to  confirm  that  all  samples  contained  sufficient  amplifiable  DNA 
(Gallagher et al. 1999) (see Table 4.2).  Thermal cycling and analysis were performed 
on  an  ABI  PRISM®  7700  Sequence  Detection  System.    Samples  were  initially 
incubated at 50
oC for 2 mins, then 95
oC for 10 mins followed by 40 cycles of 95
oC for 
15 seconds and 60
oC for 60 seconds. 
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Table 4.2. Quantitative real-time PCR (TaqMan®) primers and probes. 
 
Primer/Probe  Sequence (bp)  Final 
concentration 
in PCR (µM) 
BKV (MM) 5’ 
BKV (MM) Probe  
 
BKV (MM) 3’ 
TTG CTT CTT CAT CAC TGG CAA 
FAM-CAT ATC TTC ATG GCA AAA TAA ATC TTC 
ATC CCA TTT 
AGT CCT GGT GGA GTT CCT TTA ATG 
0.3 
 
0.2 
0.3 
BKV (AS strain) 5’ 
BKV (AS strain) Probe 
 
BKV (AS strain) 3’ 
TTG CTT CTT CAT CAC TGG CAA 
FAM- CAT ATC CTC ATG GCA GAA TAA ATC TTC 
ATC CCA TTT 
AGT CCT GGT GGA GCT CCT TTA ATG 
0.3 
 
0.2 
0.3 
JCV5’ 
JCV Probe 
JCV3’ 
TTC TCC CAG CAA TGA AGA GCT T 
FAM - CAC ACC CAA ACC ATT G 
TGC TAT TGC TTT GAT TGC TTC AG 
0.9 
0.2 
0.9 
SV40 5’ 
SV40 Probe 
SV403’ 
TTT GGG CAA CAA ACA GTG TAG C 
FAM- AAG CAA CTC CAG CCA TCC ATT CTT CTA T 
TGT TTG GTT CTA CAG GCT CTG C 
0.5 
0.2 
0.5 
-globin5’ 
-globin Probe 
-globin3’ 
GGC AAC CCT AAG GTG AAG GC 
FAM- CAT GGC AAG AAA GTG CTC GGT GCC T 
GGT GAG CCA GGC CAT CAC TA 
0.5  M 
0.2  M 
0.5  M 
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4.2.3  Degenerate PCR 
4.2.3.1 Design of polyomavirus degenerate PCR assays 
Polyomavirus  degenerate  PCR  primers  were  designed  based  on  large  T  antigen 
sequences  since  defective,  integrated  genomes  lacking  the  large  T  antigen  coding 
sequences are unlikely to be associated with transformation (Cole & Conzen 2001).  
Sequences in the 5’ end of the large T gene were avoided since SV40 sequences from 
this region are present in many cloning vectors and are known to be a source of PCR 
contamination (Lopez-Rios et al. 2004b).  Since HRS cells generally constitute 1% or 
less of the total cellular mass, we aimed to develop assays with the ability to detect a 
single copy genome present in <1% of the cells in any sample. 
 
Amino  acid  sequences  from  all  available  large  T  antigen  sequences  were  aligned 
using  ClustalW,  courtesy  of  the  BCM  search  launcher 
(http://dot.imgen.bcm.tmc.edu/multi-align/multi-align.html), and conserved blocks of 
amino acids were identified (see Figure 4.2).  Three peptide motifs were selected for 
design  of  degenerate  primers.    The  single  forward  primer  was  derived  from  the 
sequence E/DDVKG, which is conserved in all polyomaviruses except the Kilham 
strain of murine polyomavirus.  Since codons for E (glutamic acid) and D (aspartic 
acid) have the same nucleotides in positions 1 and 2, both amino acids are covered by 
this primer (see Table 4.3).   
 
The conserved sequence VNLE was selected for design of the reverse primer; two 
primers  were  synthesised  with  one  including  all  nucleotide  sequences  encoding 
KVNLE and the other including all those encoding PVNLE (see Table 4.3).  A third 
reverse primer, based on the sequence TMNEY, was also synthesised (see Table 4.3);      
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although  this  sequence  is  not  perfectly  conserved  across  all  polyomaviruses,  the 
resultant primer has low degeneracy (16-fold) and therefore use of this primer was 
predicted to result in an assay with superior sensitivity.  Clamp sequences of 15-16 
nucleotides were added to the 5’ end of each primer.  These sequences were based on 
the consensus nucleotide sequence at the relevant position of the viral genomes, with 
some  modifications  to  ensure  a  reasonably  high  melting  temperature  (Tm).    The 
presence of clamp sequences within the primers stabilises the primer binding.  Primers 
including  clamp  sequences  plus  two  nucleotides  of  non-degenerate  polyomavirus 
sequence were also synthesised separately for use in second round PCRs (see Table 
4.3).  The EDVKG and CLAMP-EDVKG primers were labelled with FAM and the 
CLAMP-VNLE  was  labelled  with  HEX;  all  primers  were  synthesised  by  TAG 
Newcastle Ltd. (Gateshead, UK). 
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EDVKG   KVNLE   TMNEY 
BKV        -----   -----   ----- 
JCV        -----   -----   ----- 
LPV        D----   -----   ----- 
SV40        -----   -----   ----F 
HaPV        -----   -----   -A--- 
Py (Crawford)    -----   -----   ----- 
Py (strain A2)    -----   -----   ----- 
Py (strain A3)    -----   -----   ----- 
Py (Kilham)     -VLAE   -----   -S--- 
BPyV        -----   P----   -C--- 
BFDV        -----   P----   ---N- 
GHPV        -----   P----   ---H- 
 
Figure  4.1.  Conserved  amino  acid  motifs  within  the  large  T  antigen  of 
polyomaviruses. BKV - BK virus; JCV - JC virus; LPV -lymphotropic papovavirus; 
SV40 - simian virus 40; HaPV - hamster polyomavirus; Py - murine polyomavirus; 
BPyV - bovine polyomavirus; BFDV - budgerigar fledgling disease virus; GHPV - 
goose haemorrhagic polyomavirus. 
- denotes amino acid identity.   
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Table  4.3.  Degenerate  PCR  primers  for  detection  of  polyomaviruses.  Clamp 
sequences are shown in italics. 
 
Primers  Fold 
Degeneracy 
Forward Primer EDVKG 
*GTTTATGGTTGTCTTTGANGAYGTNAARGG 
 
64 
Reverse Primer KVNLE 
GTTTCGGTGTTTCTTTTCNARRTTNACYTT 
 
128 
Reverse Primer PVNLE 
GTTTCGGTGTTTCTTTTCNARRTTNACNGG 
 
256 
Reverse Primer TMNEY 
GTTTGAGGCACAGAATAYTCRTTCATNGT 
 
16 
Forward CLAMP-EDVKG 
*GTTTATGGTTGTCTTTGA 
 
0 
Reverse CLAMP-VNLE 
#GTTTCGGTGTTTCTTTTC 
 
0 
 
N = A + G + C + T; Y = C + T; and R = A + G.   
* FAM-labelled oligonucleotides 
 
# HEX-labelled oligonucleotide. 
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4.2.3.2 Degenerate PCR methodology 
PCR reaction mixtures contained 1 µg DNA template, 4 µM of each primer, 200 µM 
dNTPs  (Amersham  Pharmacia  Biotech,  Buckinghamshire,  UK),  10x  PCR  buffer 
containing  1.5  mM  MgCl2,  5x  Q-solution  and  1.25  units  of  HotStarTaq  DNA 
polymerase (all from Qiagen).  Thermal cycling was performed on a GeneAmp PCR 
System 2400 (Applied Biosystems) using the following parameters: 95
oC for 15 mins, 
followed by five cycles of 94
oC for 60 s; 44
oC for 2 mins; 72
oC for 3 mins, followed 
by 35 cycles of 94
oC for 60 s; 55
oC for 2 mins; 72
oC for 3 mins followed by a final 
extension step at 72
oC for 7 mins.  The lower annealing temperature (44
oC) used in 
the initial five amplification cycles enables the primer to anneal to the template via its 
degenerate sequence.  The annealing temperature is then raised to 55
oC for the rest of 
the  reaction  to  allow  more  specific  amplification.    Following  amplification  with 
primer pair EDVKG/KVNLE or EDVKG/PVNLE, 1 µl of first round products was 
subjected to a further 20 cycles of amplification using primers CLAMP-EDVKG and 
CLAMP-VNLE and an annealing temperature of 45
oC.   
 
Amplification products were purified through EDGE Biocolumns in the Quickstep
TM 
PCR purification kit (VHBio).  One microlitre of purified product was mixed with 12 
µl HiDi Formamide, 0.25 µl of water and 0.25 µl of a 1:4 dilution of the GeneScan
TM 
size  standard  GeneScan
®-350  [ROX]
TM.    Analysis  was  performed  using  the  ABI 
PRISM
®  310  Genetic  Analyzer  and  GeneScan
®  analysis  software  (Applied 
Biosystems) to give  greater sensitivity and fragment size resolution than could be 
obtained by conventional electrophoresis. 
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4.2.3.3 Assay specificity and sensitivity 
The following templates were used to validate the specificity of the assay: SV40 viral 
DNA  (Form  1;  Invitrogen,  Paisley,  UK);  DNA  from  the  COS-7  cell  line,  which 
contains integrated SV40 large T antigen (Gluzman 1981); DNA extracted from cell 
culture supernatants containing BPyV; and plasmids containing the complete JCV, 
BKV, LPV and hamster polyomavirus (HaPV) genomes.  All samples were assayed in 
a background of 1 µg of DNA extracted from the T-lymphoblastoid J-JHAN cell line.  
In addition, DNA from the rabbit papovavirus (strain 443; LGC Promochem, London 
UK), a known but uncharacterised polyomavirus, was tested.  DNA was extracted 
from tissue culture supernatants using the QIAamp UltraSens Virus Kit (Qiagen).   
 
Replicates  of  serial  10-fold  dilutions,  predicted  to  contain  from  10
6  to  10  viral 
genomes, of SV40 and BPyV were assayed in a background of high molecular weight 
DNA to determine assay sensitivity.  Semi-log dilutions of viral templates were used 
to determine sensitivities in the range 10
2 - 10
4 viral genomes per 1 µg DNA. 
 
4.2.3.4 Hodgkin lymphoma samples 
Following optimisation and validation of the degenerate assays, DNA from the HL 
biopsies was assayed using each primer set.  In addition, a second round PCR was 
performed using the CLAMP primers (see Table 4.3).  Negative controls, with water 
replacing the DNA template, were included after each sample in order to control for 
PCR contamination, and J-JHAN DNA (1 µg) was used to control for non-specific 
amplification.  A conventional PCR assay for β-globin, which amplifies a 110 base 
pair product, was performed on all samples to verify the presence of amplifiable DNA 
(Saiki et al. 1988).        
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4.2.3.5 Cloning of degenerate PCR products for sequence analysis 
Degenerate  PCR  products  were  cloned,  using  the  TOPO
TM
  TA  Cloning
®  kit 
(Invitrogen Ltd.) and transformed into competent cells (see Section 2.2.17).  Plasmid 
DNA  was  extracted  from  the  subsequent  bacterial  culture  using  the  High  Pure 
Plasmid Isolation Kit (Roche) (see Section 2.2.17).  Sequence analysis was performed 
on an ABI PRISM
® 3100 Genetic Analyzer (Applied Biosystem), as described in 
Section 2.2.18, to further characterise degenerate PCR products in the anticipated size 
range for amplicons of polyomavirus genomes.  Nucleotide sequences were entered 
into blastn searches (http://www.ncbi.nlm.nih.gov/BLAST) for identification.  
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4.3  RESULTS 
In order to determine whether polyomaviruses are involved in the pathogenesis of HL, 
biopsy samples were first screened using sensitive PCR assays for the known human 
polyomaviruses  JCV  and  BKV,  and  the  primate  virus  SV40.    All  samples  were 
negative in these assays despite the presence of amplifiable DNA. 
 
Degenerate PCR assays with the potential to identify novel polyomaviruses were then 
designed and validated.  Primers were derived from the 3’ region of the large T gene 
and therefore do not amplify the SV40 sequences that are most frequently present in 
cloning vectors (Lopez-Rios et al. 2004).  Three assays, utilising a common forward 
primer,  were  developed.    Primer  pairs  had  the  expected  specificities:  JCV,  BKV, 
SV40, LPV and HaPV templates were amplified using the reverse primer KVNLE, 
whereas  BPyV  was  amplified  more  efficiently  using  the  PVNLE  reverse  primer.  
JCV,  BKV  and  LPV  genomes  were  also  successfully  amplified  using  the  reverse 
primer  TMNEY;  despite  an  imperfect  sequence  match,  SV40  was  also  efficiently 
amplified using this primer.  All amplification products were of the expected size – 
146  bp  for  the  EDVKG/KVNLE  or  EDVKG/PVNLE  assays  and  208  bp  for  the 
EDVKG/TMNEY assay (see Figure 4.3a).  When DNA from the rabbit papovavirus 
(RabPyV) was used as template, negative results were obtained using the PVNLE and 
TMNEY  reverse  primers  but  a  146  bp  product  was  generated  using  the 
EDVKG/KVNLE  primer  set  (see  Figure  4.3b).    The  nucleotide  sequence  of  this 
amplification product, and the predicted translation, were found to have homology 
with  known  polyomavirus  genomes  and  large  T  antigens,  respectively.    This 
nucleotide sequence has been deposited as GenBank accession number AY911513.       
  114 
The ability to amplify sequences from a previously uncharacterised member of the 
polyomavirus family confirms the usefulness of these assays. 
 
Analysis  of  serial  dilutions  of  template  DNA,  in  a  background  of  1  µg  of  high 
molecular weight DNA, was performed in order to determine assay sensitivity.  To 
have the ability to detect a single copy viral genome present in 1% of the cells, the 
assay should be able to detect 1.5 x 10
3 genomes in a 1 µg DNA sample.  Using the 
EDVKG and KVNLE or PVNLE primers we were able to detect 10
3.5 genome copies 
of SV40, JCV, BKV and BPyV, but could not consistently detect 10
3 copies.  Using 
the CLAMP primers in a second round reaction, we were able to detect 10
2.5 SV40 
genomes and 10
3 BPyV genomes.  As predicted, the assay incorporating the TMNEY 
primers was most sensitive having the ability to detect <10
2 SV40 genomes. 
 
DNA samples from 35 cases of cHL were assayed using the above degenerate PCR 
assays  for  polyomaviruses,  on  multiple  occasions.    No  PCR  products  in  the 
anticipated size range were detected on GeneScan analysis.  Given the sensitivity of 
these assays and their ability to detect a wide range of polyomavirus genomes, it is 
therefore highly unlikely that any of the HRS cells in our HL cases are infected by 
polyomaviruses.   In  addition,  since the assays are based on large T antigen, it is 
unlikely that these cells harbour defective, integrated genomes. 
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Figure 4.2. Electropherograms from GeneScan analysis of degenerate PCR products: 
a)  upper  panel:  amplification  of  SV40  sequences  using  primer  pair  EDKVG  and 
KVNLE; middle panel: amplification of bovine polyomavirus sequences using primer 
pair  EDKVG  and  PVNLE;  lower  panel:  amplification  of  SV40  sequences  using 
primer pair EDKVG and TMNEY. b) Amplification of partial genomic sequence from 
rabbit papovavirus.  Arrows indicate specific polyomavirus PCR products; * indicates 
ROX350 size marker (Applied Biosystems).  
 
 
a) 
*  *  *  *  *  *  *  *  * 
*  *  *  *  *  *  *  * 
*  *  *  *  *  *  *  * 
b) 
*  *  *  *  *  *  *  *  *      
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4.4  DISCUSSION 
The epidemiological features of young adult non-EBV-associated HL suggest that an 
infectious  agent  is  involved  in  disease  pathogenesis  (Gutensohn  &  Cole  1980).  
Previous studies from our laboratory indicate that herpesviruses are unlikely to be 
involved and the available data do not support the idea that EBV is using a ‘hit and 
run’ mechanism in non-EBV-associated HL cases (Gallagher et al 2002; Gallagher et 
al 2003). 
 
In our search for a potential viral etiological agent of young adult cHL, we designed a 
number of highly sensitive degenerate PCR assays capable of detecting the presence 
of  both  novel  and  known  polyomaviruses  down  to  10
2.5  genome  copies.    The 
specificity of these assays was demonstrated using DNA from BKV, JCV, BPyV, 
LPV, HaPV and COS-7 cells (known to contain integrated SV40).  A partial sequence 
from  a  previously  uncharacterised  rabbit  polyomavirus  was  successfully  amplified 
using  this  method  demonstrating  the  validity  of  these  assays.    The  rabbit 
polyomavirus amplified PCR product was sequenced and entered into the GenBank 
database (accession number AY911513). 
 
We used these polyomavirus-specific degenerate PCR assays and QRT-PCR assays, 
specific for SV40, JCV and BKV, to screen DNA samples from a group of 35 cHL 
patients.  No novel or known polyomavirus genomes were detected in any of these 
cHL cases providing strong evidence that polyomaviruses are not directly involved in 
HL pathogenesis. 
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Two  new  human  PyVs,  the  KI  and  WU  viruses,  have  recently  been  identified 
(Allander et al 2007; Gaynor et al 2007).  In Sweden, the KI virus was detected within 
1% (6/637) of nasopharyngeal aspirates using PCR (Allander et al 2007).  Sequence 
analysis indicated low homology (<30% amino acid identity) with known PyV, but 
phylogenetic analysis suggested a close relation with known primate PyVs.  The KI 
virus would have been detected by our EDVKG/KVNLE degenerate PCR assay if 
present in any of our samples.  In Australia, the WU virus was initially detected in the 
nasopharyngeal aspirate of a child with pneumonia (Gaynor et al 2007).  Sequence 
analysis indicated that the small T antigen, large T antigen, and the VP1, VP2 and 
VP3 capsid proteins were encoded, and phylogenetic analysis showed divergence with 
all known PyV.  A screening programme in both Australia and the USA, using WU-
specific conventional PCR primers, revealed that 2% (43/2135) of patients with acute 
respiratory tract infections had the WU virus.  If present within any of our samples, 
this virus would have been detected by the EDVKG/TMNEY degenerate PCR assay.
b 
 
The  putative  virus  for  young  adult  cHL  remains  elusive  but  complementary 
techniques  for  virus  discovery,  such  as  Virochip  analysis  (Wang  et  al  2003)  or 
representational difference analysis (MacKenzie et al 2006) which do not require a 
priori knowledge of the likely agent, need to be explored before a direct role for 
viruses in this disease can be excluded. 
bSince completion of this thesis, a new human PyV, the Merkel cell PyV, has been identified in 8 
out of 10 patients with Merkel cell carcinoma (GenBank accession number NC010277; Feng et al. 
2008).  Although the large T antigen has been identified within this virus, it would not be detected 
with any of our three degenerate PCR assays. 
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CHAPTER 5 
 
INVESTIGATION OF GENOME IMBALANCES AND GENE EXPRESSION 
IN cHL-DERIVED CELL LINES 
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5.1  INTRODUCTION 
Previous  studies  using  conventional  CGH  have  detected  recurrent  chromosomal 
imbalances in HRS cells and cHL-derived cell lines (Chui et al 2003; Joos et al 2000; 
Joos et al 2002; Joos et al 2003).  Array-CGH should help to refine the location of 
these imbalances. 
 
Joos and colleagues (2003) analysed cells from four EBV-negative cHL-derived cell 
lines,  HDLM2,  KMH2,  L1236  and  L428,  using  M-FISH,  FISH  and  conventional 
CGH.    Recurrent  gains  were  detected  in  9p24  (in  all  four  cell  lines),  2p16-p13 
(KMH2, L1236 and L428), 5p15 (HDLM2, KMH2 and L428) and 12p13 (HDLM2, 
L1236 and L428).  Both arms of chromosome 18 displayed losses of chromosomal 
material in HDLM2, KMH2 and L428.  Some gains were detected in just two of these 
EBV-negative  cell  lines:  1q31-q44,  2q23-q31,  3q26.1-q29,  5q34-q35,  6p25-p22, 
7q21,  7q31,  7q34-q35,  8p23-p22,  8q24.1-q24.3,  9q34,  11q24-q25,  16q23-q24  and 
17q11.2-q22.  Likewise, losses in 13q21-q31 were found in only KMH2 and L428. 
 
Chui et al. also used conventional CGH to examine chromosomal imbalances in four 
cHL-derived cell lines (Chui et al 2003): EBV-negative KMH2, L1236, L428 and 
EBV-positive L591.  A gain of chromosomal material in 9p24-p23 was detected in all 
four cell lines. Recurrent gains in 2p16-p13 and losses in chromosome 13, 15p11.1, 
21p13  and  22p13  were  identified  within  the  3  EBV-negative  cell  lines.    A  large 
number of imbalances were common to only two of the EBV-negative cell lines.  The 
EBV-positive L591 cell line had a different pattern of chromosome changes with a 
lower number of gains and losses.      
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Despite the different protocols and analysis methods used, the results of this latter 
study are largely similar to those reported by Joos et al. (2003).  When the results for 
the KMH2, L1236 and L428 cell lines are compared between the two studies, the 
imbalances reported in L428 show the most similarity.  Recurrent gains of 2p13-p16 
and 9p24, and recurrent losses in 13q were reported by both groups, suggesting that 
cHL is associated in some way with chromosomal imbalances within these regions.   
 
Conventional CGH is limited in its mapping resolution of 20 Mb (Kallioniemi et al 
1994).  However, array-CGH provides a more sensitive and quantitative approach to 
assess  DNA  copy  number  aberrations  within  tissue  samples  (Pinkel  et  al  1998; 
Snijders et al 2001; Solinas-Toldo et al 1997).   
 
This chapter will describe the detailed analysis of chromosomal imbalances in cHL-
derived cell lines using array-CGH.  As previously discussed (see Section 1.3), some 
of the cHL-derived cell lines have an uncertain association with the HRS cells in the 
tumours from which they originated (Wolf et al 1996), but conventional CGH analysis 
of these  cell lines  in  our laboratory  has  confirmed that they contain  chromosome 
abnormalities similar to those identified in single HRS cells (Chui et al 2003).   
 
Gene expression microarray studies of breast and prostate cancer cells have indicated 
that chromosomal imbalances have a significant impact on global gene expression 
patterns (Phillips et al 2001; Pollack et al 1999).  Given the recent identification of 
chromosome imbalances by conventional CGH analysis, it seemed possible that a 
similar  process  may  occur  in  cHL.    Gene  expression  profiling  was  therefore      
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performed on 3 cHL-derived cell lines, using commercially available oligonucleotide 
microarrays  (Affymetrix,  UK  Ltd.,  High  Wycombe,  UK),  and  the  results  were 
correlated with specific chromosome imbalances identified by array-CGH analysis.   
 
Aims 
  To refine the location of recurrent chromosomal imbalances in cHL-derived 
cell lines using array-CGH analysis. 
  To identify recurrent chromosomal imbalances common to the cHL-derived 
cell lines. 
  To  investigate  whether  these  chromosomal  imbalances  are  reflected  in  the 
gene expression profile. 
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5.2  METHODS  
5.2.1  Cell lines 
Six stable cell lines derived from cHL tissue or body fluids were used in this study.  
Five of these were EBV-negative: L1236, L428, L540, HDLM2 and KMH2.  The 
sixth, L591, is the only stable cHL-derived cell line known to be infected with EBV 
and is described as EBV positive.  The reference cell line used in both array-CGH and 
expression  array  hybridisation  was  the  B-lymphoblastoid  cell  line  IM9,  which  is 
derived from a female patient with multiple myeloma and is considered to have a 
stable diploid karyotype (Fahey et al 1971).  The source, tissue culture conditions, 
doubling time and harvesting details for each cell line are described in Chapter 2 
(Section 2.2.7). 
 
5.2.2  RNA and DNA extraction 
RNA was extracted using TRIZOL reagent following the manufacturer’s instructions 
(Section 2.2.8).  DNA was obtained by phenol-chloroform extraction, as described in 
Section 2.2.9.   
 
5.2.3  Preparation of samples for array-CGH 
DNA (25  g) from each cell line was fragmented by sonication, using the Bandelin 
Sonopuls HD2070 (GM 2070 generator with a UW 2070 ultrasonic converter) with a 
3mm titanium  probe, then purified using DNA Clean and Concentrator
TM-25 spin 
columns (Zymo Research) in accordance with the manufacturer’s protocol. 
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5.2.4  Labelling of genomic DNA by random priming 
Following sonication, equal quantities of the reference (IM9) and test (cHL cell line) 
DNA samples were labelled with either of the fluorescent dyes cyanine 5- or cyanine 
3-dCTP  (Perkin  Elmer  Life  Sciences,  Bucks,  UK)  by  random  priming  using  the 
BioPrime DNA Labelling System (Invitrogen Ltd.) as follows.  Forty microlitres of 
2.5x random primers were added to 2  g of both test and reference DNA in black 
Treff microfuge tubes (Anachem Ltd., Bedfordshire, UK) and the volume made up to 
82  l with dH2O.  Following denaturation, by placing at 95
oC for 7 mins, the tubes 
were placed on ice.  To each of the samples, 10  l of 10x low-dCTP dNTPs, 5  l of 
either Cy5- or Cy3-dCTP (Perkin Elmer Life Sciences, Bucks, UK) and 80 units of 
high  concentration  Klenow  fragment  (BioPrime  labelling  kit,  Gibco/BRL)  were 
added.  The tubes were vortexed briefly then incubated at 37
oC O/N.  Cy5 and Cy3 
are light-sensitive reagents so care was taken to work quickly in order to keep any 
light  exposure  to  a  minimum  during  the  labelling,  hybridisation,  and  post-
hybridisation stages of the experiment. 
 
The following day, 400  l of TE buffer (pH 7.4) was added to each labelled sample 
and then the entire reaction was purified through a Microcon 30 filter (Millipore (UK) 
Limited, Watford, UK).  The Cy5- and Cy3-labelled probes were combined and a 
master mix, which contained 1 mg/ml human Cot-1 DNA (Roche Diagnostics GmbH, 
Germany),  10  mg/ml  yeast  tRNA  and  253  l  TE  buffer  (pH  7.4),  was  added.  
Addition of human Cot-1 DNA is essential in order to block repetitive sequences 
present in the human genome.  Yeast tRNA was included to aid precipitation.  The 
combined labelled target was then concentrated by purification through a Microcon 30 
filter.  The reaction volume was made up to 46  l with dH2O, to allow for a potential      
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loss of 2  l by evaporation during pre-hybridisation boiling,
c and then 9.35  l of 20x 
SSC (3 M NaCl, 300 mM sodium citrate, adjusted to pH 7.0) plus 1.65  l of 10% 
SDS were added.  The target was stored for up to an hour at 4
oC or several hours at -
20
oC until required. 
 
5.2.5  Array fabrication and processing 
Array  probes  were  prepared  at  The  Wellcome  Trust  Centre  for  Human  Genetics 
(Oxford, UK) by Dr. Samantha Knight and colleagues, as described below.  The 1 Mb 
resolution arrays were then synthesised, as described below, by the Genomics Facility 
at the Wellcome Trust Centre for Human Genetics, Oxford, UK. 
 
DNA was extracted from 5 ml cultures of BAC clones using the standard alkaline-
lysis protocol (Sambrook 1989).  The BAC DNA was amplified in two PCR reactions 
using a WGA protocol modified from a previously published method (Fiegler et al 
2003).  Each DOP-PCR was performed with 100 ng of BAC DNA template and either 
the  SANGER-DOP-2  primer  (5’-CCGACTCGAGNNNNNNTAGGAG-3’;  MWG 
Biotech,  London,  UK)  or  the  SANGER-DOP-3  primer  (5’-
CCGACTCGAGNNNNNNTTCTAG-3’;  MWG  Biotech,  London,  UK).    For  each 
clone, the DOP products from both PCR reactions were checked using agarose gel 
electrophoresis, then combined and ethanol precipitated for >48 hours at -70
oC  in 
1/10
th  volume  of  3  M  sodium  acetate  and  twice  the  volume  of  100%  ethanol.  
Precipitated DNA was pelleted, washed in 70% ethanol and resuspended O/N at 4
oC 
in 21  l of dH2O.  After a further agarose gel electrophoresis, the products were 
mixed with DMSO, to give a final arraying solution of 50% dH2O: 50% DMSO, prior 
to transfer to a 384 well plate (product code X5001; Genetix Ltd., New Milton, UK).  
cPrior to hybridisation, the level of Cy5- and Cy3-dCTP incorporation in the labelled combined 
sample was measured on a Nanodrop ND-100 Spectrophotometer.  Samples were only considered 
suitable for hybridisation if >7 pmol/ l of each dye was detected. 
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The  DOP-products  were  then  spotted  in  triplicate  onto  aminosilane  coated  slides 
(CMT-GAP  slides;  Sigma-Aldrich  Company  Ltd.,  Dorest,  UK)  using  a  Gen  III 
Microarray spotter (Amersham Pharmacia Biotech).  The spots were arranged in 72 
blocks (12 x 6) on the array; each block contained 160 spots (16 x 10).  The arrays 
were  allowed  to  dry,  then  UV  irradiated  in  a  Stratalinker  (Stratagene  Europe, 
Amsterdam, The Netherlands) and baked for 2 hours at 80
oC.  The arrays were then 
sealed inside foil envelopes and stored at room temperature until required. 
 
Prior to hybridisation, the DNA on the arrays was denatured by immersing the array 
in boiling water for 2 mins, then washing in dH2O.  To improve the hybridisation 
signal, non-specific binding to the array was reduced by incubation in a blocking 
solution of 3.5x SSC, 0.1% SDS, 1% BSA at 50
oC for 45 mins.  The arrays were then 
washed briefly in dH2O and dehydrated by passing through a series of 70%, 95% and 
100% ethanol washes followed by centrifugal drying.  Arrays were stored in plastic 
containers at room temperature until use. 
 
5.2.6  Array-CGH 
In preparation for hybridisation, the labelled genomic DNA samples were denatured 
at 95
oC for 5 mins, and immediately transferred to a 37
oC heatblock for 55 mins, to 
enable the blocking step to proceed.  Coverslips were stored in 100% ethanol prior to 
use to prevent smearing or dust sticking to the surface.  During incubation of the 
probe,  the  coverslips  were  placed  into  50  ml  Falcon  tubes  (Becton  Dickinson, 
Cowley, UK) and dried in a microwave at full power for 30 seconds.  When only 5 
mins of sample incubation remained, the hybridisation chambers (Fisher Scientific 
UK, Loughborough, UK) were prepared by adding a few drops of 3.4x SSC to the      
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wells at each end of the chamber.  Both the coverslip and array slide were checked to 
make sure they were dust and smear-free before the labelled target was pipetted onto 
the centre of the coverslip, and the array slide carefully lowered onto the coverslip.  
The slide was then turned the correct way up and placed inside the hybridisation 
chamber.    The  closed  and  sealed  chambers  were  immersed  in  a  gently  shaking 
waterbath at 65
oC for over 36 hours. 
 
5.2.7  Post-hybridisation washes 
During  the  post-hybridisation  washes  the  array  slides  were  kept  in  the  dark.    On 
removal  from  the  hybridisation  chamber,  the  slide  was  placed  in  a  Coplin  jar 
containing 2x SSC, 0.03% SDS for 5 mins at room temperature.  The coverslip was 
then gently removed and discarded before transfer of the array slide to a glass slide 
holder with no base.  The holder was submerged in 2x SSC, 0.03% SDS preheated to 
65
oC, and shaken vigorously in the dark for 5 mins.  The slide and holder were then 
briefly rinsed in 0.2x SSC at room temperature and then submerged in 0.2x SSC and 
vigorously shaken for 15 mins in the dark at room temperature.  This latter wash step 
was  repeated  a  further  five  times  before  the  slide  was  removed  and  dried  by 
centrifugation.  Hybridised slides were placed in a light-proof plastic box and scanned 
immediately, as described below. 
 
5.2.8  Image acquisition and data analysis 
The fluorescent intensity data were collected from hybridised array slides by scanning 
in a GenePix 4000B machine (GRI/Axon Instruments Ltd., Essex, UK) using GenePix 
Pro 4.1 software.  The scanning process involves first exciting the fluorochromes, Cy5 
and  Cy3,  with  a  laser,  then  capturing  the  fluorescence  emission  through  a      
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photomultiplier tube (PMT).  The ideal scanned image is obtained when the same 
amount of red and green signal is acquired in each channel, resulting in a pixel ratio, 
or count ratio, of approximately 1.0.  The PMT gains were, therefore, adjusted for 
each image to give a count ratio as close to 1 as possible without spot saturation.  The 
Cy5  and  Cy3  images  of  a  slide  were  then  aligned  and  target  DNA  location  and 
identification details were imported into the software in a GenePix Array List (GAL) 
file.  Absent or poor quality spots  were identified on the screen array image and 
flagged.    Abnormal  spots  occur  either  when  flecks  of  dust  interfere  with  the 
fluorescence intensity, or when there has been a problem with the Gen III Microarray 
spotter machine during array synthesis and the BAC DNA spots have unacceptable 
morphology.  All abnormal spots were excluded from the data analysis. 
 
The data were stored in a GenePix Results file (GPR) and imported into Microsoft 
Excel.    Clones  representing  regions  within  the  X  and  Y  chromosomes  were  not 
analysed since our samples were not sex matched.  A number of previous publications 
have excluded chromosome Y from analysis after variable hybridisation results were 
observed  in  normal  versus  normal  hybridisations  (Lage  et  al.  2003;Snijders  et  al. 
2001). 
 
A series of customised Macro files were used in Excel to complete the analysis, as 
outlined in Figure 5.1.  Briefly, the fluorescent intensity of the local background was 
subtracted from the raw intensity of each spot.  The reference versus test DNA spot 
intensity ratio was calculated (ie Cy5/Cy3), and then the median of all spot ratios 
within each block was  calculated.  Normalisation of each spot intensity ratio was 
achieved by dividing the intensity ratio by the median of all spot ratios within each      
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block.  For each clone, the mean and standard deviation (SD) across the identical 
triplicate spots were calculated.  Any spot with a SD>0.2 was discarded from analysis.  
If 2 of the triplicate spots representing a clone had a SD>0.2, the clone was discarded 
from further analysis.  The mean normalised fluorescent intensity ratios were depicted 
in a chart, from which clones representing gains and losses of chromosomal material 
were identified.      
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Background intensity subtracted from raw spot intensity 
 = fluorescent intensities of each Cy3 and Cy5 dye per spot. 
Control:test spot intensity ratio calculated for all evaluable spots. 
Median of all spot intensity ratios within each block calculated. 
For each clone set where SD≥0.2, outlying spot data removed until SD≤0.2 
(minimum number of spots per clone accepted for analysis was 2). 
Intensity ratio for each spot normalised by dividing the intensity ratio of each spot 
by the median of all spots within each block. 
Mean and standard deviation of this normalised intensity ratio 
 calculated for each triplicate clone. 
Mean of the normalised ratio of a BAC clone versus the chromosomal location of that clone displayed in 
a chart, and gains and losses in chromosomal material identified (Figure 1b). 
Local background 
fluorescent intensity 
calculated. 
Fluorescence intensity of each  
spot calculated (ie the median  
of pixel intensities). 
Image files generated by 
GenePix Pro 4.1 software. 
Data imported into Excel spreadsheet. 
Any flagged spots of poor quality are excluded from further analysis. 
(a)      
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Figure 5.1. Schematic diagram of the array-CGH analysis process.  (a) The flow chart 
outlines each stage in the analysis of array-CGH data collected from the image file 
produced by GenePix Pro 4.1 software.  (b) The results of analysis are displayed in 
chart form, generated by Excel, as shown here.  Clones representing a gain or loss of 
chromosome material can be identified on this chart as spots with a mean fluorescent 
intensity ratio >1.15 or <0.85.   Examples of gains and losses are indicated by red 
arrows. 
 
 
 
(b) 
Loss of 
chromosome 5 
Gain in 
chromosome 11      
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Locus information for clones, associated with a gain or loss of chromosomal material, 
was obtained from the Ensembl database website (www.ensembl.org).  Each of these 
clones  was  checked  against  the  Database  of  Genomic  Variants  (compiled  by  the 
Centre for Applied Genomics, Ontario, Canada; http://projects.tcag.ca/variation/) for 
the presence of known copy number variations observed in normal individuals (Iafrate 
et al 2004; Zhang et al 2006).  This database provides details of structural variations 
in  the  human  genome,  involving  segments  of  DNA  >1  kb  from  healthy  control 
samples,  and  is  continually  updated  from  peer-reviewed  research  studies.    Clones 
mapping to known regions of variation in normal control samples were recorded but 
discarded  from  further  analysis  for  this  study.    Some  clones  displayed  recurrent 
characteristic  deviations  from  the  ratio  1.0  in  normal  DNA  versus  normal  DNA 
hybridisations, performed routinely by Dr Samantha Knight and Dr Regina Regan at 
the WTCHG in Oxford.  These clones were also discarded from further analysis.  
 
Genes of known function located within regions of gain or loss were identified using 
the Ensembl database website.  Accurate positions for these regions and genes were 
defined in terms of base pairs from the p-telomere, or megabase (Mb) position. 
 
5.2.9  Dye-swap hybridisation 
For  each  pair  of  test  and  reference  genomic  DNA  samples,  a  second  ‘dye-swap’ 
hybridisation  was  performed  where  the  samples  were  labelled  with  the  different 
fluorescent  dye  (Cy5-  or  Cy3-dCTP)  from  that  which  was  used  in  the  first 
hybridisation.  The dye-swap aids interpretation of a sample since a genuine gain, 
indicated by a high intensity ratio in the first hybridisation, will be represented as a 
low intensity ratio in the dye-swap experiment.  Also, the Cy3 and Cy5 dyes are      
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known to be incorporated slightly differently within certain regions of DNA, such as 
GC-rich  DNA,  and  this  can  generate  false  positives  during  hybridisation.    Dye-
swapping will highlight any such artefact introduced by dye-labelling. 
 
5.2.10  Gene expression array hybridisation 
Total RNA from IM9, KMH2, L428 and L591 cultured cells was sent to the Sir Henry 
Wellcome Functional Genomics Facility for Human Genomics (Glasgow University) 
where  RNA  amplification,  fragmentation  of  cRNA  and  labelling  were  performed 
according to the protocol outlined by Affymetrix.  IM9 total RNA was used as the 
reference sample.  The labelled samples were hybridised with the GeneChip
® Human 
Genome U133 Plus 2.0 array (Affymetrix), as laid out in the manufacturer’s protocol.  
This array contains >22,000 probe sets.  For each expression measurement, 11 pairs of 
probes (each 25 bp in length) are routinely present on the array.  Each pair consists of 
a perfect  match  probe,
 which is  perfectly complementary to  a subsequence  of the 
target
 mRNA, and a mismatch probe, which is identical to the corresponding
 perfect 
match probe except that the middle (13th) base has been changed to its Watson–Crick 
complement.  The  probe  sequences  are  derived  from  sequences  published  on  the 
following databases:  GenBank
®  (http://www.ncbi.nlm.nih.gov/Genbank/index.html), 
dbEST (http://www.ncbi.nlm.nih.gov/dbEST/) and RefSeq (http://www.ncbi.nlm.nih.
gov/RefSeq/). 
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5.2.11  Gene expression array analysis 
A routine set of statistical analysis methods were applied to all samples, analysed 
using gene expression arrays, by Dr Pawel Herzyk (Sir Henry Wellcome Functional 
Genomics Facility of Human Genomics, Glasgow University) including robust multi-
chip average [RMA] (Irizarry et al. 2003) and rank products [RP] (Breitling et al. 
2004b).  Dr Lesley Nicolson provided help with interpretation of the analyses that are 
specific to this project. 
 
In order to correct for background noise, which is caused by non-specific binding, 
low-level normalisation is performed using a statistical tool called the RMA.  This 
combines all perfect match probe distributions across the chip, and the end product is 
a summary of the log-normalised probe level data. 
 
RP analysis was subsequently used to identify genes, represented by the probe sets, 
which were differentially expressed between the cHL-derived cell line sample and the 
IM9 reference sample.  RP produces highly reliable results from hybridisations with 
high background (Breitling et al 2004).  Probe sets which do not represent genes of 
known function were discarded leaving 3058 probe sets for analysis.  The top 100 up- 
and downregulated genes, in each cell line, were identified. 
 
5.2.12  Correlation between array-CGH and gene expression array analyses 
Genes located within regions of chromosomal gain or loss in three or more cHL-
derived  cell  lines  were  compared  to  the  top  100  differentially  expressed  genes 
identified  from  our  gene  expression  array  analysis  of  3  cHL-derived  cell  lines:      
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KMH2, L428 and L591.  Our array-CGH results were also compared to the gene 
expression profile of HRS cells proposed by Schwering et al. (2003) from Affymetrix 
gene expression analysis of the HDLM2, KMH2, L428 and L1236 cHL-derived cell 
lines (Schwering et al 2003b). 
 
5.3  RESULTS 
5.3.1  Array-CGH analyses 
Following array-CGH, analysis was performed as described in Section 5.2.8.  For 
each cHL-derived cell line, the dye-swap hybridisation results were plotted onto the 
same chart as the first hybridisation results.  In Figure 5.2, the combined charts from 
array-CGH analyses of HDLM2 versus IM9 DNA and the corresponding dye-swap 
hybridisation are shown.  Each clone is represented by a single spot on the chart: blue 
for  the  test  versus  reference  DNA  hybridisation  and  pink  for  the  dye-swap 
hybridisation.  A large number of gains and losses of chromosomal material can be 
seen  to  occur  in  this  cell  line,  ranging  from  single  clones  to  contiguous  clones 
representing large regions of the genome.  Combined hybridisation charts for KMH2, 
L1236, L428, L540 and L591 are shown in Appendix A.      
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Figure 5.2.  The combined hybridisation charts from array-CGH of HDLM2 DNA versus IM9 DNA.  Each blue spot on the chart represents the 
mean intensity fluorescent ratio of a single clone, represented by triplicate spots on the array.  The mean intensity fluorescent ratio of each clone 
in the dye-swap hybridisation is represented by a pink spot on the chart.      
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Hybridisations with a high level of background noise display a high level of scattering 
in their analysis chart and have a high percentage of spots discarded from the analysis, 
for example the hybridisations of KMH2 and L428 shown in Appendix A.  Samples 
of low quality display a high level of scattered clones, but since the quality of all 
DNA  samples  was  checked  by  measurement  on  a  Nanodrop  ND-1000 
Spectrophotometer (Nanodrop Technologies Ltd., Delaware, USA) before and after 
labelling it is more likely that the high level of scattering observed on some of the 
hybridisation charts is due to smears or dust on the array resulting in high background 
fluorescence. 
 
Tables of gains and losses in chromosomal regions from each cHL-derived cell line 
were compiled (see Tables 5.1 and 5.2) and compared with published conventional 
CGH analyses (Chui et al 2003) of the HDLM2, KMH2, L1236, L428 and L591 cell 
lines (shown in red in Tables 5.1 and 5.2).  HDLM2, KMH2 and L1236 display the 
greatest number of additional affected chromosome regions, whilst L591 displays the 
lowest.  Recurrent gains in 2p and 9p, previously identified by conventional CGH, 
were  identified  in  all  six  cHL-derived  cell  lines  using  array-CGH.    A  previously 
reported  recurrent  gain  in  7p  was  observed  in  all  except  the  HDLM2  cell  line.  
Similarly, a recurrent loss of chromosome material in 14q was observed in all except 
HDLM2. 
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Table 5.1.  Chromosomal regions in each cHL-derived cell line where a gain of DNA 
has been identified by array-CGH.  Chromosome regions in red had previously been 
identified using conventional CGH (Chui et al 2003; Joos et al 2003). 
 
Cell Line  Chromosome regions gained 
HDLM2  2p25.3, 2p22.2-p16.1, 2p11.2, 2q11.2, 2q24.3, 2q36.3, 3q12.3, 3q25.3, 3q25.32-q29, 
4p15.31, 4q22.3, 5p15.33-p15.2, 5p14.2, 5p13.2-p12, 5q11.2, 5q23.1-q23.2, 5q34-
q35.3, 6p22.3, 6q27, 7q21.13, 7q21.3, 8q11.22-q11.23, 8q22.3-q23.1, 8q23.3-q24.22, 
9p24.3-p21.1, 9q31.1, 9q34.3, 10q11.22, 11q12.3, 12p13.33-p12.3, 12q13.12, 14q12, 
14q23.1, 14q32.33, 15q25.1, 16p12.1, 16q21-q22.1, 17p12, 17q11.2, 17q21.31-q22, 
17q23.2, 18p11.21, 18q22.1, 18q23, 19p12, 19q12-19q13.12, 22q12.1 
KMH2  1p36.31-p36.23, 1p36.21, 1q23.3, 1q25.1, 1q31.3-q32.2, 1q41-q42.11, 1q42.13-q42.2, 
1q43, 2p25.3-p25.1, 2p21-p16.1, 2p13.1-p12, 2q14.2, 2q24.2-q24.3, 2q36.3, 3p14, 
3q25.1, 3q26.1-q26.32, 3q27.3, 3q28, 4q25, 5p14.3, 5p12, 5q13.3, 5q23.1, 5q35.2, 
6p25.3-p25.2, 6p24.3, 6p24.1, 6p22.3, 7p11.2, 7q34, 7q36.1-q36.3, 8p23.3, 9p21.2, 
10q23.31, 10q23.33, 10q26.13-q26.2, 10q36.13, 11p15.4-p15.3, 11p15.1, 11p14.1, 
11q12.2-q12.3, 12q13.13, 12q13.3, 12q21.31, 12q23.1, 12q24.21-q24.31, 14q21.3, 
14q24.3, 14q32.2-q32.31, 15q22.2, 15q22.31, 15q22.33-q23, 16p13.2, 16p13.13, 
16q13.2-q13.13, 16q22.1-q22.2, 16q23.1-q23.3, 17p12, 17q21.2-q21.31, 18q12.1, 
21q22.12 
L1236  1p31.1, 1q23.2, 1q24.2, 1q25.3-q31.3, 1q32.2, 1q41-q42.11, 1q42.2-q43, 2p25.3-p22.3, 
2p22.1-p13.3, 2q24.2, 2q31.1, 2q36.3, 3p26.3-p26.1, 3p24.3, 3p14.2, 3q12.3, 3q13.13, 
3q13.32, 3q21.1, 3q21.3-q25.1, 3q25.31-q26.31, 3q26.33, 4p15.31, 4p13, 4q13.1, 
4q21.1, 4q24-q27, 5p15.33-p15.32, 5p14.2, 5p13.1, 5q11.2, 5q22.2, 5q23.1-q23.2, 
5q31.1, 5q31.3, 6p22.3, 6p21.32, 6p11.2, 6q14.3, 7p22.2, 7p21.1-p14.3, 7p14.1, 
7p11.2, 7q11.23-q21.11, 7q21.13-q22.2, 8p12, 8q24.21-q24.3, 9p24.3-p21.1, 10p15.1-
p13, 10p12.31, 10p12.1, 10p11.23-cent, 10q11.21, 10q21.3, 10q23.31, 11p14.1, 
11q13.1, 11q22.3-q23.1, 11q23.3-q25, 12p13.32-p12.3, 12p21.1-cent, 12q12-q13.13, 
12q13.3, 14q22.3-q23.1, 15q11.2, 15q23, 15q24.3-q25.2, 16q22.1, 16q23.2, 17p12, 
17q21.31, 17q22, 18p11.21, 18q21.1, 18q23, 20p13-p12.1, 20p11.21, 20q11.23-q12, 
20q13.12 
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Cell Line  Chromosome regions gained 
L428  2p22.1-p16.1, 2p14-p12, 3p26.3, 3q26.31, 5q11.2, 6p22.33, 6p21.1, 6p12.1, 6q21, 
6q23.3-q24.2, 7p11.2, 7q32.1, 7q32.3-q33, 8p11.21, 8q24.21-q24.3, 9p24.3-p24.2, 
9q33.2-q33.3, 11q24.3-q25, 12p12.1, 12q13.13, 15q14, 15q25.1, 16p11.2, 16q23.1, 
17p11.2, 17q12, 17q25.3, 20q13.13 
L540  1p36.22-36.21, 1p31.1, 2p25.3-p23.3, 2p23.1-p22.3, 2p16.3, 2p12-p11.2, 2q11.2-q22.3, 
2q23.2-q33.3, 2q34, 2q36.3, 3p26.3, 3p12.3, 3q26.1, 4p15.31, 4q22.3, 4q31.21, 4q35.1-
q35.2, 5p15.33, 5q23.2, 5q34-q35.2, 6p25.3, 6p25.1-p24.3, 6p24.1-p22.1, 7p14.2-
p14.1, 7q11.23-q21.13, 7q22.1, 7q22.3-q31.31, 7q31.33-q32.1, 7q32.3-q34, 7q36.2-
q36.3, 8q11.23, 8q21.3, 9p24.3-p21.1, 9q31.1, 11q13.5, 11q22.3-q23.3, 11q24.2-q25, 
12p13.2, 12p12.3-p12.1, 12p11.22, 12q21.31, 13q34, 14q23.3-q31.3, 14q32.13-q32.31, 
14q32.33, 15q11.2, 15q21.1, 15q26.1-q26.3, 16q12.2, 16q21-q22.1, 17p22, 17p12, 
17q11.2-q12, 17q21.2-q21.32, 17q22-q23.3, 18p11.21-q11.2, 18q22.1, 19p12, 
19q13.32, 19p13.2, 20p13-p11.21, 20q11.21-q12, 20q13.13-q13.33, 22q12.3 
L591  6p22.3, 7p21.3-p21.2, 7q21.13, 9p24.1-p22.3, 9p21.3-p21.1, 10q11.22, 11q24.2, 11q25, 
18p11.21 
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Table 5.2.  Chromosomal regions in each cHL-derived cell line where a loss of DNA 
has been identified by array-CGH.  Chromosome regions in red had previously been 
identified using conventional CGH (Chui et al 2003; Joos et al 2003). 
 
Cell lines  Chromosome regions lost 
HDLM2  2p24.3, 2p23.3, 2q22.1, 2q33.1, 2q33.3-q35, 2q37, 3p14.1, 3p12.1, 3q11.2, 3q12.2, 
3q13.11-q21.2, 3q25.1, 3q29, 4p16.3, 4p16.1-p12, 4cent-4q13.1, 4q25, 4q33, 4q34.1, 
5p15.32, 5p14.1, 5cent-q11.2, 5q13.2-q15, 5q21.3, 5q33.1-q34, 6q26, 7p22.3-p14.3, 
7p14.1, 7q21.11, 8p23.3-q11.23, 8q12.3, 11p14.1, 12q12, 12q13.13, 12q23.1, 
12q24.32-q24.33, 15q15.1, 15q24.3, 15q25.3-q26.3, 16q12.1-q12.2, 16p13.13, 16q21-
q23.3, 16q24.3, 17p13.1, 17q11.2-q12, 17q23.2-q23.3, 17q24.2-q25.3, 18p11.32-
p11.21, 18q12, 18q22.1, 19p12, 20p13-p11.23, 20q11.23-q13.33, 21q21.1, 22q13.2-
q13.33  
KMH2  2q33.3-q34, 3p25.2, 3q13.2-q13.31, 3q21.1-q21.2, 4q13.3, 4q28.2, 4q35.1-q35.2, 
5q14.1, 5q32-q33.3, 6p21.31, 6q14.1, 6q21-q22.1, 6q22.32, 6q24.2-q24.3, 7p22.3, 
7p15.1, 7q32.1, 8p21.2, 8p11.21, 8q12.2, 8q13.3, 8q22.3, 9p22.3, 9q21.11, 9q21.13, 
9q21.31, 9q22.11, 10q22.3, 10q25.1-q25.2, 11q23.1, 11q23.3, 11q24.3-q25, 12q14.3, 
12q21.31, 13q12.11, 13q12.12, 13q12.3, 13q13.3, 13q14.11, 13q14.2-q14.3, 13q21.2-
q21.33, 13q22.2-q22.3, 13q31.1, 13q31.3-q32.1, 13q32.3-q33.2, 14q13.2, 14q32.33, 
15q11.2, 15q13.3, 15q15.1, 15q22.31, 16q12.1-q12.2, 18p11.31, 18q12.1, 18q12.3, 
18q12.3-q21.1, 18q21.22, 18q23, 20p13-p12.2, 20p11.23, 20q13.13, 22q11.22, 
22q12.1-q13.31 
L1236  1p36.22, 1p36.12-p36.11, 1p34.3, 1q31.1, 1q32.1, 2q11.2, 2q13, 2q27, 3p14.3, 
3q13.31, 3q26.2, 3q27.2-q29, 4p16.3, 4p16.1, 4p15.1-p14, 4q13.1, 4q28.2-q28.3, 
4q31.21-q31.22, 4q31.3-q32.1, 4q34.1-34.2, 4q35.1, 5q11.2, 5q13.1-q14.3, 5q22.2, 
5q32, 6p21.31-6p21.1, 6p12.3-p12.1, 6q14.1, 6q15-q22.31, 6q22.33-q23.3, 6q24.2, 
7p21.3-p21.2, 7p15.2, 7q31.1, 7q32.1, 7q32.3-q34, 7q36.1-q36.3, 8p23.3-p23.1, 
8q12.2, 9q21.13, 9q21.32-q21.33, 9q22.2-q34.3, 10q22.1, 10q22.3, 10q26.13, 11p15.5-
p15.2, 11p14.3-p14.2, 11p13, 11q12.2-q13.4, 11q14.1, 12q14.1, 12q21.1-q21.2, 12q22-
q23.3, 12q24.13-q24.21, 12q24.23-q24.31, 12q24.33, 13q12.11-q14.3, 13q21.33-q31.1, 
13q31.3-q33.2, 13q34, 14q11.2-q12, 14q21.2-q22.1, 14q23.3-q24.1, 14q24.3, 
14q32.13, 14q32.33, 15q21.3, 15q22.31, 15q25.2-q25.3, 16p13.3, 16p13.13-p11.2, 
16q12.1, 16q21.1, 16q23.1-q23.2, 17p13.3-p11.2, 17q12, 17q21.2-q21.31, 17q23.2-
q23.3, 17q24.2-q25.3, 18p11.31, 18q22.1, 18q23, 19p13.3-p13.2, 19p13.11, 19q12-
q13.12, 19q13.31-q13.32, 20q13.33, 21q22.11, 21q22.13, 21q22.3, 22q11.21-q13.33      
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Cell lines  Chromosome regions lost 
L428  4p15.31, 4p15.1, 4q34.1, 5q11.2, 5q12.3, 5q13.3, 5q14.3, 5q21.2, 6p22.1, 6p12.3, 
7p21.3, 9q21.2-q21.31, 9q21.33, 9q22.2-q33.1, 9q34.13, 9q34.3, 11q11.1-q23.3, 
12p11.21, 12q21.31, 12q21.33-q22, 12q24.21, 12q24.31, 12q23.2-q23.3, 13q12.11-q34, 
14q32.33, 15q21.3, 15q22.31, 15q25.2, 18q11.2-q12.1, 18q12.3, 18q21.1, 18q21.32-
q23, 20p11.23 
L540  1p31.1-p21.3, 1p13.3-p12, 2q11.2, 3p25.1, 3p24.2, 3p14.2-p14.1, 3q13.13, 4q33, 
5q31.2, 5q32, 6p22.2, 6p21.2-p12.3, 6p12.1, 6q12-q22.1, 6q22.31-q27, 7p15.1, 7p14.1, 
7q21.11, 7q21.13, 8p23.3-p12, 8q11.23, 8q12.2-q12.3, 8q13.2, 8q23.3-q24.3, 9p21.13-
q22.3, 9q22.32-q34.3, 10p15.3, 10p15.1-p12.33, 10p21.31-p11.21, 10q11.21-q26.3, 
11p11.2, 11q12.1, 11q25, 12q13.3-q14.1, 12q24.11-q24.13, 13q12.11-q33.3, 14p15.5, 
14p15.33, 14p15.1, 14q11.2-q13.2, 14q21.1, 14q21.3-q22.3, 15q22.31, 15q24.1, 
15q24.3-q25.1, 16p13.3, 16p11.2, 16q21-q23.3, 16q24.1, 17p13.2-p13.1, 17p11.2, 
17q25.2-q25.3, 18q12.2-q23, 19q12, 19q13.12, 22q11.21, 22q13.1-q13.2 
L591  2q34, 3p21.31, 5q14.1, 7q31.2-q31.32, 7q32.3-q34, 7q36.1-q36.3, 8p23.3-p21.2, 8p12, 
11q23.1, 12q21.31, 13q32.2, 14q32.2-q32.33, 16q12.1, 22q11.22 
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Array-CGH  results  from  all  6  cHL-derived  cell  lines  were  combined  in  order  to 
identify regions that were commonly gained or lost within three or more cell lines.  
The results are displayed in ideograms (see Figures 5.3 and 5.4) showing the location 
of each clone that was gained or lost within three or more cell lines.  The coloured 
circles each represent the presence of a gain, or loss, of this clone within a different 
cell line.  Genes with known functions, that are located in these regions, are shown in 
Appendices B and C.  The regions containing the largest number of chromosomal 
gains in the cell lines were: 2p21-p16.1, 6p22.3 and 9p24.2-p21.2 (see Figure 5.3).   
 
Gains in 2p21-p16.1 were identified only within the EBV-negative cell lines but not 
in  the  EBV-positive  L591  cell  line.    Known  functional  genes  located  within  this 
region are FSHR (49.04-49.23 Mb), PRKCE (45.73-46.26 Mb), REL (60.96-61.00 
Mb)  and  BCL11A  (60.53-60.63  Mb)  (see  Appendix  B).    Gains  in  6p22.3  were 
observed  in  the  six  cHL-derived  cell  lines  within  regions  containing  the  MYLIP 
(16.23-16.25  Mb),  FAM8A1  (17.70-17.71  Mb),  NUP153  (17.72-17.81  Mb),  ID4 
(19.945-19.948  Mb)  and  CDKAL1  (20.64-21.34  Mb)  genes  (see  Appendix  B).  
However, only one region (22.57-22.66Mb), represented by the RP11-33I5 clone, was 
gained within all the cell lines.  There are no genes with known function in this clone, 
or directly adjacent to this region.   
 
From the 19 clones gained within 9p24.2-p21.2, only five clones include genes of 
known function: SMARCA2 (20.05-21.83 Mb), VLDLR (25.25-26.44 Mb), ATL1 
(50.09-50.16  Mb),  MLLT3  (20.33-20.61  Mb),  MOBKL2B  (27.31-27.51  Mb)  and 
IFNK (27.514-27.516 Mb).      
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A large number of clones corresponding to a loss of chromosome material, within 
three or more cell lines,  were located within 8p23.2-p12, 9q21.13-q34.3, 13q and 
22q13.1-q13.31 (see Figure 5.4), with the latter three regions affected only within 
EBV-negative cell lines.  Many functional genes are located within these regions (see 
Appendix  C).    Gains  in  9q22  and  9q33-q34  have  been  previously  identified  by 
conventional CGH analysis of the L428 and L1236 cHL-derived cell lines (Joos et al 
2003).  In our results from hybridisation of L1236, one gain in 9q21.2 was identified, 
although chromosomal imbalances were not identified in adjacent clones or clones 
near to this region.  Two gains in 9q33.2-q33.3, 1.6 Mb apart, were identified in our 
L428 hybridisations.  This region, therefore, warrants further analysis.  The region of 
loss on chromosome 13 is the largest area of imbalance identified in our analysis with 
regions across the whole of the q-arm affected.  This anomaly was also reported from 
conventional CGH analysis of cHL-derived cell lines and case samples (Chui et al 
2003; Joos et al 2000; Joos et al 2002; Joos et al 2003). 
 
Several  novel  chromosome imbalances  were  also identified, and the Ensembl and 
Genecard databases were used to locate the genes with known function located within 
these regions (see Appendices B and C).  Selected genes and their known functions 
are listed in Tables 5.3 and 5.4. 
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Table 5.3. Selected genes of interest in newly identified regions of gain (details from 
www.ensembl.org and www.genecards.org). 
 
Chromosome 
Location 
Gene  Mb position  Function 
5q22.2  APC (Adenomatous 
polyposis coli protein) 
112.10-
112.20 Mb 
Tumour suppressor that promotes rapid 
degradation of CTNNB1 and participates 
in Wnt signalling 
8q24.12  TAF2 (TAF2 RNA 
polymerase II, TATA box 
binding protein (TBP)-
associated 
factor) 
120.81-
120.91 Mb 
Stabilizes transcription factor (TFIID) 
binding to core promoter (Transcription 
factor TFIID is one of the general factors 
required for accurate and regulated 
initiation by RNA polymerase II) 
11q23.3  IGSF4 (Immunoglobulin 
superfamily member 4) 
114.55-
114.88 Mb 
Acts as a tumour suppressor in non-
small-cell lung cancer (NSCLC) cells; 
interaction with CRTAM promotes 
natural killer (NK) cell cytotoxicity and 
IFN-gamma secretion by CD8+ cells in 
vitro as well as NK cell-mediated 
rejection of tumours expressing CADM3 
in vivo 
17q22  HLF (hepatic leukaemia 
factor) 
50.69-50.75 
Mb 
Rearranged in acute B-cell leukaemia, 
with translocation t(17;19); 
transcription from RNA polymerase II 
promoter 
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Table 5.4. Selected genes of interest in newly identified regions of loss (details from 
www.ensembl.org and www.genecards.org). 
 
Chromosome 
Location 
Gene  Mb position  Function 
6q21  WISP3 (Wnt inducible 
signalling pathway 
protein 3) 
112.48-112.49 
Mb 
Overexpressed in colon tumours;  
involved in cell growth and 
differentiation 
6q24.3  SHPRH (SNF2 histone 
linker PHD RING 
helicase) 
146.22-146.32 
Mb 
Involved in DNA repair 
15q22.31  RAB11A (RAB 11A 
oncogene) 
63.94-63.96 
Mb 
RAS related GTP-binding protein 
16q12.1  ZNF423 (zinc finger 
protein) 
48.04-48.42 
Mb 
An early B-cell factor associated zinc 
finger protein 
17q25.3  TIMP2 (tissue inhibitor 
of metalloproteinase 2) 
76.36.76.43 
Mb 
Involved in the invasive phenotype of 
acute myelogenous leukaemia 
17q25.3  RAB40B  78.20-78.24 
Mb 
A member of RAS oncogene family; 
involved in small GTPase mediated 
signal transduction 
18q21.33  BCL2 (B-cell 
CLL/lymphoma 2) 
58.94-59.13 
Mb 
Suppresses apoptosis in a variety of cell 
systems including factor-dependent 
lymphohaematopoietic and neural cells; 
regulates cell death by controlling 
mitochondrial membrane permeability;  
appears to function in a feedback loop 
system with caspases;  
inhibits caspase activity either by 
preventing the release of cytochrome c 
from the mitochondria and/or by binding 
to the apoptosis-activating factor   
(APAF-1) 
18q21.33  FVT (Follicular 
lymphoma variant 
translocation protein 1) 
59.14-59.18 
Mb 
Involved in t(2;18)(p11;q21) in follicular 
lymphoma 
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Figure 5.3.  Ideogram depicting locations of clones representing gains in 
chromosomal material within each cHL-derived cell lines.   Yellow circles - HDLM2; 
pink circles - KMH2; red circles - L1236; green circles - L428; pale blue circles - 
L540; dark blue circles - L591. 
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Figure  5.4.    Ideogram  depicting  locations  of  clones  representing  losses  in 
chromosomal material within each cHL-derived cell lines.   Yellow circle - HDLM2; 
pink circle - KMH2; red circle - L1236; green circle - L428; pale blue circle - L540; 
dark blue circle - L591.      
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In the initial analysis, only clones with intensity ratios within the defined threshold, in 
both initial and dye swap experiments, were scored as regions of gain (intensity ratios 
>1.15) or loss (intensity ratios <0.85); however, when the intensity ratios of all clones 
in these regions with multiple imbalances (e.g., 2p22.1-p13.3) were examined, many 
had intensity ratios close to the threshold or one of the replicates was above or below 
the threshold.  This suggests that these clones may also be regions of gain or loss.  By 
checking the intensity ratios within the most commonly gained (2p22.1-p13.3, 6p22.3, 
9p24.3-p21.2)  or  lost  (8p23.1-p12,  9q21.31-q34.3,  13q12.11-q34,  22q13.1-q13.31) 
regions across all 6 cell lines, it was possible to identify the smallest region of overlap 
(SRO) (Figure 5.2).  The Ensembl database was used to identify functional genes 
within the SROs (see Tables 5.5 and 5.6), which may play a role in the pathogenesis 
of cHL, although further array-CGHs of these cell lines would be required to confirm 
that these regions are indeed gained or lost.  Some of these genes have been reported 
to be associated with cHL, and these will be discussed in depth at the end of this 
chapter (Section 5.4).      
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Figure 5.5. Schematic diagrams depicting smallest regions of overlap across three or 
more  cHL-derived  cell  lines.    Diagrams  a),  b)  and  c)  show  regions  of  gain,  and 
diagrams d), e), f) and g) show regions of loss.  The megabase (Mb) position within 
the  chromosome  is  indicated  for  each  region.    HDLM2  (yellow),  KMH2  (pink), 
L1236 (red), L428 (green), L540 (pale blue) and L591 (dark blue).      
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Table 5.5. Selected genes with known function that are located within gained chromosome regions identified as smallest regions of overlap 
(SROs) in three or more cells lines (details from www.ensembl.org and www.genecards.org). 
. 
REGIONS OF GAIN 
SRO (Mb position)  Gene  Location (Mb)  Known function 
2p21-2p16.1  
(44.37-60.79 Mb) 
PRKCE (Protein kinase C 
epsilon type 
45.73-46.26 Mb  Receptor for phorbol esters, a class of tumour promoters;  
involved in apoptosis and in the NF B pathway 
  MSH2 (mutS homolog 6 
(E. coli)) 
47.48-47.56 Mb  Encodes a DNA mismatch repair protein;  
part of the BRCA1- associated genome surveillance complex (BASC) 
  MSH6 (mutS homolog 6 
(E. coli)) 
47.86-47.88 Mb  Encodes a DNA mismatch repair protein;  
part of the BRCA1- associated genome surveillance complex (BASC);  
involved in apoptosis 
  RTN4 (reticulon 4)  55.05-55.13 Mb  Interacts with BCL-XL and BCL-2 reducing their anti-apoptotic activity; 
 regulation of apoptosis 
  BCL11A (B-cell 
CLL/lymphoma 11A) 
60.53-60.63 Mb  Functions as a myeloid and B-cell proto-oncogene; may play important roles in 
leukemogenesis and haematopoiesis; 
essential for lymphopoiesis; involved in B- and T-cell differentiation 
6p22.3  
(16.12-23.48 Mb) 
DEK (oncogene)  18.33-18.37 Mb  Interacts with histones; binds DNA;  
involved in viral genome replication;  
involved in regulation of transcription from RNA polymerase II promoter;  
a chromosomal translocation involving DEK is found in a subset of acute myeloid 
leukaemia (AML) 
  ID 4  (Inhibitor of DNA 
binding 4) 
19.94-19.98 Mb  An oncogene candidate in bladder cancer 
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REGIONS OF GAIN (continued) 
SRO (Mb position)  Gene  Location (Mb)  Known function 
6p22.3  
(16.12-23.48 Mb) 
E2F3 (transcription 
factor) 
20.51-20.60 Mb  Regulation of progression through cell cycle;  
transcription initiation from RNA polymerase II promoter 
9p24.1 
(4.81-6.06 Mb) 
JAK2 (Janus kinase 2)  4.97-5.11 Mb  Mediates the activation of STAT proteins; also activated in leukaemia or 
constitutively expressed in acute lymphoblastic leukaemia (ALL) 
  CD274  5.44-5.46 Mb  Interacts with the co-inhibitory molecule Programmed Death Receptor-1 (CD279) 
on T-cells reducing TCR-mediated proliferation and cytokine production; essential 
for T lymphocyte proliferation and production of IL10 and IFNG; 
upregulated in B- and T-cells 
  PDCD1lG2 (CD273 
antigen) 
5.5-5.56 Mb  Involved in the co-stimulatory signal;  
essential for T lymphocyte proliferation and IFN  production  
9p21.3-p21.2  
(24.93-28.20 Mb) 
IFNK (interferon, kappa)  27.514-27.516 Mb  May play a role in the regulation of immune cell function;  
Provides cellular protection against viral infection in a species-specific manner;  
involved in JAK-STAT signalling pathway 
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Table 5.6. Selected genes with known function that are located within lost chromosome regions identified as smallest regions of overlap 
(SROs) in three or more cells lines (details from www.ensembl.org and www.genecards.org). 
 
REGIONS OF LOSS 
SRO (Mb position)  Gene  Location (Mb)  Known function 
8p23.1-p12  
(25.97-30.97 Mb) 
BNIP3L 
(BCL2/adenovirus E1B 
19 kDa protein-interacting 
protein 3-like) 
26.29-26.32 Mb  Induces apoptosis;  
interacts with viral and cellular anti-apoptosis proteins;  
can overcome the suppressors BCL-2 and BCL-XL, although high levels of BCL-
XL expression will inhibit apoptosis;  
may function as a tumour suppressor. 
  TRIM35  (Tripartite 
motif-containing protein 
35) 
27.19-27.22 Mb  Haemopoietic lineage switch protein;  
induces apoptosis 
  CLU (clusterin)  27.51-27.52 Mb  Involved in DNA double-strand break repair by end joining (non homologous 
recombination) and V(D)J recombination;  
involved in apoptosis 
  ESCO2 (Establishment of 
cohesion 1 homolog 2) 
27.68-27.71 Mb  Involved in the cell cycle: required for the establishment of sister chromatid 
cohesion and couple the processes of cohesion and DNA replication to ensure that 
only sister chromatids become paired together. 
  PBK (PDZ binding 
kinase) 
27.72-27.75 Mb  Expression is regulated by E2F; 
seems to be active only in mitosis;  
may also play a role in the activation of lymphoid cells 
  ELP3 (Elongator complex 
protein 3) 
28.00-28.10 Mb  May play a role in chromatin remodelling and is involved in acetylation of 
histones H3 and probably H4;  
regulation of transcription from RNA polymerase II promoter 
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REGIONS OF LOSS (continued) 
SRO (Mb position)  Gene  Location (Mb)  Known function 
9q21.32-q22.32 
(85.05-96.55 Mb) 
DAPK1 (death-associated 
protein kinase 1) 
89.30-89.51 Mb  Involved in apoptosis; 
Triggered by IFN  
  CKS2 (CDC28 protein 
kinase 2) 
91.11-91.12 Mb  Involved in the G1/S transition of the cell cycle; 
involved in spindle organisation 
9p31.1-q31.3 
(102.62-112.93 Mb) 
RNF20 (ring finger 
protein 20) 
103.33-103.36 Mb  Interacts with p53; 
transcriptional activator;  
chromatin modification 
  PPP3R2 (Protein 
phosphatase 2B 
regulatory subunit 2) 
103.393-103.397 
Mb 
T cell receptor signalling pathway;  
involved in apoptosis;  
Wnt signalling pathway 
  TAL1 (T-cell acute 
lymphocytic leukaemia 1) 
47.45-47.46 Mb  Implicated in the genesis of haemopoietic malignancies; 
may play an important role in haemopoietic differentiation 
  IKBKAP (I B kinase 
complex-associated 
protein) 
110.66-110.73 Mb  Interacts preferentially with MAP3K14/NIK followed by IKK-alpha and IKK-
beta; 
regulation of transcription 
13q12.11-q21.1 
(19.03-55.46 Mb) 
TNFRSF19 (tumour 
necrosis factor receptor 
superfamily, member 19) 
23.04-23.14 Mb  Can mediate activation of JNK and NF B;  
may promote caspase-independent cell death 
  CENPJ (centromere 
protein J) 
24.35-24.39 Mb  May play an important role in cell division and centrosome function. 
  BRCA2 (Breast cancer 
type 2 susceptibility 
protein) 
31.78-31.87 Mb  Regulation of progression through cell cycle; 
DNA repair; 
chromatin remodelling 
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REGIONS OF LOSS (continued) 
SRO (Mb position)  Gene  Location (Mb)  Known function 
13q12.11-q21.1 
(19.03-55.46 Mb) 
TNFSF11 (tumour 
necrosis factor receptor 
superfamily, member 11) 
42.03-42.08 Mb  May be an important regulator of interactions between T-cells and dendritic cells 
and may play a role in the regulation of the T-cell-dependent immune response; 
cell differentiation 
  RB1 (retinoblastoma 1)  47.77-47.95 Mb  A key regulator of entry into cell division that acts as a tumour suppressor; 
directly involved in heterochromatin formation by maintaining overall chromatin 
structure and, in particular, that of constitutive heterochromatin by stabilising 
histone methylation; 
acts as a transcription repressor of E2F target genes by recruiting chromatin-
modifying enzymes to promoters 
13q21.2-q31.3 
(57.66-90.51 Mb) 
MYCBP2 (MYC binding 
protein 2) 
76.51-76.79  Mb  May function as a facilitator or regulator of transcriptional activation by MYC 
  NDFIP2 (Nedd4 family 
interacting protein 2) 
78.95-79.02 Mb  May be involved in endocytosis; 
may be involved in NF B and MAPK signalling pathways; 
induced by T-cell activation 
 
13q32.2-q33.2 
(97.34-105.49 Mb) 
EBI2 (EBV-induced G 
protein-coupled receptor 
2) 
98.74-98.75 Mb  Membrane protein which is a probable mediator of EBV effects on B lymphocytes 
or of normal lymphocyte functions 
22q13.2 (40.49-
42.57 Mb) 
BIK (BCL2-interacting 
killer (apoptosis-
inducing)) 
41.83-41.85 Mb  Accelerates programmed cell death; 
binds to the apoptosis repressors BCL-XL, BHRF1 and BCL-2. 
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5.3.2  Gene expression analysis 
Following gene expression array analysis, RP analysis (as described in Section 5.2.11) 
was used to identify the top 100 up- and downregulated genes in the KMH2, L428 
and L591 cHL-derived cell lines.  The top 20 differentially expressed genes for each 
cell line are listed in Appendix B, along with corresponding chromosomal locations.  
Those genes which are differentially expressed within all three cell lines are listed in 
Table 5.7. 
 
In  addition,  some  differentially  expressed  genes  were  common  to  the  two  EBV-
negative cHL-derived cell lines only (see Table 5.8). 
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Table  5.7.  Genes  which  are  upregulated  or  downregulated  within  all  three  cHL-
derived cell lines that were screened by gene expression array analysis. 
  Gene  Chromosome region 
Upregulated  
SORT1 
ID2 
IL1R2 
CD200 
FAM8A1 
NQO2 
PSD3 
ACO1 
PHYH 
SCGB1A1 
APLP2 
1p13.3 
2p25.1 
2q12-q22 
3q13.2 
6p22.3 
6p25.2 
8p22 
9p21.1 
10p13 
11q12.3 
11q24.3 
Downregulated  
VANGL1 
ID3 
MIG-6 
DNASE1L3 
GPR15 
EDNRA 
GUCY1A3 
GUCY1B3 
SH3MD2 
GABRG2 
GFOD1 
PKHD1L1 
PTS 
TEAD4 
TNFRSF19 
KCTD12 
PRKCH 
CCL3///CCL3L1///CCL3L3 
HYK 
CYSLTR1 
NAP1L3 
RPA4 
BTK 
CD99 
1p13.1 
1p36.12 
1q36.23 
3p14.3 
3q12.1 
4q31.22 
4q32.1 
4q32.1 
4q32.3 
5q34 
6p24.1 
8q23.1 
11q23.1 
12p13.33 
13q12.12 
13q22.3 
14q23.1 
17q12 
20q11.21 
Xq21.1 
Xq21.32 
Xq21.33 
Xq22.1 
Yp22.3 
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Table 5.8.  Differentially expressed genes in the EBV-negative cHL-derived cell lines 
KMH2 and L428. 
 
  Gene  Chromosome region 
Upregulated   AKT3 
ZNF238 
MEIS1 
ENO3 
PRKCA 
KLHL15 
BCOR 
1q44 
1q44 
2p14 
17p13.2 
17q24.2 
Xp11.22 
Xp11.4 
Downregulated   VMD2L2 
SLAMF6 
SLAMF7 
CBLB 
PDCD6 
ARL4 
ASB15 
MRPL15 
PFKFB3 
CSTF2T 
PDLIM1 
MGST1 
GREM1 
SEC14L1 
GMIP 
CD37 
ADA 
ZD77D08 
SEPT6 /// N-PAC 
1p34.1 
1q23.3 
1q23.3 
3q13.11 
5p15.33 
7p21.3 
7q31.32 
8q11.23 
10p15.1 
10q21.1 
10q24.1 
12p12.3 
15q13.3 
17q25.2 
19p13.11 
19q13.33 
20q13.12 
22q11.1 
Xq24 
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5.3.3.  Correlation of array-CGH and gene expression array analyses 
The genes identified in regions of chromosomal imbalance were compared with those 
which were differentially expressed in our gene expression array analyses.  Those 
within the up- or downregulated regions on the X and Y chromosomes could not be 
included in this comparison since the sex chromosomes had not been analysed by 
array-CGH as previously explained (Section 5.2.7).  Only three genes located within 
regions of chromosomal imbalance, and present in more than two cHL-derived cell 
lines  in  our  array-CGH  analysis,  also  appeared  within  the  top  100  differentially 
expressed genes (see Table 5.9).  FAM8A1 and APLP2 were both upregulated in all 
three assayed cell lines and are located on regions of chromosomal gain.   
 
A  member  of  the  tumour  necrosis  factor  receptor  superfamily,  TNFRSF19,  was 
downregulated in all three assayed cell lines, and its corresponding clone was within a 
region of loss in the KMH2, L1236, L428 and L540 cell lines. 
 
Previously, Schwering et al. (2003) had assessed the gene expression profiles of the 
HDLM2, KMH2, L428 and L1236 cHL-derived cell lines, compared to normal B-
cells,  using  Affymetrix  gene  expression  arrays  and  the  L1236  cell  line  by  serial 
analysis of gene expression (SAGE) (Schwering et al 2003a; Schwering et al 2003b).  
When our array-CGH results for L1236 were compared to the SAGE analysis of the 
same cell line, 31.4% (11/35) of the downregulated B-cell specific, lymphoid-specific 
and haematopoietic-specific genes were located close to regions of loss identified by 
array-CGH of the L1236 cell line, but none was represented by clones on our CGH-
array.  Recurrent abnormalities identified by array-CGH in three or more cHL-derived 
cell lines were then compared to the up- and downregulated genes that were most      
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specific to cHL cell lines in the study by Schwering et al. (2003).  Two of these genes 
(Syk  and  GPR18)  were  located  within  chromosome  bands  (8p23.1  and  13q32.3, 
respectively) in which a loss had been detected in our array-CGH analysis.  One clone 
on (RP11-297N6 (11.40-11.57 Mb)) our CGH-array is located on the same region as 
the BLK gene (11.38-11.45 Mb).  Although this clone is unchanged in our HDLM2 
array-CGH results, adjacent clones are lost.   The SYK gene is located at 92.60-92.70 
Mb on 9q22.31.  In our L540 array-CGH results, clone RP11-240L7 (92.43-92.60 
Mb),  which  slightly  overlaps  this  region,  is  lost,  although  adjacent  clones  are 
unchanged.  Our results confirm that the regions containing the BLK and SYK genes 
are lost in cHL-derived cell lines, although only in the HDLM2 and L540 cell lines.      
  166 
Table  5.9.    Genes within regions of chromosomal imbalance, identified by array-
CGH  analysis,  which  were  also  differentially  expressed  in  gene  expression  array 
analysis.  Each gene was represented on the CGH array by a single clone, listed in the 
table, and the gain or loss of this clone was identified in more than two cell lines. 
 
Clone  Gene  Location  Gain  Upregulated 
RP11-68J15  FAM8A1  6p22.3  HDLM2 
KMH2 
L1236 
L540 
- 
KMH2 
L428 
L591 
RP11-567M21  APLP2  11q24.3  - 
L1236 
L428 
L540 
L591 
KMH2 
- 
L428 
- 
L591 
Clone  Gene  Location  Loss  Downregulated 
RP11-760M1  TNFRSF19  13q12.12  KMH2 
L1236 
L428 
L540 
KMH2 
- 
L428 
L591 
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5.4  DISCUSSION 
We have successfully shown that array-CGH  can be used to  analyse and identify 
chromosomal  imbalances  within  six  cHL-derived  cell  lines.    Comparison  of 
chromosomal gains and losses across all six cell lines allowed the identification of 
previously reported recurrent imbalances in cHL and, in addition, the detection of 
several new imbalances.  Any genes of known function located within these regions 
of interest were identified. 
 
Our results correlated well with conventional CGH analysis of cHL-derived cell lines 
previously performed within our laboratory (Chui et al 2003), although some small 
differences were seen in comparison to those chromosomal imbalances reported by 
Joos  et  al.  (2003).    By  combining  the  results  from  all  six  cHL-derived  cell  line 
hybridisations,  we  identified  several  regions  of  recurrent  chromosomal  imbalance, 
present in three or more cell lines: gains on 2p22.1-p13.3, 6p22.3 and 9p24.3-p21.2, 
and a loss on 13q12.11-q34.  These have also been detected in previous conventional 
CGH analysis; however, the increased resolution of array-CGH and the identification 
of  SROs  across  these  regions  has  enabled  us  to  ‘fine-tune’  the  location  of  these 
recurrent regions of gain and loss from that previously described as: 2p16-p13, 6p25-
p22 and 9p24-p23, and 13q21-q31 respectively.  For example, a gain of 2p16-p13 was 
detected by Chui et al. following conventional CGH analysis of the KMH2, L1236, 
and L428 cell lines (Chui et al 2003).  We observed a gain in 2p22.1-p13.3 within all 
five  EBV-negative  cHL-derived  cell  lines  assayed.    By  identifying  the  exact 
megabase position of the region of gain on this chromosome within each cell line, the 
SRO common to all five cell lines was defined as 44.37-60.79 Mb (2p21-p16.1). 
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Several  new  regions  of  recurrent  imbalance  were  identified  from  our  array-CGH 
analysis: a gain of 16q22.1, and losses of 5q, 7p, 7q, 8p, 8p, 9q, 10q, 15q, 17q, 20p, 
20q and 22q.  The T-cell acute lymphocytic leukaemia 1 (TAL1) gene is located 
within  the  recurrent  region  of  loss  identified  on  9q31.1-q31.3  and  a  translocation 
involving this gene, t(9;17)(q34;q23), has recently been identified in four paediatric 
NHL  patients  (Lones  et  al  2007).    It  was  suggested  that  this  translocation  had 
contributed to poor prognosis, although further studies are required to confirm this.   
 
A recent study by Feys et al. (2007) aimed to identify new chromosomal imbalances 
in the HDLM2, KMH2, L1236 and L540 cell lines (Feys et al 2007a).  Thirty-five 
new imbalances were detected and the study focused on a gain on 12q13.3 (L1236) 
and losses on 15q26.1 (HDLM2) and 16q12.1 (KMH2).  The RGMA gene (91.38-
91.43 Mb) is located immediately adjacent to a clone (RP11-266O8; 91.55-91.71 Mb) 
on our CGH-array which showed evidence of a deletion in the HDLM2 cHL-derived 
cell line.  The next clone (RP11-41P8) at 92.11-92.27 Mb is also deleted in this cell 
line.  FISH studies are warranted to confirm this deletion. 
 
Six clones on our CGH-array lie within 16q12.1 and 5 of these are deleted in our 
KMH2  results.    The  RP11-147B17  clone  (49.09-49.26  Mb)  is  located  before  the 
CYLD gene (49.33-49.40 Mb), identified as deleted by Feys et al. (2007), but is not 
gained or lost within our results.  However, clone RP11-424K7 (49.62-49.80 Mb) 
lying  beyond  the  CYLD  gene  is  deleted  in  our  KMH2  results.    Our  results  are 
consistent,  therefore,  with  Feys  et  al.  (2007)  and  warrant  further  investigation  by 
FISH.      
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As mentioned, Feys  et  al. (2007) reported  an amplification of clone  RP11-474N8 
(12q13.3;  55.58-55.75 Mb), which was  also  gained in  our  L1236  cell lines.   The 
STAT6 gene is located nearby at 55.77-55.79 Mb, but no clone on our array is located 
on this region.  However we did detect amplification of the next clone, RP11-181L23 
(12q13.3-q14.1; 56.52-56.29 Mb), within the L1236 cell line.  Our results, therefore, 
strongly suggest that the region inbetween these clones is amplified, and that STAT6 
would be affected in this cell line.  STAT6 is a signal transducer and transcription 
activator that is known to be induced by IL13, a cytokine frequently expressed by 
HRS  cells.    Immunoblotting  and  IHC  assays  have  demonstrated  the  constitutive 
phosphorylation of STAT6 in the HDLM2, KMH2, L428 and L540 cHL-derived cell 
lines and HRS cells from 78% of cHL cases assayed (Skinnider et al 2002).  In the 
presence of a neutralising anti-IL13 antibody, cellular proliferation was significantly 
decreased  in  cHL-derived  cell  lines  and  STAT6  phosphorylation  was  inhibited 
(Skinnider et al 2002). 
 
Some changes were unique to the EBV-positive cHL-derived cell line L591.  A gain 
of chromosomal material at 7p21.3-p21.2 was identified.  The only known functional 
gene within this region encodes a presynaptic cytomatrix protein, Piccolo (PCLO), 
which may act as a scaffolding protein and is thought to be involved in both the 
organization of synaptic active zones and in synaptic vesicle trafficking.  The deletion 
of  region  7q31.2-q36.3  could  result  in  a  downregulation  or  dysfunction  of  the 
suppression of tumorigenicity 7 (ST7) gene. 
 
These results suggest that the pattern of chromosomal abnormalities may be different 
in  EBV-associated  and  non-EBV-associated  cases  of  cHL,  with  fewer  changes  in      
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EBV-negative  cells.    However,  some  degree  of  caution  must  be  exercised  in 
extrapolating results from the L591 cell line (Niedobitek 2006).  Although derived 
from a cHL patient, there is no definitive proof that it is derived from HRS cells and 
the pattern of EBV expression in L591 cells is reminiscent of B-lymphoblastoid cell 
lines rather than primary EBV-associated cHL (Schaadt et al 1989).  However, L591 
cells do display typical features of HRS cells, such as expression of the CD15 antigen 
(Drexler  1993;  Vockerodt  et  al  2002)  and  the  EBV  gene  expression  pattern  may 
simply reflect drift in vitro as seen in Burkitt’s lymphoma cell lines. 
 
Using gene expression array analysis, we identified differentially expressed genes in 
three cHL-defined cell lines and compared these results with those from our array-
CGH  analysis  in  order  to  see  if  changes  in  chromosomal  material  will  affect 
expression profile. When our array-CGH analyses of the cHL-derived cell lines was 
compared to results from gene expression array analysis of the KMH2, L428 and 
L591 cell lines, three highly differentially expressed genes (i.e., within the top 100 
upregulated or downregulated genes following RP analysis of each cell line) were 
located  within  regions  of  chromosomal  imbalance  identified  by  our  array-CGH 
analyses: FAM8A1 (6p22.3), APLP2 (11q24.3) and TNFRSF19 (13q12.12).  When 
overexpressed, the TNFRSF19 gene is known to activate the JNK pathway and it can 
induce  apoptosis  by  the  caspase-independent  pathway  (Eby  et  al  2000).    The 
downregulation of this gene in cHL-derived cell lines may prevent apoptosis by this 
pathway, and may help explain how HRS cells escape apoptosis in the GC.  Further 
analysis of these genes by RT-PCR using RNA extracted from other cHL-derived cell 
lines will confirm if these genes are downregulated in all cHL-derived cell lines.   
      
  171 
Kluiver et al. (2007) performed array-CGH analyses of four cHL-derived cell lines 
and compared the results with those from serial analysis of gene expression (SAGE) 
for the L1236 and L428 cell lines (Kluiver et al 2007).  It was found that only 17.8% 
and 18.4% of differentially expressed genes in L428 and L1236, respectively, mapped 
to regions of gain or loss, indicating that differential gene expression is not a direct 
result  of  copy  number  changes.  Kluiver  et  al.  (2007)  suggested  that  noncoding 
regions,  such  as  interspersed  repeat  elements  like  Alu  repeats  or  LINEs,  may 
significantly contribute to differential gene expression (Wang et al 2006).  However, 
probe sets not relating to a gene of known function, but which may contain such 
repeat elements, were removed from our gene expression array analyses.  It must be 
considered,  therefore,  that  non-translated  genes  or  as  yet  unidentified  coding 
sequences may be of importance in cHL, but have been undetected by our study.  
Further understanding of the genome is required to answer these questions. 
 
As  previously  mentioned,  our  results  confirmed  the  presence  of  recurrent 
chromosomal  imbalances  within  cHL-derived  cell  lines:  gains  on  2p22.1-p13.3, 
6p22.3 and 9p24.3-p21.2, and a loss on 13q12.11-q34.   
 
The BCL11A proto-oncogene is located within 2p16.1 and is known to be expressed 
at high levels within germinal centre B-cells (Liu et al 2006).  Since HRS cells are 
derived from pre-apoptotic germinal centre B-cells, the functional implications of this 
gene  should  be  considered.    Translocations  involving  the  immunoglobulin  heavy 
chain (IgH) locus, on 14q32.3, and BCL11A, on 2p16.1, were reported within 3 B-cell 
chronic lymphocytic leukaemia (CLL) cases (Satterwhite et al 2001) and BCL11A      
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was proposed as a candidate oncogene for cHL following detection of a gain within 
2p  by  conventional  CGH  analysis  of  44  cHL  cases    (Martin-Subero  et  al  2002).  
Further  investigation  by  FICTION  identified  breakpoints  within  the  REL  locus 
adjacent to BCL11A, not within BCL11A, which suggested that REL may be the gene 
affected in cHL instead. 
 
We detected amplification of the REL oncogene (2p16.1; 60.96-61.00 Mb) within the 
KMH2, L1236 and L428 cell lines.  REL is a member of the NF B family and has 
been a focus of interest in previous cHL studies (Barth et al 2003; Joos et al 1996; 
Joos et al 2003; Rodig et al 2005; Xiao et al 2004).  Two IHC studies showed nuclear 
staining for REL in HRS cells from 23/25 and 51/59 cHL cases (Rodig et al 2005; 
Xiao  et  al  2004).    Like  BCL11A,  REL  was  also  involved  in  chromosomal 
translocations with the immunoglobulin loci in HRS cells from cHL cases (Martin-
Subero et al 2006).  When the regions of gain on 2p across all six cHL-derived cell 
lines were aligned and an SRO identified at 2p21-p16.1, REL lay just outside this 
region.  However, it should still be considered in this study since it is located in a 
region of gain on three cHL-derived cell lines.  REL was not within our top 100 list of 
upregulated genes from gene expression array analysis of the KMH2, L428 and L591 
cell lines, so we have no evidence that gains of REL are associated with increased 
expression.  A recent publication by Kluiver et al. presented SAGE and array-CGH 
analysis of the KMH2, L1236, L428 and L591 cell lines (Kluiver et al 2007).  From 
array-CGH analysis, a SRO on 2p16.1-p13.3 (59-71 Mb) was identified, but SAGE 
analyses of the L1236 and L428 cell lines failed to detect tags corresponding to the 
REL gene.  Furthermore, no increased expression of the REL mRNA was detected by 
QRT-PCR.  These results suggested that REL is not a candidate in the pathogenesis of      
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cHL.    When  the  location  of  our  identified  SRO  on  2p  (44.37-60.79  Mb)  was 
correlated with the SRO (59-71 Mb) by Kluiver et al. (2007), a region of 2p16.1 (59-
60.79 Mb) was scored as a gain in both array-CGH studies.  This region includes the 
proto-oncogene BCL11A, suggesting that the functional association of this gene with 
cHL should be further investigated. 
 
Amplifications  within  the  6p21-p23  region  have  previously  been  reported  within 
several  types  of  neoplasia,  including  NHL,  large  B  cell  lymphoma  and  follicular 
lymphoma (Stokke et al 2001; Monni et al 1996; Kuchiki et al 2000), and it has been 
suggested that this region may contain a number of potential oncogenes (Santos et al 
2007).  A number of functional genes are located within the 6p22.3 region commonly 
gained  within  the  cHL-derived  cell  lines  assayed  in  our  investigation:  NUP153; 
FAM8A1; ID4 (inhibitor of DNA binding 4) which has been suggested as a oncogene 
candidate in bladder cancer (Wu et al 2005); and CDKAL1 (CDK5 regulatory subunit 
associated protein 1-like 1), previously proposed as an oncogene (Hurst et al 2004).  
The CDKAL1 gene lies downstream from E2F3 (6p22.3), which is located within the 
SRO  we  identified  on  6p22.3.    Overexpression  of  this  transcription  factor  is 
associated  with  aggressive  tumours  in  human  bladder  cancer,  prostate  cancer  and 
retinoblastoma (Olsson et al 2007; Orlic et al 2006).  It has been suggested that E2F3 
may mediate HLX9 activation via the phophatidylinositol 3 kinase (PI3K) pathway 
which will in turn stimulate the expression of the cytokine interleukin 6 (IL6) (Nagel 
et al 2005).  IL6 has been shown to be expressed by HRS cells (Herbst et al 1997) and 
has been suggested to stimulate ‘B’ symptoms in HL patients (Reynolds et al 2002). 
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The presence of a recurrent chromosomal gain on 9p24.3-p21.2 was also confirmed 
by  this  study.    This  region  includes  the  following  genes  of  known  function: 
SMARCA2  (SWI/SNF  related,  matrix  associated,  actin  dependent  regulator  of 
chromatin,  subfamily  a,  member  2)  involved  in  transcriptional  activation;  ATL1 
(GTP-binding  protein  3);  MLLT3  (meloid/lymphoid  or  mixed-lineage  leukaemia 
Drosophila  homolog)  which  is  involved  in  a  chromosome  translocation, 
t(9;11)(p22;q23),  associated  with  acute  leukaemias;  MOBKL2B  (Mps  one  binder 
kinase activator-like 2B) which is a member of the MOB1/phocein family (mitotic 
checkpoint  genes);  VLDLR  (very  low  density  lipoprotein  receptor);  and  IFNK 
(interferon kappa) which is known to regulate immune cell function and is known to 
aid cellular protection against viral infection and genes.  The JAK2 gene is located 
within 9p24 and is a tyrosine kinase involved in the JAK-STAT signalling pathway.  
It has been proposed by several groups as a potential oncogene in cHL (Chui et al 
2003; Kluiver et al 2007; Joos et al 2000; Joos et al 2002; Joos et al 2003; Weber-
Matthiesen et al 1995).  A clone including the JAK2 gene (9p24) was not present on 
our CGH-arrays but the SRO (4.81-6.06 Mb) includes the JAK2 gene (4.97-5.11 Mb).  
JAK2 was not included in the 100 most upregulated genes in this study and similarly 
Kluiver et al. (2007) reported no increase in JAK2 expression in both SAGE analysis 
and QRT-PCR analysis (Kluiver et al 2007).  Conversely, a translocation involving 
JAK2, t(4;9)(q21;p24), has  been recently reported in  one NSHL  case  using  FISH 
analysis, providing support for the idea that dysregulation of this gene may be crucial 
(Van Roosbroeck et al 2007). 
 
Losses  within  13q  have  previously  been  reported  within  cHL  and  other 
haematological malignancies (Wada et al 1999; Struski et al 2007; Schraders et al      
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2005; Joos et al 2003; Chui et al 2003).  A number of functional genes have been 
identified within this region and require further investigation to determine if they have 
a  role  in  the  pathogenesis  of  cHL:  TNFRSF19  (tumor  necrosis  factor  receptor 
superfamily, member 19) which can mediate activation of JNK and NF B and may 
promote caspase-independent cell death; GTF3A (general transcription factor IIIA); 
POSTN (periostin) which is overexpressed in breast cancer; ELF1 (E74-like factor 1 
(ets domain transcription factor)) known to be expressed in lymphoid and myeloid 
cells;  RCBTB1  (regulator  of  chromosome  condensation  (RCC1)  and  BTB  (POZ) 
domain  containing  protein  1),  also  known  as  the  chronic  lymphocytic  leukaemia 
deletion region gene 7 (Mabuchi et al 2001; Solomou et al 2003); LECT1 (leukocyte 
cell derived chemotaxin 1) which is known to suppress tumour angiogenesis (Hayami 
et al 1999); and MYCBP2 (MYC binding protein 2) which regulates transcription 
activation  by  MYC.    Three  SROs  were  identified  on  chromosome  13q,  but  the 
possibility  of  the  loss  of  the  whole  of  the  q-arm  should  be  considered.    Further 
investigation  of  this  region  using  FISH  or  FICTION  is  required  to  answer  this 
question.    Chui  et  al.  (2003)  analysed  20  cHL  cases  by  conventional  CGH  and 
observed that the loss of 13q was associated with poorer outcome (Chui et al 2003).   
 
Since all the EBV-negative cHL-derived cell lines contained recurrent imbalances on 
2p, 6p, 9p and 13q, and these cell lines are known to originate from cHL patients with 
poor prognosis, it may be that accumulation of all of these recurrent imbalances is 
associated with a poor prognosis. 
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Following the success of our in-house arrays in this investigation, we moved on to use 
array-CGH  to  examine chromosomal  imbalances  within laser  microdissected  HRS 
cells from a cHL biopsy.  This process will be discussed in Chapter 6.      
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                                                        CHAPTER 6 
 
  ANALYSIS OF PRIMARY HRS CELLS BY ARRAY-CGH   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section  6.2.1  of  this  chapter  was  presented  in  a  poster  at  the  5
th  European 
Cytogenetics Conference in Madrid in 2005: 
 
K.S. Wilson, E. Ballabio, R. Regan, A. Hedman, R. Jarrett, S. Knight and S. Tosi 
DOP-PCR  products  amplified  from  genomic  DNA  can  be  used  reliably  in  whole 
genome  array  CGH  studies  for  the  detection  of  deletions  and  duplications  in 
leukaemia.        
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6.1  INTRODUCTION 
In  the  previous  chapter  I  described  the  use  of  array-CGH  in  the  successful 
identification of chromosomal gains and losses in genomic DNA extracted from HL-
derived  cell  lines.    The  next  step  was  to  use  these  arrays  to  investigate  genomic 
imbalances in primary HRS cells, isolated from cHL biopsies, to determine if there 
were changes common to these tumour cells.   
 
HRS cells were isolated using LMD, a method by which a laser cuts single or groups 
of whole cells from a tissue section, leaving the DNA undamaged.  This method has 
been successfully used in our laboratory to isolate HRS cell for conventional CGH 
(Chui  et  al  2003),  and  for  the  investigation  of  NFKBIA  mutations  (Lake  et  al., 
manuscript submitted). 
 
In  Chapter  1  (see  Section  1.6.4),  WGA  was  presented  as  an  effective  method  of 
amplifying DNA from  very small quantities of starting material, and  the different 
WGA  methods  were  discussed.    In  a  previous  study  in  our  laboratory,  recurrent 
chromosomal  gains  and  losses  were  identified  following  investigation  of  20  cHL 
cases  using DOP-PCR as  the method of WGA following laser microdissection of 
HRS cells (Chui et al 2003).  Briefly, cytospins were prepared using aliquots of 1-5 x 
10
5 viable cells from cHL biopsies and IHC was performed using a CD30 monoclonal 
antibody (Chui et al 2003).  HRS cells were identified by positive staining for the 
CD30  antigen  in  addition  to  morphological  criteria.    Following  a  series  of 
optimisation experiments, it was found that microdissecting 10 single HRS cells into 
the lids of 5 PCR tubes (i.e., 10 cells per lid), instead of 50 cells into one single lid,      
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resulted  in  a  higher  yield  and  better  size  range  of  DOP-products.    Lysis  buffer, 
containing a non-ionic detergent and proteinase K, was pipetted into each lid prior to 
microdissection,  thereby  allowing  DNA  lysis  to  be  performed  immediately  after 
microdissection.    The  DOP-PCR  reagents  were  added  directly  to  the  lysate.  
Following amplification, the five DOP-products from each cHL case were pooled, 
ethanol-precipitated  and  approximately  1.5  g  of  each  sample  was  labelled.    A 
reference sample was prepared with exactly the same methodology.  Conventional 
CGH was performed with approximately 0.8-1  g of labelled test and reference DOP-
products, and normal male metaphase target slides (Vysis). 
 
Following  on  from  the  success  of  this  study,  it  was  proposed  that  the  same 
methodology should be used to prepare DNA samples from HRS cells for array-CGH.  
This would enable the investigation of chromosome abnormalities and imbalances in 
cHL  at  a  higher  resolution  than  had  been  possible  with  conventional  CGH.    As 
resolution  increases,  however,  the  representativeness  of  the  test  DNA  samples 
becomes more critical and it is important, therefore, to have a good quality starting 
sample and to use a WGA technique which maintains a good representation of the 
starting DNA. 
 
It  was  recognised  that  validation  and/or  optimisation  of  the  methods  would  be 
required  before  proceeding  to  the  analysis  of  cHL  biopsy  samples.    This  chapter 
describes  the  optimisation  experiments  which  were  performed,  culminating  in  the 
successful analysis of a primary cHL case using array-CGH.  
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Aims 
  To establish methods for analysing HRS cells, obtained by LMD, by array-
CGH 
  To optimise DOP-PCR for amplification of good quality, highly representative 
genomic DNA from small numbers of isolated HRS cells 
  To  identify  stable  chromosomal  gains  and  losses  within  HRS  cells  and  to 
speculate on their possible involvement in the pathology of cHL. 
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6.2  OPTIMISATION EXPERIMENTS 
A series of optimisations and modifications were made to the original protocol and are 
described below.  All materials, methods and analysis procedures have been described 
in  detail  within  chapters  2  and  5.    The  cell  lines  discussed  in  this  chapter  were 
cultured by Sabrina Tosi, June Freeland and I.  Cytospins were prepared and laser 
microdissected, performed by Lesley Shield and myself. 
 
6.2.1  Validation of DOP-PCR products for use in array-CGH 
In order to investigate if the product of our DOP-PCR protocol is a good genomic 
representation which can be used successfully for array-CGH, we used DOP-PCR to 
amplify  a  cell  line  with  known  chromosomal  imbalances  and  compared  the 
subsequent array-CGH data with that produced from non-amplified DNA from the 
same  cell  line.    Previous  publications  have  advocated  that  amplification  bias  is 
reduced and efficient hybridisation of a DOP-amplified sample DNA is achieved if 
the reference DNA is also DOP-amplified (Daigo et al 2001; Tsubosa et al 2005).  
Therefore, in these optimisation experiments DOP-amplified normal human genomic 
DNA was used as the reference sample in the hybridisations. 
 
6.2.1.1 The GF-D8 cell line 
GF-D8  is  a  human  myeloid  leukaemia  cell  line  that  was  established  from  the 
peripheral blood of a patient suffering from acute myeloid leukaemia FAB subtype 
M1 (Rambaldi et al 1993; Tosi et al 1999).  This cell line has been fully characterised 
by a number of molecular cytogenetic techniques (Tosi et al 1999), including M-FISH 
and CGH to metaphase chromosomes.  A number of gains (in chromosome 7, 8q, 11q 
and  13),  losses  (in  chromosome  5q,  11p,  12p,  15q,  17p  and  Yq),  unbalanced 
translocations  and  structural  abnormalities  were  identified  (see  Table  6.4).    The      
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multiple, complex chromosome imbalances present within this leukaemia cell line 
make it an ideal model to use for testing the validity of our DOP-PCR protocol.   
 
Table 6.1. Chromosomal rearrangements present in the GF-D8 cell line, identified by 
M-FISH and conventional CGH (modified from Tosi et al. (1999)).   
47,X,der(Y)t(Y;12)del(Y),der(5;15)t(5;7)t(7;15), inv(7)x2, der(7)t(7;15)del(7)del(15), 
dup(8),  +der(8)trp(8)ins(8;11)dup(11),  der(11)dup(11)t(8;11)trp(8),  der(11)t(11;17), 
der(12)t(7;12)del(12), +13, -15, -17 
del,  deletion;  der,  derivative  chromosome;  dup,  duplication;  ins,  insertion;  inv, 
inversion; t, translocation; trp, triplication 
 
6.2.1.2 Array-CGH performed using the GF-D8 cell line 
Five hybridisations were performed using DOP-amplified and non-amplified GF-D8 
DNA (see Figure 6.1).  Normal genomic male DNA was simultaneously prepared 
alongside the cell line DNA and used as reference DNA in the hybridisations.  The 
non-amplified DNA samples were prepared, labelled and hybridised by Miss Erica 
Ballabio.  With the exception of a very small number of outlying clones, the results 
obtained  using  the  non-amplified  genomic  DNA  and  the  DOP-amplified  products 
were concordant (see Figure 6.2).  The DOP-amplified array-CGH results confirmed 
the gains of 7q, 8, 11q and the entire chromosome 13, which were detected in the 
original CGH, performed using metaphase chromosomes by Dr Sabrina Tosi (Tosi et 
al 1999) (see Table 6.2). The losses of 5q, 11p, 12p, 15, 17p and 20q could also be 
identified.  However, some smaller chromosomal regions of imbalance identified in 
the non-amplified GF-D8 array-CGH results were not detected in the DOP-amplified 
DNA (see Tables 6.2 and 6.3).  It was concluded, therefore, that although array-CGH      
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using DOP-PCR products can be successfully used to identify the chromosomal gains 
and losses, it is possible that very small changes, for example gains or losses in single 
clones, may be missed. 
Figure 6.1. Array-CGH analysis results obtained using a) non-amplified and b) DOP-
amplified genomic DNA of the GF-D8 cell line.      
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  Figure 6.2. Scatterplot of the array-CGH data from both the non-amplified and amplified 
GF-D8  DNA  demonstrating  a  good  correlation  between  these  sets  of  data,  with  the 
exception of a few clones.      
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Table 6.2. Comparison of the gains identified by CGH to chromosomes (Tosi et al 
1999), array CGH of non-amplified DNA and array CGH of DOP amplified DNA. 
 
GAINS IN GF-D8 CELL LINE 
CGH to Chromosome  Array CGH with 
non-amplified DNA 
Array CGH with 
DOP-amplified DNA 
  1p36.31-p32.3   
7pter->q22.1  7pter   
  7q21.3-q22.3   
7q33-qter  7q33-qter  7q34-qter 
8q22.3-qter  Whole chr 8  Whole chr 8 
  9q33.3-qter   
11q21-qter  11q22.2-qter  11q22.2-qter 
  12q13.12-q14.1   
  12q24.11-qter   
Whole chr 13  Whole chr 13  Whole chr 13 
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Table 6.3. Comparison of the losses identified by CGH to chromosomes (Tosi et al 
1999), array CGH of non-amplified DNA and array CGH of DOP amplified DNA. 
LOSSES IN GF-D8 CELL LINE 
CGH to Chromosome  Array CGH with 
non-amplified DNA 
Array CGH with 
DOP-amplified DNA 
5q11-qter  5q11.2-qter  5q11.2-qter 
11p11-pter  11p11-pter  11p11.2-pter 
12p11.2-p13.3  12p11.23-p13.2  12p11.23-p13.2 
15q14-q24  15q14-q21.3 
15q25-q26.2 
Whole chr 15 
17p11-pter  17p12->q12  17p13.3->q12 
    20q13.13-q13.3
Yq12-qter  Yq11-q11.23 
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6.2.2  Comparison of different fixation and staining methods prior to  
array-CGH 
It has been reported that staining using some chromogenic reagents can affect the 
integrity and downstream use of DNA, particularly in PCR (Gjerdrum and Hamilton-
Dutoit 2005).  An experiment was performed to investigate the possible downstream 
effects  of  fixation  and  staining  in  our  assays.    Two  cytospins  of  IM9  cells  were 
stained  with  either  a  CD30  monoclonal  antibody,  using  the  ABComplex  method 
(Dako),  or  with  eosin  G  and  thiazine  using  the  DiffQuik  staining  system  (Dade 
Behring Inc., IL, U.S.A.).  From each slide, 10 single IM9 cells were microdissected 
into each of 20 0.2 ml tubes and digested with proteinase K.  DOP-PCR was then 
performed using the UN1 DOP-primer.  The positive genomic DNA control consisted 
of 60 pg of normal female genomic DNA (Promega).  When the DOP-products were 
examined under UV light following electrophoresis on a 1% agarose gel and ethidium 
bromide staining, those derived from DiffQuik-stained cells were considerably fainter 
in intensity than those from CD30-stained cells (see Figure 6.3a).  Each set of DOP-
products  were  combined,  purified,  quantified  using  the  Nanodrop  ND-1000 
Spectrophotometer and 500 ng was examined again by electrophoresis (see Figure 
6.3b).  The DOP-products amplified from DiffQuik-stained laser microdissected cells 
were  smaller  in  size  than  those  derived  from  CD30-stained  cells.    Therefore,  the 
DiffQuik fixation and staining protocol either inhibits amplification of larger products 
or  degrades  genomic  DNA.    Poor  CGH  hybridisation  using  DOP-DNA  from 
DiffQuik-stained cells has been reported (Hirose et al 2001), and more recently it was 
suggested that components in the DiffQuik process may in some way reduce DOP-
product size (Huang et al 2005a).  There was no evidence that CD30 staining using 
the described protocol inhibited the downstream reactions.      
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(a) 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. (a) DOP-PCR products from amplification of laser microdissected IM9 
cells stained with either CD30 monoclonal antibody or the DiffQuik staining system. 
(b) Combined and ethanol precipitated DOP-PCR products (500 ng) from 200 CD30-
stained or 200 DiffQuik-stained laser microdissected cells. 
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6.2.3  Comparison of array-CGH using different cell numbers 
6.2.3.1 Array-CGH of cHL samples using 200 laser microdissected HRS cells 
Authors of current publications describing the use of laser microdissected cells as 
templates  for  DOP-PCR  have  used  large  numbers  of  cells  (100-5000)  as  starting 
material for their amplification reactions (Daigo et al 2001; Hughes et al 2004; Peng 
et al 2003; Peng et al 2004).  Due to the difficulty of obtaining large numbers of HRS 
cells from a cHL case sample, and following discussions with Dr Stefan Joos, we 
initially microdissected 200 HRS cells from 4 cHL cases (#5440, 6625, 6666 and 
6992) and performed DOP-PCR.  The cases were selected on the basis of having large 
numbers of strongly CD30-staining HRS cells with good morphology on the cytospin 
preparations.    A  reference  DNA  sample  was  prepared  by  the  same  methodology: 
microdissection of 200 IM9 cells and DOP-PCR.  The combined DOP-products from 
each sample were then labelled and hybridised to our CGH-array.  A representative 
hybridisation chart (case #6992, male diagnosed with NSHL) is shown in Figure 6.4.  
For each of the 4 cHL cases, background levels were high and large numbers of 
clones had an intensity ratio outside the threshold level. 
 
It was concluded that DOP-amplification products from 200 cells did not produce a 
good representation of the genome.  The question was whether the template DNA 
quality was  too poor  for amplification of highly  representative DNA products,  or 
whether  increasing  the  number  of  laser  microdissected  cells  would  improve  the 
quality of the hybridisation. 
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Figure 6.4.  Hybridisation chart from the array-CGH of 200 cells-DOP-amplified case 
6992 DNA versus 200 cells-DOP-amplified IM9 DNA. 
  
In order to investigate whether increasing the number of microdissected cells, used for 
DOP-amplification,  would  improve  the  analysis  of  array-CGH,  a  number  of 
optimisation  experiments  were  performed  initially  using  IM9  cells  and  the  cHL-
derived cell lines HDLM2 and L428. 
 
Cytospins  of  IM9  cells  were  stained  with  the  CD30  monoclonal  antibody,  as 
described earlier (see Section 2.2.8), and 10 cells were microdissected into each of 
120 tubes.  Following proteinase K digestion and DOP-PCR, each DOP-product was 
electrophoresed to check quality.  Equal amounts of DNA (5  l) from 20, 40, 60, 80 
and 100 tubes were then combined to represent DOP-products from 200, 400, 600, 
800 and 1000 IM9 cells, respectively.  These products were ethanol precipitated and 
were used as the sample DNA for array-CGH.   
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As was mentioned in Section 6.2.3, reference DNA should also be amplified by DOP-
PCR if it is to be hybridised with DOP-amplified sample DNA, in order to decrease 
any sequence amplification bias.  Therefore 120 DOP-PCR reaction tubes were set up, 
each containing the equivalent of 10 cells (60 pg) of IM9 DNA.  The DNA had been 
extracted, using phenol/chloroform, from the same batch of IM9 cells from which the 
cytospins  had  been  prepared.    Successful  DOP  amplification  was  confirmed  by 
electrophoresis and equal quantities from each of 20, 40, 60, 80 and 100 tubes were 
combined  to  represent  starting  templates  of  200,  400,  600,  800  and  1000  cells, 
respectively.  The combined DNA products were ethanol precipitated and used as 
reference DNA in array-CGH.  
 
Equal  amounts  (2  g)  of  each  of  the  sample  and  reference  amplified  DNA, 
corresponding  to  200,  400,  600,  800  and  1000  template  cells,  were  labelled  and 
hybridised to the 1Mb resolution arrays. 
 
Analysis of each of the five hybridisations showed that each successive increase in the 
number of microdissected cells, used as template for DOP-PCR, improved the quality 
of  hybridisation  (see  Figure  6.5),  as  judged  by  the  mean  intensity  ratios  on  the 
hybridisation charts (i.e., the mean of the normalised ratios is <0.7 or >1.3) (see Table 
6.4).  For example, 9.3% and 12.4% of clones displayed mean intensity ratios of 
below  0.7,  or  above  1.3  in  the  hybridisation  of  DOP  DNA  from  200  IM9  cells, 
whereas in the hybridisation of 1000 IM9 cell-derived DNA, only 0.7% and 3.2% of 
clones  lay  outside  these  threshold  limits  respectively.    Also  the  number  of  spots 
excluded  from  analysis,  due  to  abnormal  hybridisation,  decreased  as  more 
microdissected cells were used to generate the DOP-amplified sample DNA.  Only      
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2.6% of clones were excluded from analysis of the 1000 cell-DOP-amplified product, 
compared with 4.7% of clones on the 200 cell-DOP-amplified product.  The analysis 
of the 600 cell-DOP-amplified product was unsatisfactory, due to smearing of the 
array,  so  this  was  excluded  from  analysis.    The  thresholds,  of  the  mean  of  the 
normalised  ratios,  differ  to  those  used  in  the  cell  line  array-CGH  analyses  in  the 
previous chapter because a higher level of scattering of spots was seen in the DOP-
amplified laser microdissected DNA hybridisations.  Widening the thresholds allowed 
more spots to be included in the analysis. 
 
It  was  concluded  from  this  set  of  experiments  that  the  greater  the  number  of 
microdissected cells from which DOP-PCR products could be pooled, the greater the 
representation of the template genome and the more accurate the array-CGH results.     
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(a) 
(b)      
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(c) 
 
 
Figure 6.5.  Four array-CGH analyses of laser microdissected, DOP-amplified IM9 
DNA  versus  laser  microdissected,  DOP-amplified-IM9  DNA:  a)  200  cells-DOP-
amplified; b) 400 cells-DOP-amplified; c) 800 cells-DOP-amplified; d) 1000 cells-
DOP-amplified. 
 
 
(d)      
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Table 6.4.  The percentage of probes with ratios lying outwith the threshold range 
<0.7 and >1.3, and the percentage of clones excluded from analysis due to SD >0.2. 
 
 
 
% of probes with 
mean intensity 
ratio >1.3 
% of probes with 
mean intensity 
ratio <0.7 
% of probes 
excluded from 
analysis 
200 cells-DOP-amplified  12.4  9.3  4.7 
400 cells-DOP-amplified  7.5  3.9  6.6 
800 cells-DOP-amplified  3.6  1.8  3.3 
1000 cells-DOP-amplified  3.2  0.7  2.6 
 
 
6.2.2.2 Validation of 1000 cell-DOP-amplified HRS cell DNA for array-CGH 
In  order  to  validate  the  use  of  DOP-amplified  PCR  products  from  1000 
microdissected cells for array-CGH, the previous experiment was repeated using 1000 
microdissected HRS cells, which had been isolated from HDLM2 cell cultures.  The 
reference sample was DOP-amplified IM9 DNA, as described in the previous section.  
 
A  second  dye-switch  hybridisation  was  performed  using  an  array  from  the  same 
batch.  The combined charts (see Figure 6.6) were compared with the array-CGH 
analysis of the non-amplified cell line DNA (see Figure 5.2 in Chapter 5).  Although 
spots on the hybridisations chart from the experiment using laser microdissected cells 
and DOP-amplified DNA were not as close to the intensity ratio of 1 as the original 
experiment, the main changes were detected.      
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Figure  6.6.  Array-CGH  analysis  of  (a)  1000  cells-DOP-amplified  HDLM2  DNA 
versus 1000 cells-DOP-amplified IM9 DNA and (b) non-amplified HDLM2 DNA 
versus non-amplified IM9 DNA. 
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6.2.2.3 Validation of 6000 cells-DOP-amplified HRS cell DNA for array-CGH 
Before examining a cHL case, a final optimisation experiment designed to investigate 
the  quality  of  hybridisation  with  DOP-amplified  DNA  derived  from  6000  laser 
microdissected cells  was  performed.   Cytospins prepared from  fresh  HDLM2  cell 
culture were used, as in the previous experiment.  Reference sample DOP-amplified 
DNA  was  derived  from  6000  laser  microdissected  IM9  cells.    A  dye-switch 
hybridisation was also performed, using an array from the same batch. 
 
As expected, the resulting hybridisations had a reduced background noise from that 
seen in the hybridisations using 1000 cells-DOP-amplified DNA, with markedly less 
scattering (see Figure 6.7).  
 
 
Figure 6.7. Hybridisation chart of 6000 cells-DOP-amplified HDLM2 DNA versus 
6000 cells-DOP-amplified IM9 DNA. 
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6.3  ARRAY-CGH OF A cHL CASE SAMPLE 
From the preceding experiments, it was clear that increased cell numbers markedly 
improved the quality of the array-CGH analysis and a primary cHL tumour, from 
which large numbers of HRS cells were available, was subsequently analysed. 
 
6.3.1  Preparation of DNA sample from case #6992 
Cytospins were made from cell suspensions that had been frozen in liquid nitrogen 
when the fresh biopsy sample was processed (protocol described in Sections 2.2.2 and 
2.2.17 of Chapter 2).  DNA was prepared from 6000 laser microdissected HRS cells 
as described in Section 6.2.4.  The reference DNA was the 6000 cell-DOP-amplified 
IM9 DNA that was used in Section 6.2.4.  Array-CGHs and analysis were performed 
as described in Chapter 5. 
 
6.3.2  Results 
The  dye-swap  hybridisation  charts  were  combined  (see  Figure  6.8).    ‘Sliding 
averages’ were calculated for every 5 contiguous clones in the two hybridisations, to 
produce a ‘moving window’ (see Figure 6.9).  For example, in each chromosome, the 
intensity ratios for clones 1-5 were averaged, then the intensity ratios for clones 2-6, 
then clones 3-6, etc.  The resultant average intensity fluorescent ratios were plotted on 
a  hybridisation  chart  (see  Figure  6.9).    This  had  the  effect  of  smoothing  out  the 
scattering of outlying spots, so that chromosomal imbalances could be identified by 
eye prior to detailed analysis. 
 
Regions identified with a gain or loss of chromosomal material are detailed in Table 
6.5.    Chromosomal  imbalances  which  had  been  identified  in  three  or  more  cHL-     
  199 
derived cell lines were detected within this case: gains in 2p, 3q, 4p, 5q, 7q, 8q, 9p 
and 12p, and losses in 6q, 8p, 9q, 10q, 13q, 15q, 16q, 17q, 18p, 18q, 20q and 22q.  A 
large  number  of  novel  chromosome  imbalances  were  also  identified.    Functional 
genes  located within all chromosomal regions  of imbalance within this case were 
identified  using  the  Ensembl  database  (www.ensembl.org)  and  selected  genes  are 
shown in Tables 6.6 (gains) and 6.7 (losses). 
 
To our knowledge, this is the first time that chromosomal imbalances within the HRS 
cells of a cHL case have been analysed using array-CGH. 
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Figure 6.8. Array-CGH analysis of 6000 cells-DOP-amplified DNA from HRS cells 
of the cHL case 6992 versus 6000 cells-DOP-amplified DNA from IM9 cells. 
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Figure 6.9. Array-CGH chart showing sliding averages of 6000 cells-DOP-amplified 
6992 DNA versus 6000 cells-DOP-amplified IM9 DNA. 
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Table 6.5. Gains and losses of chromosomal regions identified within cHL case 6992 
DNA. 
 
  Chromosomal regions of imbalance in case #6992 
Gains  1p36.12, 1p31.1, 1p22.3, 1q21.3, 1q24.1, 1q24.2, 1q25.2, 1q25.3, 1q31.2, 1q31.3, 
1q32.1, 1q32.2, 1q32.3, 2p25.2, 2p25.1, 2p24.3, 2p24.1, 2p23.3, 2p23.1, 2p22.3, 2p22.2, 
2p22.1-p21, 2p21-p16.3, 2p16.2-16.1, 2p15, 2p14, 2p13.3, 2p13.2, 2p12, cent-2q11.2, 
2q12.1, 2q21.3, 2q22.1, 2q22.3, 2q24.3, 2q31.1, 2q32.1, 2q32.2, 2q33.1, 2q33.2, 2q33.3, 
2q36.1, 3q13.33, 3q22.3, 3q26.31, 4p15.31, 4p15.1, 4p14, 4p13, 4q13.1, 4q13.2, 4q25, 
4q26, 4q27, 4q28.3, 4q31.21, 4q35.1, 5p15.32, 5p15.31, 5p13.3, 5p13.2, 5p13.1, 5q12.1, 
5q12.3, 5q14.3, 5q15, 5q21.3, 5q22.2, 5q22.3, 5q23.1, 5q23.3, 5q31.3, 5q34, 7p21.3, 
7p13, 7p11.2, 7q21.2, 7q21.3, 7q31.31, 7q31.33, 7q32.3-q33, 7q35, 8q11.21, 8q11.22-
11.23, 8q21.12, 8q21.3, 8q23.1, 8q24.12, 8q24.22-24.23, 9p24.2, 9p24.1, 9p23, 9p22.3, 
9p22.2, 9p21.3, 9p21.2, 9p21.1, 9q21.13, 9q21.2, 9q21.31, 9q21.32, 9q33.1, 10p11.23, 
10q11.22, 10q21.1, 11q14.3, 12p13.32-13.31, 12p13.2-13.1, 12p12.3, 12p12.1, 
12p11.22, 12q12, 12q13.11, 12q13.13, 12q13.3, 12q14.1, 12q15, 12q21.2, 12q21.31, 
12q21.32, 12q21.33, 12q22, 12q24.23, 14q12, 14q21.1, 14q22.1, 14q22.2, 14q22.3, 
14q23.1-23.2, 14q23.3, 14q24.1, 14q24.2, 14q31.1, 14q31.3, 14q32.12, 14q32.2-32.31, 
16q12.2, 17p13.2, 17p12, 17q12-21.1, 17q21.32, 17q21.33, 17q23.2, 17q24.2, 18p11.21, 
18q12.3, 18q22.3, 19q13.42-13.43, 20p12.3, 20p12.1, 20q11.22, 20q11.23, 20q13.2-
13.31, 20q13.32, 22q13.2 
Losses  1p36.32, 1p36.22, 1p36.13, 1p36.11, 1p35.2, 1p34.3, 1p34.2, 1p32.3, 1p13.3, 1q12, 
1q42.11, 1q42.12, 1q42.2, 1q42.3, 1q43, 1q44, 2q21.2, 3p25.3, 3p22.1, 3p21.31, 3p21.1, 
3q12.1, 3q23, 3q25.31, 3q26.2, 3q27.2, 3q28, 4p15.31, 4q28.1, 4q35.1, 4q35.2, 5p13.2, 
5q32, 6p21.32, 6p24.1, 6p21.32, 6p21.31-21.2, 6p21.1, 6p12.3, 6p12.1, cent, 6q12, 
6q14.1, 6q15, 6q16.1, 6q21, 6q22.33-23.1, 6q23.2, 6q23.3, 6q24.1, 6q25.2, 6q25.3, 
6q27, 7p21.2-21.1, 7p12.3, 7q11.22, 7q11.23, 7q32.1, 7q36.1,8p23.1, 8p21.2, 8p12, 
8q21.13, 8q21.3, 8q22.1, 9p21.3, 9q31.3, 9q34.11, 9q34.3, 10p13, 10q22.3, 10q24.2, 
10q25.3, 10q26.12, 10q26.3, 11p15.1, 11p15.5, 11p15.4, 11p15.2, 11p14.3, 11q13.2, 
11q13.4, 11q13.5, 11q23.1, 11q24.2, 11q23.3, 12p13.32, 12q13.13, 12q24.23, 13q12.11, 
13q12.12, 13q12.13, 13q12.2, 13q12.3, 13q13.1-13.2, 13q13.3, 13q14.12, 13q14.3, 
13q21.31, 13q31.2, 13q31.3, 13q32.2, 13q32.3, 13q34, 14q24.3, 15q11.2, 15q13.3, 
15q14, 15q15.1, 15q15.3, 15q21.1, 15q21.3, 15q22.31, 15q24.3, 15q26.1, 15q26.3, 
16p13.13, 16q12.1, 16q21, 16q22.1, 16q24.1, 16q23.2, 17p13.2, 17p13.1, 17p12, 
17p11.2, 17q21.2, 17q25.3, 18p11.31, 18q11.2, 18q22.3, 18q23, 19p13.2, 19p13.11, 
19q12, 19q13.12, 19q13.32, 20q13.13, 21q11.2, 21q21.1, 21q22.2, 21q22.3, 22q11.23, 
22q13.2 
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Table 6.6. Selected genes with known function in newly identified regions of gain 
(details from www.ensembl.org and www.genecards.org). 
Chromosome 
Location 
Gene  Position (Mb)  Function 
1q31.2  RGS18 (Regulator of 
G-protein signalling 
18) 
190.39-190.42  Negative regulation of signal 
transduction 
1q32.1  PIK3C2B 
(Phosphatidylinositol-
4-phosphate 3-kinase 
C2 domain-containing 
beta polypeptide) 
202.65-202.72  Involved in apoptosis, Toll-like receptor 
signalling pathway, JAK-STAT 
signalling pathway and T cell receptor 
signalling pathway 
1q32.1  IKBKE (I kappa-B 
kinase epsilon) 
204.71-204.73  Phosphorylates inhibitors of NF B; may 
play a special role in the immune 
response 
1q32.2  IL20 (interleukin 20)  205.105.205.109  Acts through STAT3, Cytokine-cytokine 
receptor interaction, JAK-STAT 
signalling pathway;  
1q32.2  IL24 (interleukin 24)  205.13-205.14  Selectively induces apoptosis in human 
breast cancer cells; involved in cytokine-
cytokine receptor interaction and the 
JAK-STAT signalling pathway 
2p23.3  NCOA1 (Nuclear 
receptor coactivator 1) 
24.66-24.84  Involved in co-activation mediated by 
STAT3, STAT5A, STAT5B and STAT6 
transcription factors;  
displays histone acetyltransferase activity 
toward H3 and H4 
2p22.2  BIRC6 (Baculoviral 
IAP repeat-containing 
protein 6) 
32.43-32.69  May protect cells from undergoing 
apoptosis 
2p14  MEIS1 (myeloid 
ecotropic viral 
integration site 1 
homolog (mouse)) 
66.51-66.65  Acts as a transcriptional regulator of 
PAX6; required for haematopoiesis, and 
megakaryocyte lineage development 
2q11.2  ZAP70 (70 kDa zeta-
associated protein) 
97.69-97.72  Associates with the T-cell antigen 
receptor zeta chain (CD3Z); plays a role 
in lymphocyte activation 
4q35.1  MLF1IP (Myeloid 
leukaemia factor 1 
interacting protein) 
185.85-185.90  Component of the CENPA-NAC 
(nucleosome-associated) complex, a 
complex that plays a 
central role in assembly of kinetochore 
proteins, mitotic progression and 
chromosome segregation; 
interacts with the N-terminal domain of 
Kaposi's sarcoma- associated herpesvirus 
latent nuclear antigen (LNA); interacts 
with myeloid leukaemia factor 1 
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Chromosome 
Location 
Gene  Position (Mb)  Function 
5p13.1  FYB (FYN (an 
oncogene) binding 
protein ) 
39.14-39.25  Acts as an adapter protein of the FYN 
and SH2-domain-containing leukocyte 
protein-76 (SLP76) signalling cascades 
in T cells; modulates the expression of 
IL2 
5q22.2  APC (adenomatosis 
polyposis coli) 
112.10-112.20  Tumour suppressor; promotes rapid 
degradation of CTNNB1 and participates 
in Wnt signalling 
5q22.2  MCC (mutated in 
colorectal cancers) 
112.38-112.85  Candidate for the putative colorectal 
tumour suppressor gene located at 5q21; 
involved signal transduction and negative 
regulation of cell cycle progression 
8q24.12  TAF2 (TAF2 RNA 
polymerase II, TATA 
box binding protein 
(TBP)-associated 
factor) 
120.81-120.91  Stabilizes transcription factor (TFIID) 
binding to core promoter (Transcription 
factor TFIID is one of the general factors 
required for accurate and regulated 
initiation by RNA polymerase II) 
9p21.3  IFNB1 (interferon, 
beta 1, fibroblast) 
21.0671-
21.0679 
Involved in cytokine-cytokine receptor 
interaction, Toll-like receptor signalling 
pathway, Jak-STAT signalling pathway, 
natural killer cell-mediated cytotoxicity; 
induction of apoptosis 
9p21.2  IFNK (interferon, 
kappa) 
27.514-27.516  May play a role in the regulation of 
immune cell function;  provides cellular 
protection against viral infection in a 
species-specific manner; involved in 
JAK-STAT signalling pathway 
12p12.3  PIK3C2G 
(Phosphatidylinositol 
3-kinase, class 2, 
gamma polypeptide) 
18.30-18.69  Involved in apoptosis, Toll-like receptor 
signalling pathway, JAK-STAT 
signalling pathway and T cell receptor 
signalling pathway 
20q13.2  NFATC2 (nuclear 
factor of activated T-
cells, cytoplasmic 2) 
49.44-49.59  Plays a role in the inducible expression 
of cytokine genes in T cells, especially in 
the induction of IL-2, IL-3, IL-4, TNF-
alpha or GM-CS;  related to the 
NF B/REL proteins 
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Table 6.7. Selected genes of known function in newly identified regions of loss 
(details from www.ensembl.org and www.genecards.org). 
 
Chromosome 
Location 
Gene  Position 
(Mb) 
Function 
6p21.31-21.2  CDKN1A (cyclin-
dependent kinase 
inhibitor 1A (p21, 
Cip1)) 
36.75-36.76  May be the important intermediate by which 
p53 mediates its role as an inhibitor of 
cellular proliferation in response to DNA 
damage;  
regulator of cell cycle, cyclin dependent 
kinases 2 and 4 (CDK2/CDK4) inhibitor 
protein; 
involved in cell cycle exit of 
megakaryocytes;  
inhibits cycle progression 
6q15  MAP3K7 
(transforming growth 
factor beta-activated 
kinase 1) 
91.28-91.35  A component of a protein kinase signal 
transduction cascade; 
mediator of TGF-beta signal transduction; 
stimulates NF B activation and the p38 
MAPK pathway 
9p21.3  MTAP 
(methylthioadenosine 
phosphorylase) 
21.79-22.00  Often co-deleted with CDKN2A in adult 
acute T cell type leukaemia;  
plays a major role in polyamine metabolism 
and is important for the salvage of both 
adenine and methionine 
10q26.3  BNIP3 
(BCL2/adenovirus 
E1B 19kDa interacting 
protein 3) 
133.63-
133.64 
An apoptosis-inducing protein that binds to 
the adenovirus E1B 19 kDa protein or to 
BCL-2, 
and which can overcome BCL-2 suppression; 
can also interact with BHRF1 of EBV 
13q12.12  TNFRSF19 (tumour 
necrosis factor receptor 
superfamily, member 
19) 
23.04-23.14  Can mediate activation of JNK and NF B;  
may promote caspase-independent cell 
death.apoptosis and induction of apoptosis 
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6.4  DISCUSSION 
Prior  to  this  project,  LMD  and  DOP-PCR  had  been  used  successfully  within  our 
laboratory to isolate HRS cells and prepare the extracted DNA for conventional CGH 
(Chui et al 2003), but the methodology required optimisation for array-CGH.  This 
chapter  has  discussed  the  optimisation  experiments  performed  to  determine  the 
conditions required to perform array-CGH using laser microdissected HRS cells. 
 
The validity of DOP-PCR was demonstrated by comparison of the hybridisation of 
amplified  and  non-amplified  DNA  extracted  from  the  fully  characterised  human 
myeloid leukaemia cell line, GF-D8.  Good reproducibility of known chromosomal 
changes  was  demonstrated  using  amplified  DNA,  but  some  subtle  changes  were 
missed.  These findings  are consistent  with  other studies  showing that DOP-PCR 
occasionally produces false positives and false negatives in hybridisation (Hughes et 
al 2004). 
 
Previous experiments in our laboratory compared the use of PEP-PCR and DOP-PCR 
for  conventional  CGH  analysis.    Although  PEP-PCR  products  were  highly 
representative of the sample template, DOP-PCR was the method of choice since it 
consistently  generated  much  larger  amounts  of  DNA  and  the  products  were 
sufficiently representative for use in conventional CGH (Dr Daniel Chui, unpublished 
data).  It was decided to continue with DOP-PCR to prepare our laser microdissected 
samples for array-CGH since DOP-PCR was universally recognised as the preferred 
method  of  WGA  for  CGH  and  array-CGH.    However,  the  results  of  the  above 
experiments suggest that laser microdissection of primary HRS cells coupled with 
DOP-PCR may not result in optimal products for use in array-CGH.  Towards the end      
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of  the  project  commercial  MDA  kits  became  available  (i.e.,  GenomiPhi  and 
TempliPhi, Amersham Biosciences), but pilot experiments (data not shown) suggested 
that the DNA in our laser microdissected samples was not of sufficient quality to 
capitalise  on  this  methodology.    However,  GenomePlex,  a  proprietary  technology 
from Sigma-Genosys has produced promising initial results (Feys et al 2007b). 
 
From a series of optimisation experiments, it was found that increasing the number of 
laser  microdissected  cells,  lowers  the  sequence  bias  and  background  noise  of  the 
downstream array-CGH.  To put this finding into practice, a cHL case (#6992) was 
selected, on the basis of the large amounts of good viable cells available from biopsy 
material, and 6000 HRS cells were laser microdissected.  DOP-PCR was performed, 
followed  by  array-CGH  analysis.    Chromosomal  gains  and  losses  were  identified 
within this cHL case, many of which had been identified previously.  As discussed in 
Chapter 5, conventional CGH analysis of cHL-derived cell lines and biopsy material 
identified  recurrent  chromosomal  imbalances  (Chui  et  al  2003;  Joos  et  al  2003).  
Within the 6992 cHL case, gains in 2p, 7q, 9p, 12q, 14q, and 17p, and losses in 4q, 
6q, 11q, 13q and 14q were identified. 
 
All genes with known function located within all regions of gain and loss within this 
case  were  identified,  and  particular  attention  was  paid  to  any  genes  with  known 
involvement in apoptosis, the cell cycle, the NF B or Wnt signalling pathways, the 
pathogenesis of other tumours, and T-cell/B-cell growth, differentiation or function. 
Many of the gained chromosomal regions encode proteins which play an active role in 
signalling  pathways  implicated  in  the  aetiology  of  cHL:  the  Jak/STAT  signalling 
pathway (IL20, IL24, IFNB1, IFNK and PIK3C2G), the NF B pathway (IKBKE and      
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NFATC2), the Wnt signalling pathway (APC) and the cell cycle pathway (MCC).  
The MAP3K7 and TNFRSF19 genes are located within regions of chromosomal loss 
identified in this case.  These genes are known to be involved in the NF B pathway. 
 
In Chapter 5, several SROs were identified by comparing regions of gain and loss 
across the six cHL-derived cell lines.  When the fluorescence intensity ratio of clones 
representing  these  regions  were  examined  in  the  hybridisation  results  from  case 
#6992, some ratios were found to be close to the threshold, or above or below the 
threshold in one replicate only.  Although further hybridisations would be required to 
verify these results, these results suggest that these are regions of imbalance.  In this 
way, three of the previously identified gained SROs were detected in the results from 
case #6992: 2p21-p16.1 (44.37-60.79 Mb), 9p24.1 (4.81-6.06 Mb) and 9p21.3-p21.2 
(24.93-28.20 Mb).  These regions of the genome are known to contain the BCL11A 
(60.53-60.83  Mb)  and  Rel  (60.96-61.00  Mb),  JAK2  (4.97-5.11  Mb)  and  IFNK 
(27.514-27.516  Mb)  genes,  respectively.    The  SROs  for  three  regions  of  loss  on 
chromosome 13q were also identified from the hybridisation results for case #6992. 
 
These results lend further support to the idea that there is a recurrent pattern of gains 
and losses of chromosomal material in cHL.  Further work is required to be performed 
to delineate the precise areas affected and the key genes (or RNAs) involved.  Further 
experiments  are  therefore  warranted.    In  order  to  improve  the  quality  of  the 
hybridisations  and  reduce  the  number  of  HRS  cells  required  for  analysis,  it  is 
necessary to try and improve the quality of the starting sample material.  In addition, 
newer methods of WGA, such as the technology used in the GenomePlex kit, may      
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improve  the  representativeness  of  the  amplified  product  and  this,  in  turn,  should 
improve the quality of the hybridisation. 
 
To conclude, we have demonstrated that sufficient DNA can be extracted from laser 
microdissected  HRS  cells,  from  a  cHL  biopsy  sample,  to  perform  DOP-PCR  and 
array-CGH.    We  have  successfully  used  this  methodology  to  detect  previously 
reported recurrent regions of chromosomal imbalance within a cHL case, in addition 
to  identifying  several  novel  chromosomal  imbalances  which  warrant  further 
investigation.     
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CHAPTER 7 
 
FINAL DISCUSSION 
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This thesis presents different approaches used to investigate the pathogenesis of cHL.  
In  the  search  for  a  potential  viral  agent  involved  in  the  aetiology  of  non-EBV-
associated  cHL  cases,  cases  were screened for  the MV  and PyV  using molecular 
biological techniques (Chapters 3 and 4).  Array-CGH has been successfully used in 
Chapter 5 to detect recurrent chromosomal gains and losses within six cHL-derived 
cell lines and results were compared to gene expression array data from three cHL-
derived cell lines to assess whether or not these chromosomal imbalances had any 
influence on gene expression.  In Chapter 6, HRS cells were laser microdissected 
from  a cHL  biopsy  and analysed by array-CGH, resulting in  the identification of 
recurrent chromosomal gains and losses, in addition to some previously unreported 
imbalances. 
 
7.1  THE SEARCH FOR POTENTIAL PATHOGENIC AGENTS FOR cHL 
The aetiology of non-EBV-associated cHL is unknown, but epidemiological studies 
have suggested that delayed exposure to a common infectious agent may play a key 
role.  Viruses are the most likely candidates since they are widespread and infect 
individuals at an early age.  As a result of previous molecular biology studies within 
this  laboratory,  the  involvement  of  known  herpesviruses  (Armstrong  et  al  1998; 
Gallagher et al 2002) and SV40 (MacKenzie et al. 2003) can be ruled out.  Using 
IHC,  QRT-PCR,  conventional  PCR  and  degenerate  PCR  assays  MV  and  PyV 
genomes were not detected within cHL biopsies (Chapters 3 and 4).   
 
Prior knowledge of the putative viral agent or virus family is a prerequisite for these 
molecular biology techniques, but several virus discovery methods are now available 
for which this is not required.  Representational difference analysis (RDA) has been      
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used within our laboratory to investigate childhood ALL (MacKenzie et al. 2006).  
However, this technique is very labour intensive and requires very good quality high 
molecular weight DNA.  An alternative method of virus discovery, which uses gene 
expression profiling for rapid detailed analysis of cDNA libraries, is serial analysis of 
gene expression (SAGE) (Velculescu et al. 1995).  SAGE is currently being used in 
our laboratory by Dr Alice Gallagher as a method to detect viral transcripts present in 
HRS  cells  from  biopsy.    Transcripts  corresponding  to  unknown  tags  in  SAGE 
libraries will be identified and used to search public databases. 
 
Rolling circle amplification (RCA) has been used to amplify circular DNA genomes, 
including the genome of a novel papillomavirus in a sample from a Florida manatee 
(Rector et al. 2004).  RCA is a well-established WGA technique that uses random 
hexamers  to  preferentially  amplify  small  circular  molecules  and  requires  no  prior 
knowledge of the viral genomic sequence.  Using a commercially available RCA kit 
(TempliPhi  100,  Applied  Biosystems),  complete  viral  genomes  have  successfully 
been amplified within our laboratory (Miss Debbie Johnson, unpublished), including 
the uncharacterised rabbit papovavirus which was analysed using our polyomavirus 
degenerate PCR assays, described in chapter 4.   
 
The ViroChip is another method of viral detection for which prior knowledge of the  
virus is not required.  This DNA microarray contains 70 mer sequences of highly 
conserved  regions  within  every  fully  sequenced  viral  genome  listed  in  GenBank 
(Wang et al 2003).  This method has been successfully used to characterise known 
viruses  within  patients  with  respiratory  tract  infections,  in  addition  to  identifying 
novel variants present (Kistler et al 2007; Kistler et al 2007).  Results correlated well      
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with  those  from  pathogen-specific  PCR  assays,  both  in  terms  of  sensitivity  and 
specificity. 
 
7.2  RECURRENT CHROMOSOME IMBALANCES IN cHL 
Molecular studies of cHL have been significantly hampered by the scarcity of HRS 
cells  within  the  lymphomas.    Advances  in  molecular  biology  and  cytogenetic 
techniques have now made it possible to identify recurrent regions of chromosomal 
imbalance  in  HRS  cells  from  cHL-derived  cell  lines  and  biopsies  (Chui  et  al. 
2003;Joos et al. 2000;Joos et al. 2002;Joos et al. 2003).  Using array-CGH analysis, 
the  presence  of  several  recurrent  changes  within  six  cHL-derived  cell  lines  was 
confirmed and the location of these chromosomal regions was refined down to the 
megabase  level.    HRS  cells  were  isolated  from  a  cHL  case  using  laser 
microdissection, and the DNA from these cells was amplified for array-CGH analysis 
using DOP-PCR as a method of WGA.  This allowed us to identify a number of 
previously identified recurrent chromosome gains and losses within this cHL case. 
 
As discussed in Chapter 1, HRS cells originate from germinal centre B-cells, but do 
not  express  BCRs and have no surface immunoglobulins.   Non-functional  B-cells 
would normally be destroyed by apoptosis, but HRS cells have survived by some, as 
yet, unknown mechanism.  Any chromosomal change which may affect a gene that is 
known to play a role in an apoptotic pathway (i.e., NF B signalling pathway, the 
CD95 death receptor pathway, the JAK-STAT signalling pathway or Wnt signalling 
pathway) must, therefore, be considered in the search for the survival mechanism of 
HRS cells.
d  All genes of known function within regions of gain or loss identified by 
dThe potential role of tumour suppressor genes (ie p53) should also be considered in the 
pathogenesis of cHL. 
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our array-CGH analysis were examined and any with known involvement in apoptotic 
pathways were highlighted as potential candidate genes in cHL. 
 
EBV infection may also enable HRS cells to escape apoptosis since the LMP1 gene in 
EBV-infected cells is known to upregulate anti-apoptotic proteins (Wang et al 1990).  
In addition, the EBV genes LMP1 and LMP2A mimic CD40 and BCR, respectively, 
which may enable EBV-infected HRS cells to bypass the apoptotic mechanism in the 
germinal centre. 
 
From  our  array-CGH  analysis  of  cHL-derived  cell  lines,  we  also  identified  many 
genes  with  known  function  in  cell  cycle regulation and DNA  repair mechanisms. 
Changes in cell cycle regulation are common in human neoplasia.  To date, only one 
study  has  directly  examined  the  expression  of  cell  cycle  genes  in  cHL  samples 
(Tzankov et al 2003). By tissue microarray analysis, overexpression of the cyclin E1 
(CCNE1) gene was reported in 84% (212/253) cHL samples.  The identification of 
DNA  repair  genes  located  within  regions  of  chromosomal  imbalance  is  not 
unexpected since the many insertions and deletions detected in HRS cell DNA will be 
introducing double-  and single-strand breaks.  In addition,  Ig gene recombination, 
identified in HRS cells, will introduce DNA strand breaks and, therefore, stimulate 
DNA repair mechanisms. 
 
Selected genes located within the regions of gain and loss in cHL-derived cell line 
DNA  can  be  further  investigated  using  FICTION  or  FISH  analysis  of  metaphase 
chromosomes  from  cHL  cell  lines  and  biopsies.    The  amplification  techniques  of 
multiplex ligation-dependent probe amplification (MLPA) and muliplex amplification      
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and probe hybridisation (MAPH) could also be used to analyse the copy number of 
these genes (Sellner & Taylor 2004).  Both techniques involve the amplification of 
specifically  bound  probes  using  universal  primers.    These  methods  are  very  cost 
effective  since  numerous  targets  can  be  amplified  simultaneously  and  fluorescent 
detection only requires one fluorescent primer.  For MAPH, genomic DNA is fixed 
onto a membrane and hybridisation takes place using a set of specific probes.  In 
MPLA, hybridisation takes place in a solution of genomic DNA and target-specific 
probe sets.  The latter is a more reliable, high throughput, contamination-free method 
than MAPH.  Also only 100-200 ng of DNA is required for optimal MLPA, compared 
with 1  g of DNA for MAPH (Sellner & Taylor 2004). 
 
High-density oligoarrays, or single-nucleotide polymorphic allele (SNP)-arrays, are 
now  available  for  analysing  these  recurrent  chromosomal  changes  to  a  higher 
resolution  (150-200  kb)  than  was  possible  with  CGH-arrays  (Bignell  et  al. 
2004;Matsuzaki et al. 2004;Wong et al. 2004;Zhao et al. 2004).  MDA is the method 
of choice for preparation of samples for SNP-array hybridisation since it can be used 
to  generate  thousands  of  high-molecular  weight  copies  of  genomic  DNA  without 
thermocycling or ligation of DNA adaptors (Dean et al. 2002;Hosono et al. 2003), and 
with a low incidence of non-specific amplification artefacts or bias among alleles.  
We performed a number of preliminary experiments (data not shown) to test laser 
microdissected  samples  amplified  by  MDA,  using  the  GenomiPhi  (Applied 
Biosystems) and Repli-g
TM (Molecular Staging, New Haven, CT) kits.    However, 
samples were found to be of insufficient quality to be used for hybridisations.  The 
failure of MDA to amplify moderately degraded DNA from formalin-fixed samples 
has been reported (Wang et al. 2004) and it is possible that some degradation of our      
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cHL case samples had occurred during sample transport and processing.  It may be 
that  snap-freezing  biopsy  samples  on  arrival  at  the  laboratory  and  laser 
microdissecting  HRS  cells  directly  from  subsequent  frozen  tissue  sections  will 
preserve the quality of the DNA within these cells.  However, this would mean a 
trade-off between obtaining whole cells and maintaining the quality of the DNA. 
 
7.3  CONCLUSION 
The techniques optimised during this project will continue to be used to assay other 
cHL  cases  within  the  Leukemia  Research  Fund  (LRF)  Virus  Centre,  at  Glasgow 
University.  Our analysis of six cHL-derived cell lines and a cHL cell line using array-
CGH has led to the identification of regions of chromosomal imbalance which may 
influence the pathogenesis of cHL.  Functional genes located within these regions 
require further investigation in order to confirm any involvement in this disease.      
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APPENDIX A 
Combined hybridisation charts of cHL-derived cell lines 
a) HDLM2 versus IM9 
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b) KMH2 versus IM9 
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c) L1236 versus IM9 
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d) L428 versus IM9 
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e) L540 versus IM9 
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f) L591 versus IM9 
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APPENDIX B 
Chromosome regions containing known functional genes in which gains were 
identified in three or more cHL-derived cell lines. 
 
No  copy  number  variations  within  these  genome  regions  were  reported  on  the 
Genome  Variation  Database  website  (http://projects.tcag.ca/variation/;  last  checked 
November 2007).  Colours at the top of each column correspond to those used for 
each cell line in Figure 5.3.  Shaded rows highlight alternate chromosomes for ease of 
viewing. 
 
Clone ID   Location  Genes  HDLM2  KMH2  L1236  L428  L540  L591 
RP11-19A8   2p16.3  FSHR  Y  Y  Y  Y  N  N 
RP11-27C22   2p21  PRKCE  Y  Y  Y  Y  N  N 
RP11-
304A15   2p13.3  ARHGAP25, BMP10  N  Y  Y  Y  N  N 
RP11-
373L24   2p16.1  REL  N  Y  Y  Y  N  N 
RP11-
436L21   2p16.3  FSHR  Y  Y  Y  Y  N  N 
RP11-440P5   2p16.1  BCL11A  N  Y  Y  Y  N  N 
RP11-
457F14   2p22.1  SLC8A1  Y  N  Y  Y  N  N 
RP11-
477P16   3q26.31  NLGN1  Y  Y  Y  Y  N  N 
RP11-84G22   4p15.31  KCIP4  Y  N  Y  N  Y  N 
CTC-1480C2   5q22.2  APC  N  N  Y  N  Y  Y 
RP11-
520O10   5q35.3  COL23A1  Y  Y  N  Y  N  N 
RP3-444C7   6p22.3  CDKAL1  Y  N  Y  N  Y  N 
RP4-625H18   6p22.3  ID4  Y  Y  Y  N  Y  N 
RP11-68J15   6p22.3  FAM8A1, NUP153  Y  Y  Y  N  Y  N      
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RP1-13D10   6p22.3  MYLIP  Y  Y  Y  N  Y  Y 
RP11-
221G19   7q33  CALD1  N  Y  N  Y  Y  N 
RP11-311I10   7q21.13  PFTK1  N  N  Y  Y  Y  Y 
RP11-22A24   8q24.12  ENPP2, TAF2  Y  Y  N  Y  N  N 
RP11-48M17   9p24.3-p24.2  SMARCA2  Y  N  Y  Y  Y  Y 
RP11-
320E16   9p24.2  VLDLR  Y  N  Y  Y  Y  Y 
RP11-
503K16   9p22.1  ATL1  Y  N  Y  N  Y  N 
RP11-15P13   9p21.3  MLLT3  Y  N  N  N  Y  Y 
RP11-27J8   9p21.2  MOBKL2B, IFNK  Y  Y  Y  N  Y  Y 
RP11-136I14   11q23.3  IGSF4  N  N  Y  N  Y  Y 
RP11-419F8   11q25  OPCML  N  N  Y  Y  N  Y 
RP11-
567M21   11q24.3  PRDM10, APLP2  N  N  Y  Y  Y  Y 
RP11-127B1   12p12.3  PIK3C2G  Y  N  Y  N  Y  N 
RP11-
144O23   12p13.2  TAS2R7, TAS2R8, TAS2R9,  Y  N  Y  N  Y  Y 
       TAS2R10, PRR4,                    
      TAS2R14, PRH1                   
RP11-437F6   12p12.1  SOX5  N  N  Y  Y  Y  N 
RP11-474N8   12q13.3  ADMR, ZBT39,   N  Y  Y  Y  N  N 
      TAC3, MYO1A                   
RP11-296I10   16q22.1  AARS  Y  Y  Y  N  N  N 
RP11-
515O17   17q22  HLF, MMD  Y  N  Y  N  Y  N 
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APPENDIX C 
Chromosome regions containing known functional genes in which losses were 
identified in three or more cHL-derived cell lines. 
 
No  copy  number  variations  within  these  genome  regions  were  reported  on  the 
Genome  Variation  Database  website  (http://projects.tcag.ca/variation/;  last  checked 
November 2007.  Colours at the top of each column correspond to those used for each 
cell  line  in  Figure  5.4.    Shaded  rows  indicate  alternate  chromosomes  for  ease  of 
viewing. 
 
Clone ID   Location  Genes  HDLM2  KMH2  L1236  L428  L540  L591 
RP11-148L24   4q34.1  FBX08  Y  N  Y  Y  N  N 
RP11-21K15   5q14.1  ARSB  N  Y  Y  N  N  Y 
RP11-24O11   5q14.3  MEF2C  N  Y  Y  Y  N  N 
RP1-23D17   6q15  SPACA1, CNR1  N  Y  Y  N  Y  N 
RP1-142L7   6q21  WISP3, TUBE1, LAMA4  N  Y  Y  N  Y  N 
RP11-386H19   6q24.2  UTRN  N  Y  Y  N  Y  N 
RP11-545I5   6q24.3  FBXO30, SHPRH  N  Y  N  Y  Y  N 
RP4-596O9   7p15.1  CREB5  Y  Y  N  N  Y  N 
RP11-177H2   8p23.1  PINX1, XKR6  Y  N  Y  N  Y  Y 
RP11-561E1   8p21.2  ADAMDEC1, ADAM7  Y  Y  N  N  N  Y 
RP11-138J2   8p21.2  PTK2B  Y  N  N  N  Y  Y 
RP11-356F24   8p21.1  EXTL3  Y  N  N  N  Y  Y 
RP11-473A17   8p12  PURG, WRN  Y  N  N  N  Y  Y 
RP11-301H15   8p12  NRG1  Y  N  N  N  Y  Y 
RP11-362L2   9q21.31  TLE4  N  Y  N  Y  Y  N 
RP11-31J20   9q31.1  ABCA1  N  N  Y  Y  Y  N 
RP11-388N6   9q31.3  PTPN3  N  N  Y  Y  Y  N 
RP11-470J20   9q31.3  PALM2  N  N  Y  Y  Y  N 
RP11-143H20   9q34.13  LAMC3  N  N  Y  Y  Y  N 
RP11-83N9   9q34.3  BTBD14A, LHX3, QSCN6L1  N  N  Y  Y  Y  N      
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RP11-574P20   10q22.3  RAI17  N  Y  Y  N  Y  N 
RP11-110K8   13q12.11  EFHA1  N  Y  Y  Y  Y  N 
RP11-187L3   13q12.11  CRYL1  N  N  Y  Y  Y  N 
RP11-760M1   13q12.12  TNFRSF19  N  Y  Y  Y  Y  N 
RP11-44J9   13q12.13  WASF3  N  Y  Y  Y  N  N 
RP11-111G7   13q12.13  ATP8A2  N  Y  Y  Y  Y  N 
RP11-125I23   13q12.2  GTF3A  N  Y  Y  Y  Y  N 
RP11-218E6   13q12.3  SLC7A1  N  Y  Y  Y  Y  N 
RP11-550P23   13q12.3  HMGB1  N  Y  Y  Y  Y  N 
RP11-98D3   13q13.3  NBEA, MAB21L1  N  Y  Y  Y  Y  N 
RP11-10M8   13q13.3  POSTN, TRPC4  N  Y  Y  Y  Y  N 
RP11-131P10   13q13.3  UFM1  N  Y  N  Y  Y  N 
RP11-2P5   13q14.11  ELF1, WBP4  N  Y  Y  Y  Y  N 
RP11-185C18   13q14.2  SETDB2, PHF11, RCBTB1  N  Y  Y  Y  Y  N 
RP11-327P2   13q14.3  ATP7B  N  N  Y  Y  Y  N 
RP11-431O22   13q14.3  LECT1, PCDH8  N  Y  N  Y  Y  N 
RP11-359P14   13q21.2  TDRD3  N  Y  Y  Y  Y  N 
RP11-552M6   13q22.1  KLF12  N  N  Y  Y  Y  N 
RP11-332E3   13q22.2  LMO7  N  Y  Y  Y  Y  N 
RP11-226E21   13q22.3  MYCBP2  N  Y  Y  Y  Y  N 
13 RP11-
74A12   13q32.1  ABCC4  N  Y  Y  Y  Y  N 
RP11-383H17   13q32.2  RANBP5  N  N  Y  Y  Y  N 
RP11-564N10   13q33.1  FGF14  N  Y  Y  Y  Y  N 
RP11-480K16   13q34  TUBGCP3  N  Y  Y  Y  N  N 
RP11-302G2   15q22.31  RAB11A  N  Y  N  Y  Y  N 
RP11-305A7   16q12.1  ZNF423  Y  Y  Y  N  N  N 
RP11-87G24   17q25.2  MGAT5B  Y  N  Y  N  Y  N 
RP11-323N12   17q25.3  PSCD1, UBP36, TIMP2  N  Y  Y  N  Y  N 
RP11-525L23   17q25.3  FOXK2, WDR45L, RAB40B  Y  N  Y  N  Y  N 
RP11-146G7   18p11.31  ARHGAP28, LAMA1  Y  Y  Y  N  N  N 
RP11-350K6   18q21.32  SEC11L3  N  Y  N  Y  Y  N 
RP11-28F1   18q21.33  BCL2, FVT1  N  Y  N  Y  Y  N 
RP11-154H12   18q23  CTDP1  N  N  Y  Y  Y  N 
RP11-526K24   20p12.1  CT006  Y  Y  N  Y  N  N      
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RP5-1096J16   20p11.23  CT026  Y  Y  N  Y  N  N 
RP5-1071L10   20q13.13  BCAS4, TMSL6  Y  Y  N  Y  N  N 
RP5-1075G21   20q13.2  CYP24A  Y  Y  Y  Y  N  N 
CTA-228A9   22q13.1  PLA2G6, SLC16A8  N  Y  Y  N  Y  N 
RP1-172B20   22q13.1  CACNA1I  N  Y  Y  N  Y  N 
RP3-437M21   22q13.2  ARFGAP3  Y  N  Y  N  Y  N 
22 CTA-268H5   22q13.31  NUP50, UPK3A, SMC1L2  Y  Y  Y  N  N  N 
RP3-398C22   22q13.31  ATXN10  Y  Y  Y  N  N  N 
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APPENDIX D 
Gene expression array analysis results for the EBV-positive cHL cell line KMH2 
Top 20 upregulated genes in KMH2 
Probe set ID  Public ID  UniGene ID  Gene Symbol 
205403_at  NM_004633  Hs.25333  IL1R2 
1566126_at  AK097242  Hs.519719  FABP6 
210650_s_at  BC001304  Hs.12376  PCLO 
223340_at  AF131801  Hs.241503  SPG3A 
204687_at  NM_015393  Hs.105460  DKFZP564O0823 
217853_at  NM_022748  Hs.520814  TENS1 
214945_at  AW514267  Hs.368516  NY-REN-7 /// LOC389347 
203420_at  NM_016255  Hs.95260  FAM8A1 
212344_at  AW043713  Hs.409602  SULF1 
231883_at  BF306374  Hs.435466  FBXW8 
220559_at  NM_001426  Hs.271977  EN1 
203354_s_at  AW117368  Hs.434255  PSD3 
212607_at  N32526  Hs.498292  AKT3 
204083_s_at  NM_003289  Hs.300772  TPM2 
223501_at  AW151360  Hs.525157  TNFSF13B 
209582_s_at  H23979  Hs.79015  CD200 
201566_x_at  D13891  Hs.180919  ID2 /// ID2B 
226602_s_at  T30183  Hs.531306  BCR /// LOC440820 
219511_s_at  NM_005460  Hs.426463  SNCAIP 
223063_at  BC004870  Hs.520494  FLJ14525 
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Top 20 downregulated genes in KMH2 
Probe set ID  Public ID  UniGene ID  Gene Symbol 
208690_s_at  BC000915  Hs.368525  PDLIM1 
211555_s_at  AF020340  Hs.77890  GUCY1B3 
224657_at  AL034417  Hs.11169  MIG-6 
1565162_s_at  D16947  Hs.389700  MGST1 
208524_at  NM_005290  Hs.159900  GPR15 
202464_s_at  NM_004566  Hs.195471  PFKFB3 
203987_at  NM_003506  Hs.292464  FZD6 
205114_s_at  NM_002983  Hs.514107  CCL3 /// CCL3L1 /// CCL3L3 
221286_s_at  NM_016459  Hs.409563  PACAP 
208018_s_at  NM_002110  Hs.126521  HCK 
204639_at  NM_000022  Hs.407135  ADA 
1559425_at  AL512701  Hs.333907  PRKCH 
219159_s_at  NM_021181  Hs.517265  SLAMF7 
218241_at  NM_005113  Hs.104320  GOLGA5 
1552497_a_at  NM_052931  Hs.492348  SLAMF6 
221942_s_at  AI719730  Hs.24258  GUCY1A3 
204608_at  NM_000048  Hs.442047  ASL 
230673_at  AV706971  Hs.170128  PKHD1L1 
203185_at  NM_014737  Hs.379970  RASSF2 
1552296_at  NM_153274  Hs.302513  VMD2L2 
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APPENDIX E 
 
Gene expression array analysis results for the EBV-positive cHL cell line L428 
Top 20 upregulated genes in L428 
Probe set ID  Public ID  UniGene ID  Gene Symbol 
203824_at  NM_004616  Hs.170563  TSPAN8 
205403_at  NM_004633  Hs.25333  IL1R2 
206118_at  NM_003151  Hs.80642  STAT4 
238553_at  BG426581  Hs.499605  LOC399753 /// LOC399768 /// LOC439983 
203354_s_at  AW117368  Hs.434255  PSD3 
203835_at  NM_005512  Hs.151641  LRRC32 
204483_at  NM_001976  Hs.224171  ENO3 
203420_at  NM_016255  Hs.95260  FAM8A1 
205141_at  NM_001145  Hs.283749  ANG /// RNASE4 
207194_s_at  NM_001544  Hs.386467  ICAM4 
1560074_at  AL119889  Hs.531704  PRKCA 
230769_at  AI916261  Hs.127350  FLJ37099 
212797_at  BE742268  Hs.485195  SORT1 
243937_x_at  BF436377  Hs.499605  LOC399768 /// LOC439983 
210695_s_at  U13395  Hs.549163  WWOX 
203335_at  NM_006214  Hs.498732  PHYH 
218910_at  NM_018075  Hs.457131  FLJ10375 
203814_s_at  NM_000904  Hs.533050  NQO2 
1555464_at  BC046208  Hs.163173  IFIH1 
205165_at  NM_001407  Hs.533070  CELSR3 
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Top 20 downregulated genes in L428 
Probe set ID  Public ID  UniGene ID  Gene Symbol 
208690_s_at  BC000915  Hs.368525  PDLIM1 
224657_at  AL034417  Hs.11169  MIG-6 
211555_s_at  AF020340  Hs.77890  GUCY1B3 
1565162_s_at  D16947  Hs.389700  MGST1 
207826_s_at  NM_002167  Hs.76884  ID3 
202022_at  NM_005165  Hs.155247  ALDOC 
205114_s_at  NM_002983  Hs.514107  CCL3 /// CCL3L1 /// CCL3L3 
219159_s_at  NM_021181  Hs.517265  SLAMF7 
208018_s_at  NM_002110  Hs.126521  HCK 
204639_at  NM_000022  Hs.407135  ADA 
208524_at  NM_005290  Hs.159900  GPR15 
1569607_s_at  BC016022  Hs.522178 
ANKRD20A /// C21orf81 /// 
LOC440841 /// LOC441425 /// 
LOC441430 
230673_at  AV706971  Hs.170128  PKHD1L1 
203921_at  NM_004267  Hs.8786  CHST2 
1552497_a_at  NM_052931  Hs.492348  SLAMF6 
1559425_at  AL512701  Hs.333907  PRKCH 
219821_s_at  NM_018988  Hs.484686  GFOD1 
204281_at  NM_003213  Hs.94865  TEAD4 
202464_s_at  NM_004566  Hs.195471  PFKFB3 
208690_s_at  BC000915  Hs.368525  PDLIM1 
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APPENDIX F 
 
Gene expression array analysis results for the EBV-positive cHL cell line L591 
Top 20 upregulated genes in L591 
Probe set ID  Public ID  UniGene ID  Gene Symbol 
209369_at  M63310  Hs.480042  ANXA3 
241942_at  AA927870  Hs.444882  PXDNL 
233052_at  AW270168  Hs.520106  DNAH8 
205403_at  NM_004633  Hs.25333  IL1R2 
209582_s_at  H23979  Hs.79015  CD200 
206707_x_at  NM_015864  Hs.484915  C6orf32 
212169_at  AL050187  Hs.103934  FKBP9 
1553044_at  NM_032602  Hs.334499  CX62 
217853_at  NM_022748  Hs.520814  TENS1 
217336_at  AL118510  Hs.512535  RPS10 /// LOC158104 /// LOC388885 /// 
LOC389127 /// LOC390842 /// LOC401817 
205719_s_at  NM_000277  Hs.325404  PAH 
206414_s_at  NM_003887  Hs.467662  DDEF2 
202336_s_at  NM_000919  Hs.369430  PAM 
209676_at  J03225  Hs.516578  TFPI 
208450_at  NM_006498  Hs.531776  LGALS2 
203665_at  NM_002133  Hs.517581  HMOX1 
203498_at  NM_005822  Hs.440168  DSCR1L1 
201566_x_at  D13891  Hs.180919  ID2 /// ID2B 
205079_s_at  NM_003829  Hs.169378  MPDZ 
212797_at  BE742268  Hs.485195  SORT1 
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Top 20 downregulated genes in L591 
Probe set ID  Public ID  UniGene ID  Gene Symbol 
211555_s_at  AF020340  Hs.77890  GUCY1B3 
224657_at  AL034417  Hs.11169  MIG-6 
205114_s_at  NM_002983  Hs.514107  CCL3 /// CCL3L1 /// CCL3L3 
207826_s_at  NM_002167  Hs.76884  ID3 
1569607_s_at  BC016022  Hs.522178  ANKRD20A /// C21orf81 /// LOC440841 
/// LOC441425 /// LOC441430 
1552531_a_at  NM_145007  Hs.375039  NALP11 
1559425_at  AL512701  Hs.333907  PRKCH 
204281_at  NM_003213  Hs.94865  TEAD4 
201522_x_at  NM_003097  Hs.525700  SNRPN /// SNURF 
203921_at  NM_004267  Hs.8786  CHST2 
209694_at  M97655  Hs.503860  PTS 
226301_at  AV729072  Hs.347144  C6orf192 
1561336_at  CA449306  Hs.476453  DNASE1L3 
1553528_a_at  NM_139052  Hs.96103  TAF5 
201487_at  NM_001814  Hs.128065  CTSC 
201367_s_at  AI356398  Hs.503093  ZFP36L2 
208524_at  NM_005290  Hs.159900  GPR15 
204472_at  NM_005261  Hs.345139  GEM 
220205_at  NM_013315  Hs.122986  TPTE 
208962_s_at  BE540552  Hs.503546  FADS1 
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